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ABSTRACT
Monocyte chemotactic peptide-1 (MCP-1) is a member of the CC chemokine family, and 
is a potent inducer of monocyte and CD45RO+ lymphocyte chemotaxis. In vivo studies 
suggest that MCP-1 recruits monocytes to sites of inflammation in a number of 
pathological conditions including atherosclerosis and rheumatoid arthritis. The cellular 
effects of MCP-1 are mediated primarily by binding to the CC chemokine receptor-2 and 
are reported to activate a number of signalling pathways. CCR2 is activated by multiple 
agonists, including MCP-1, -2, -3 and -4, however, to date the signal transduction events 
elicited by MCP-2, -3 and -4 remain unclear.
This thesis proposed to explore the signal transduction events elicited via CCR2. One of 
the aims was to compare the effects of MCP-2, -3 and -4 to those observed with the 
prototypical CCR2 ligand, MCP-1. To pursue these aims, the monocytic cell line, THP-1, 
was used as an experimental model for molecular signalling and functional studies 
alongside some supportive work being performed in the Jurkat cell line.
MCP-1, -2, 3 and -4 activated at least one member of class I PI3-kinase family in THP-1 
cells. In addition, MCP-1 was shown to activate two distinct isoforms of the class II Pl- 
kinases, PI-3K-C2a and PI3K-C20. The ramifications of PI3K activation on downstream 
signalling events were also made apparent. CCR2-mediated activation of the 
downstream effectors of PI3K (namely PKB and GSK-3a/p) were observed, as well as 
PLD, and MAPKs - all of which were at least partially dependent on PI3K
The use of Clostridial toxins permitted the examination of the role of small GTP binding 
proteins (e.g. Ras) in PI3K regulation, and the data is indicative that these proteins 
function upstream of PI3K in this system. It is evident that small GTP binding proteins 
have a potential importance as signalling components involved in modulating efficient 
CCR2 coupling to downstream pathways and subsequent functional output.
MCP-1, -2,-3 and -4 activated three distinct major MAP kinases with a similar signalling 
profiles, albeit with slightly different kinetics. The only inter-chemokine differences 
observed with regards to MAP kinase activation were those pertaining to PKC- 
dependency. Activation of ERK-1/2, p38 and JNK were observed in response to all four 
ligands although exhibited different levels of dependency on PI3K. Differential regulation 
of these MAPKs by G-proteins was also observed in this system.
With regards to the functional readout in this system, it was demonstrated that MCPs-1-4 
were capable of inducing chemotaxis, and as expected all four chemokines exhibited 
different degrees of potency. In each case, chemotaxis appeared to be a Gar mediated 
event that was dependent on PI3K, but independent of ERK-1/2 activation.
This thesis highlights the sophisticated mechanisms underlying CCR2-mediated signal 
transduction, and the subsequent chemotactic response. In particular, it conveys the 
important role of PI3Ks in cellular function and its influence on other signalling pathways. 
This study has brought us a step closer to characterising the effect of PI3K and other 
signalling molecules on events stimulated by CCR2 ligation, and identifying the factors 
that lead chemokine-mediated inflammatory disease states, such as atherosclerosis. 
Identification of the cellular response to inflammatory stimuli may, in time, lead us to 
suitable targets for therapeutic intervention.
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A List of abbreviations commonly used within the text of this thesis. For a 
comprehensive review of chemokine acronyms, see Table 1.1, and for reagent 
abbreviations see Section 2A
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Inflammation is essentially a protective response intended to eliminate both the initial 
causal agents (e.g. microorganisms, toxins) and clear necrotic cells and tissues that 
arise as a consequence of such injury. Inflammation is classified into two basic 
forms; (1) Acute inflammation, which is of relatively short duration (lasting from a few 
minutes up to a few days) and characterised by a predominantly neutrophillic 
leukocyte accumulation. (2) Chronic inflammation, which is of longer duration (days 
to years) and characterised by the influx of lymphocytes, monocytes and by ongoing 
tissue destruction and repair.
Acute inflammation is the immediate response to injury. The critical function of this 
early response is to deliver leukocytes to the site of inflammation, to counteract 
infectious agents as well as degrade necrotic tissues. Conversely, leukocytes 
themselves may also prolong inflammation, and induce damage in their release of 
oxygen free radicals, enzymes and inflammatory mediators (Tsokos et al, 1995; 
Kumar et al, 1997).
In contrast to acute inflammation which is distinguished by vascular changes 
(vasodilation), and a largely neutrophillic infiltrate, chronic inflammation is 
characterised by (1) infiltration with mononuclear cells, including macrophages, 
lymphocytes and plasma cells, (2) destruction of tissue, and (3) tissue repair 
involving proliferation of vessel wall (angiogenesis) and fibrosis.
Chronic inflammation may follow acute inflammation, and such a transition may arise 
when the acute response cannot be resolved, either because of a persistent 
infectious agent (e.g. infection) or because of interference in the normal process of 
healing (e.g. prolonged exposure to toxic agent).
"Chronic Inflammatory Cells"
Macrophages are a principle component of the mononuclear phagocyte system, 
which consists of closely related cells of bone marrow origin, and their accumulation 
is a characteristic feature of chronic inflammation. Under the influence of adhesion 
molecules and chemotactic factors (e.g. MCP-1, MIP-1a), circulating monocytes 
begin to immigrate to the site of injury. When monocytes reach extravascular tissue,
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they undergo transformation into larger, phagocytic cells called macrophages. 
Macrophages themselves may also become activated upon several inflammatory 
signals including bacterial toxins, extracellular matrix proteins (e.g. fibronectin) and 
cytokines secreted by T lymphocytes (in particular INF-y). In short, macrophages 
have three major roles in resistance to infection: Firstly, they destroy antigen by 
phagocytosis. Second, they process the antigen for immune response and serve to 
regulate this response through lnterleukin-2 production, thus promoting T cell 
proliferation and; Thirdly, they are potent effectors of the inflammatory response by 
their capacity to release arachidonic acid-derived mediators, cytokines and 
respiratory burst products (Petit and Hoffbrand, 1992).
Introduction of the appropriate leukocytes into close proximity with the offending 
infectious agent is a highly co-ordinate process involving the integration of many 
inflammatory molecules. The sequence of events in the extravasation of leukocytes 
from the vascular lumen to the extravascular space is a multistep process, 
collectively known as cell migration or chemotaxis.
Cell Migration
On a cellular level it is now accepted that leukocyte migration is a multi-step process 
that involves sequential interactions with several sets of adhesion molecules on the 
leukocyte that interact with corresponding receptors on the endothelium (For review, 
see Springer 1994). The initial step of this process is the slowing and 'rolling' of 
leukocytes on the endothelium and which is mediated by 'selectins'. Selectins are 
characterised by an extracellular domain that binds sugars (hence the “lectin” part of 
the name). These include E-selectin, exclusive to endothelium; P-selectin, present 
on endothelium and platelets; and L-selectin, found on the surface of most 
leukocytes. (Tedder, 1995; Butcher and Picker, 1996) Since a leukocyte spends only 
seconds in a venule, it is imperative that becomes rapidly tethered. Selectins have 
the ability to bind their ligands in milliseconds, thus, providing a crucial mechanism 
whereby the leukocyte is quickly anchored down, and suitably positioned for the next 
stage to take place.
The second step is mediated by via chemotactic agents and their induction of 
'integrin' adhesiveness. Rolling is ceased and firm integrin-mediated adhesion takes 
place. Integrins are a large family of molecules involved in intracellular and cell- 
substratum adhesion and can be characterised on the basis of their two-subunit
2
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composition (Oppenheim et al, 1991; Baggiolini, 1998). The engagement of the 
integrin with their cognate receptors on endothelium is the third step in this 
transmigrational process. Here, the interacting cells are linked together in close 
proximity that allows development of the traction that is associated with migration. 
The adhesion is largely mediated by endothelial adhesion molecules which include 
ICAM-1 (intercellular adhesion molecule 1) and V-CAM-1 (vascular adhesion 
molecule 1), both of which have increased surface expression following stimulation 
by various inflammatory mediators. Integrins are transmembrane heterodimeric 
glycoproteins that also function as cell receptors for the extracellular matrix (ECM); 
the principal integrin receptors for ICAM-1 are LFA-1 (CD11a/CD18) and 
CD11b/CD18, while V-CAM-1 binds to the integrin VLA-4. These proteins are 
normally expressed on leukocytes, but do not adhere to their appropriate ligands until 
the leukocytes are activated -  only at this point do they undergo the conformational 
change necessary to confer ligation to the endothelial adhesion molecules (for 
reviews; Gahmber etal, 1999; Aplin etal, 1999).
The process of slowing down the leukocyte has commonly been described as 
transient 'arrest'', and is the initial step in active cellular migration. Transendothelial 
migration, or ‘diapedesis’ involves the movement of the leukocyte through the 
endothelial cell wall and subsequent interstitial movement towards the 
chemoattractant/chemokine. This is a highly orchestrated process that requires the 
sequential co-ordination of the following events:
i) Polarisation of the cell by formation of a ‘leading edge’ and a ‘uropod’. 
Formed from the redistribution of signalling molecules, cytoskeleton, 
chemokine receptors and cell surface molecules. Probably directing cells 
along a chemotactic gradient.
ii) Protrusion of membrane extensions such as filopodia and lamellipodia. A 
reversible event that is governed by reorganisation of local F-/G-actin.
iii) Establishment and maintenance of cellular attachment co-ordinated by the 
synthesis and redistribution of activated integrin molecules (e.g. ICAM-1, 
ICAM-3, and CD44) to the leading edge.
iv) Contraction of cellular body and adhesive traction. A process regulated 
by myosin-based ATP-motors and integrin binding.
v) Release and retraction of the uropod - a mechanism thought to be under 
the control of integrin endocytosis.
(Lauffenburger etal, 1996; Nieto etal, 1997; Sanchez-Madrid etal, 1999)
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After extravasation, leukocytes emigrate toward the site of injury along a chemical 
gradient, in a process referred to as 'chemotaxis'. Both exogenous and endogenous 
substances can act as chemotactic agents for leukocytes, including: soluble bacterial 
products, components of the complement system (e.g. C5a), products of the 
arachidonic metabolism pathway (e.g. leukotriene B4) and cytokines, particular those 












Figure 1.1 Sequence of events in leukocyte emigration in 
inflammation (simplified). The leukocytes (1) roll, (2) arrest 
and adhere to endothelium, (3) transmigrate through 











In the case of the phagocytic chemokines, receptor-mediated interaction is followed 
by the engulfment of the foreign agent in a phagocytic process. Once internalised by 
the ingesting leukocyte, a 'respiratory burst' is induced. This is characterised by a 
rapid, marked increase in the consumption of oxygen by the cell, resulting in the 
production of toxic metabolites, such as superoxide, hydrogen peroxide, hydroxyl 
radicals and myeloperoxidase (Beron et al, 1995). It is important to note that even in 
the absence of an oxidative burst, other constituents of leukocyte granules are 
capable of killing bacteria or infectious agents. These include lysozyme, lactoferrin, 
defensins and bactericidal permeability increasing protein (BPI).
1.2 Chemokines
The Chemokine Superfamily
Chemokines are a rapidly growing superfamily of proinflammatory cytokines that 
serve to attract and activate specific types of leukocytes (For reviews see Baggiolini, 
1997; Hendrick, 1997; Thelen, 2001). Over 13 years ago, the first chemokine, now 
known as CXC chemokine ligand 8 (CXCL8), formerly known as interleukin-8 (IL-8) 
was identified as a neutrophil attracting factor, and opened the doors to a new 
concept in chemotactic agents. In recent years, these chemotactic cytokines, which 
are in the 8- to 17-kDa molecular mass range, have been shown to selectively attract 
certain subsets of leukocyte populations to sites of inflammation. This superfamily 
has been divided into 4 groups (CXC, CX3C, CC and C) pertaining to the position of 
the first two N-terminal cysteines of the amino acid sequence (Figure 1.2).
Figure 1.2 Schematic Representation of chemokine 
Families




















The CXC (or a) family has the first two NH2-terminal cysteines separated by one non­
conserved amino acid residue. The CXC chemokines can be divided into two 
subclasses based on the presence or absence of an ELR amino acid motif positioned 
immediately upstream of the first N-terminal cysteine. The presence or absence of 
this motif has been associated with distinct and opposite functional effects. For 
example, ELR+ CXC-chemokines are quite often angiogenic whereas lack of ELR 
renders these chemokines angiostatic (Schall and Bacon, 1994).
In contrast, the CC (or p) family holds these cysteines in juxtaposition, the C (y) 
family has just a single NH2-terminal residue, while the CX3C (or 8) family has three 
intervening amino acids separating these cysteine residues. Most of the chemokines 
fall into the CXC or CC families since there is only one C (lymphotactin) and one 
CX3C chemokine (fractalkine) identified in humans.
'Fractalkine', the only member of the CX3C is a notable exception to other soluble 
chemokines in that it is an integral membrane protein, heavily substituted with mucin­
like carbohydrates and a chemokine domain at its N-terminus. Such a structure 
supports the view that soluble secreted chemokines bind to, and are immobilised by 
cell surface heparan sulphates or other glycosaminoglycans (GAGs). It is thought 
that the immobilisation of chemokines by GAGs forms stable, solid-phase chemokine 
foci and gradients required for efficient trafficking (Witt and Lander, 1994). Consistent 
with this proposal, immobilised IL-8 and RANTES have been shown to promote 
leukocyte migration and adhesion, respectively (Middleton et al, 1997). Binding of 
chemokines to GAGs has also been shown to induce multimerisation, increase their 
effective local concentration and optimise receptor occupancy (Hoogwerf et al, 1997). 
A clearer understanding of chemokine-GAG interactions may be useful in explaining 
functional differences between chemokines that according to other criteria, have 
been judged as functionally redundant.
The other exception to the rule is the C chemokine 'lymphotactin' and is so far the 
only member of this putative family. Although it is the correct size, and shows 
characteristic sequences common to CC chemokines, it has a lone cysteine at the N- 
terminal domain. Nevertheless, it is upregulated in several inflammatory conditions 
and is a potent attractant for T lymphocytes (Murdoch and Finn, 2000).
During the last 5 years, the development of EST databases has been primarily 
responsible for the identification of many new chemokines and their receptors. 
Chemokines represent ideal candidates for discovery through bioinformatics because
6
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of their relatively small size and highly conserved motifs, and this has resulted in the 
rapid identification of new chemokines. Unfortunately, this has also led to severe 
trouble with chemokine nomenclature, as multiple names have been published for 
the same molecule. Recently, the ‘definitive’ update for chemokine classification 
was proposed by the Nomenclature Committee of the International Union of 
Pharmacology XXII and the various names and acronyms were reassigned 
accordingly (Murphy et al, 2000). The CC chemokines, were renamed ‘CCL’ 
(CXCL1-27) , and ‘CXCL’ was reassigned to all the CXC chemokines (CXCL1-14). 
In spite of the revised nomenclature, chemokines continue to be referred to by their 
classical names, so to avoid confusion, all classical names shall be used from hereon 
in. The complete revised list of identified chemokines to date (showing revised and 
classical names) is shown in Table 1.1.
Table 1.1 Chemokines and their Receptors
CHEMOKINE
(classical/systematic name)
RECEPTOR TARGET CELLS MAIN EFFECT
CXC (ELR+)





















SDF-1a/p CXCL4 CXCR4 Ubq. T, DC, BM Embryonic Gl, CNS. B. Cell 
dev. Antagonism of tHIV-1 
Entry.
BCA-1 CXCL13 CXCR5 B B cell development
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Table! 1 Chemokines and their receptors (continued)
CC (P)
MIP-1a CCL3 CCR1, CCR5, CCR9 M Ma. NK. Bas. 
DC. BM. B. T
NK activation. IgE/IgG prod. mHIV 
entry antagonism. T costim.MIP-1P CCL4
MDC CCL22 CCR4 DC. T. (Th1>Th2) Intra-thymic Dev. Trafficking. +/- 
ive selection. Th2 responsesTECK CCL25 CCR9/11 Ma. Thy. DC.
TARC CCL17 CCR4/8 T cell lines
RANTES CCL5 CCR1/CCR3/CCR5 M. Ma. NK. DC. 
Tm. T. Bas.
T cell prolif. mHIV-1 entry' 
antagonism
DC-CK-1 CCL18 CCR1 r  >T Promotes T :DC antigen pres.
HCC-1 CCL14 CCR1/CCR9 M. Anti-proliferative for progenitor 
BM.HCC-2 CCL15 CCR1/CCR3
HCC-4 CCL16 CCR1/CCR8 M. Lym.
MIP-3a CCL20 CCR6 PBMC. BM. Tm > 
T
MIP-3P CCL19 CCR7
l-Az T cell homing
MCP-1 CCL2 CCR2, D6 T. M. Bas. NK, T, Bas degran. Mon/mac 
activationMCP-2 CCL8 CCR1, CCR2, CCR3, 
CCR5? D6
T. M. Bas. Eo.
MCP-3 CCL7 CCR1/CCR2/CCR3/ T. M. Bas. Eo. DC
MCP-4 CCL13 CCR2/CCR3 T. M. Bas. Eo. DC Eo,Bas degran.
Eotaxin CCL11 CCR3 Eo. Eo activation
Eotaxin-2 CCL24 CCR3 Eo. Th2. Bas
I-309 CCL1 CCR8 T Th2 responses?
MIP-5 CCR1/CCR3 T. M. N. ?
MPIF-1 CCL23 CCR1 M. Tk Anti-proliferative for myeloid cells
6C-kine CCL21 CCR7/CCR11 T. B. Mes. Anti-proliferative for BM 
progenitor
C(Y)








Multiple CC and 
CXC (ERL+) 
chemokines
DARC RBC. Coreceptor for Malarial parasite.
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Legend for Table 1.1. Chemokines: IL-8, lnterleukin-8; GRO-a/p/y, Growth related
oncogene-a/p/y; ENA-78, Epithelial derived attractant-78, LDGF-PBP, Leukocyte derived 
growth factor-platelet basic protein; GCP-2, Granulocyte chemotactic protein-2; PF4, Platelet 
factor-4; MIG, Monokine induced by Interferon-gamma; IP-10, Interferon^ inducible protein- 
10; ITAC, Interferon-inducible T cell alpha chemoattractant; SDF-a/p, Stromal-cell derived 
factor-a/p; BCA-1, B cell attracting chemokine-1; MIP-1 and -3  ot/p, Macrophage 
Inflammatory protein-1 and -3  a/p; MDC, Monocyte derived chemokine; TECK, Thymus- 
expressed chemokine; TARC, Thymus and activation-regulated chemokine; RANTES, 
Regulated on activation normal T cell expressed and secreted; DC-CK-1 (PARC), Dendritic 
cell chemokine-1 (Pulmonary and activation-regulated chemokine); HCC-1,2,4, Human CC 
cytokine 1,2,4; LARC, Liver and activation-regulated chemokine; ELC, EBI1-ligand 
chemokine (EBI1+CCR7), MIP-3 ap and MIP-5 (See MIPa/p); MCP-1, -2, -3, -4, Monocyte 
chemotactic protein-1,2-3,-4; MPIF-1, Myeloid progenitor inhibitory factor-1; 6C-kine/SLC, Six- 
cysteine chemokine/Secondary lymphoid tissue chemokine. Cells: N, Neutrophils; B, B 
cells; T, T cells; T*. activated T cells; JM, Memory T cells; TN, Naive T cells, TR, Resting T 
cells; Th1/2, T helper cell type 1 & 2; Thy, Thymocytes; Bas, Basophils; Mes, Mesangial 
cells; RBC, Red blood cells; PBMC, Peripheral blood mononuclear cells; Endo, Endothelial 
cells; NK, Natural killer cells ; Ubq, Ubiquitously expressed; DC, Dendritic cells; Lym, 
Lymphocytes.
The Functional Role of Chemokines
The capacity of chemokines to both activate and attract various subpopulations of 
leukocytes has placed these molecules as key modulators in a vast array of 
biological processes. From early cellular development, its maturation and 
homeostasis, right through to ultimate cell death, it is becoming increasing clear that 
chemokines play an intrical part in each process. Fifteen years of research has 
pinpointed these proteins to organogenesis, embryogenesis and development 
(Wilkinson et al, 1999) angiogenesis (Voest et al, 1995) as well as both positive and 
negative regulators of apoptosis (Cerdan et al, 2001). Chemokines and their 
receptors have now been heavily implicated in various aspects of T-lymphocyte 
biology, in a way which is quite distinct from the established role as chemotactic 
agents for the movement of leukocytes in inflammation (for Reviews see Ward and 
Westwick, 1998, Ward et al, 1998). For example, the effects of chemokines on T 
cell function(s) have been shown in thymic development (Mebius et al, 1996; 
Campbell et al, 1999), lymphoid trafficking and differentiation of the Th1/Th2 subsets 
(Siveke et al, 1998; Sebastiani et al, 2001). The acknowledgement that many of 
these T cell responses can be attributable to chemokines is crucial to the search for
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novel therapeutic strategies for immune deficiencies, autoimmune diseases and 
transplantation.
Transgenic and Knockout Mice: Modeis of Chemokine Action
The targeted disruption of chemokine and chemokine receptor genes as well as the 
expression of chemokines as transgenes has identified important roles for these 
molecules in specific aspects of the inflammatory response. The ability of 
chemokines to direct leukocyte infiltration depends on a low regional expression 
level. In studies with MCP-1 transgenic mice, the systemic overexpression of a 
mouse mammary tumor virus long terminal repeat-MCP-1 transgene led to a general 
paralysis of the response to this chemokine (Grewal et al, 1997). As well as 
persistent expression of MCP-1 expression and insulitis, the macrophage infiltrate did 
not result in progressive tissue destruction. Therefore, additional costimulatory 
signals are required for the activation of macrophages.
Knockout mice with a targeted disruption for either MCP-1 or its cognate receptor 
(CCR2) gene show a reduced capacity to recruit monocytes and have suggested a 
fundamental role for these molecules in the generation of atherosclerotic lesions 
(Boring et al, 1998; Lu et al, 1998). Mice deficient for CCR5 show an increased 
humoral response toT cell-dependent antigenic challenge, suggesting a novel role for 
CCR5 in downmodulating T cell-dependent immune responses (Zhou et al, 1999). 
Targeted disruption of the eotaxin gene demonstrated that eotaxin enhances the 
magnitude of early but not late eosinophil recruitment after antigen challenge 
(Rothenberg et al, 1997). CXCR4 is broadly expressed by cells of the immune and 
central nervous system and mediates the migration of resting leukocytes and 
hematopoietic progenitors in response to its ligand SDF-1 (Bleul et al, 1996) 
Essentially identical lethal defects were seen in mice deficient for either CXCR4 or 
SDF-1. These include severely reduced B lymphopoiesis, reduced myelopoiesis in 
bone marrow, defective formation of the large vessels supplying the gastrointestinal 
tract, as well as cardiac defects and abnormal cerebellar development (Zou et al, 
1998; Ma et al, 1998;Tachibana et al, 1998). In normal mice, CXCR5 is expressed 
on mature B cells and a subpopulation of T helper cells. CXCR5 knockout mice lack 
inguinal lymph nodes and possessed little or no normal Beyer's patches. Lymphocyte 




Chemokines in the pathogenesis of disease.
Chemokines and their receptors have been extensively implicated in several disease 
states including arthritis, multiple sclerosis, pneumonia (for review see Lukacas and 
Kunkel, 1998; Gerard and Rollins, 2001), psoriasis (Schroder et al, 1996), 
atherosclerosis (Boring et al, 1998; Gosling et al 1999) cancer and tumour 
progression (Schneider et al, 2001). Chemokine receptors themselves have been 
targeted as vehicles of cellular invasion by a wide variety of microorganisms. These 
range from the binding of malarial parasite Plasmodium vivax, to the Duffy blood 
group antigen (a promiscuous chemokine receptor on erythrocytes), to the platelet 
activating factor receptor (PAFR), which is a window of entry for Streptococcus 
pneumoniae. However, the most impressive use of cellular receptor entry by a 
pathogen has to be that of the human immunodeficiency virus type 1 (HIV-1).
An exciting series of discoveries was the finding that certain chemokine receptors act 
as coreceptors for the HIV-1 virus, and this was based on the observation that a 
number of chemokines, such as RANTES and SDF-1 can suppress the infection of T 
cells with M tropic and T tropic HIV-1 strains, respectively (Cocchi et al, 1995; Bleul 
et al, 1996; Lu et al, 1997). Attractive as it may be to hypothesise that inappropriate 
activation of the chemokine network is responsible for disease pathology, the only 
human disease for which there is indisputable evidence for an association with 
chemokine expression is HIV. In all other cases, roles for chemokines have been 
largely inferred from animal models. Figure 1.3 shows the five major categories of 
disease in which animal models show a role for chemokines and for which correlative 
data exist in humans.
Monocyte chemoattractant protein-1
Monocyte chemoattractant protein-1 (MCP-1) is a member of the CC subfamily of 
chemokines and serves to attract an activate monocytes both in vitro and in vivo 
(Oppenheim et al, 1991). The gene was originally identified from its mouse 
homologue, JE, cloned from PDGF-stimulated mouse 3T3 cells, and was the first 
PDGF-inducible gene to be described (Ping et al, 1996). The human homologue, 
gene name "small inducible cytokine A2" [SCYA2], encodes MCP-1 and this is 




Increased levels of MCP-1 and MIP-1a found in synovial tissue. Anti- 
MCP-1 and RANTES ameliorated AA in rats. DNA vaccines to CC 
chemokines inhibit progression of AA (Yousef et al, 2000)
Models: Autoimmune Arthritis (AA)
Multiple Sclerosis. High levels of RANTES, MIP-1a, and MCP-1 in 
inflammatory lesions. IP-10 and MIG recruit T cells to lesion. CCR5 
not necessary for development, but implicated in disease progression 
(Sorensen et al, 1999). MCP-1 and CCR2 viewed as crucial potential 
therapeutic targets (Simpson et al, 2000).
Models: Experimental allergic encephalitis (EAE). Humans.
Inflammation and Allergy
Infection
HIV. Evidence that individuals deficient in CCR5 cell surface 
expression (due to homozygous carriage of A32 deletion) conveys 
protection towards HIV virus.
CXCR4 shown to be coreceptor for T-tropic strains of HIV (Lu et al, 
1997).
AIDS: Although likely to be multifactoral, AIDS pathogenesis is 
thought to involve chemokine receptor expression. General 
broadening of viral tropism and variable degree of usage of additional 
chemokine receptors. Promotes virulence?
CCR5 and CCR3 implicated in AIDS dementia. (Littman, 1998) 
Models: SIV, Human.
Transplantation
Allograft. Heart and skin transplants. Neutrophil and monocyte-active 
chemokines, such as MIP-2, KC and MCP-1, respectively, appear 
around graft wounds. Alteration in chemokine profile develops several 
days after graft: Persistence of MCP-1 expression with CXCR3 ligands 
(IP-10, MIG, l-TAC), appearing along side CCR5 ligands (MIP-10 and 
RANTES).
Mice deficient in CCR2, CCR5 and CXCR4 all demonstrated an 
improved survival rate to grafts. Most impressive response to allografts 
was shown with CXCR3 knockout mice (Hancock et al, 2000).
Models: Heart allograft, sponge allografts
Asthma
Th2 cells have significant role in atopy and allergic disease. 
Correlation of this Th2 has been observed with expression of CCR4 
and CCR8, and therefore makes these receptors potential candidates 
for therapy. (D’Ambrosio et al, 1998)
In asthmatics, there is significant upregulation of eotaxin in bronchial 
mucosa, and CCR3 expression on infiltrating eosinophils. Th2 
cytokines (esp. IL-13) induce eotaxin, MCP-1 and MIP-1a in the lung. 
Some CC chemokines cause degranulation of basophils, thus 
exacerbating local inflammation.
Chemokine neutralisation studies and gene targeting only partially 
reduce recruitment - due to redundant action of leukocyte-attracting 
chemokines in the lung. (Gonzalo etal, 1998)
Models: Human, Rat asthma models.
Neoplasia
Chemokines recruit tumour-associated leukocytes, in particular MCP-1. 
Contribution to tumour angiogenesis in breast cancers through 
macrophage infiltration (MCP-1). CC and CXC chemokines and 
receptors expressed by many tumour cells.
IL-8 stimulates proliferation in lung cancers. (Gerard and Rollins, 2001) 
Chemokines have a role in malignant transformation?
Models: Rat tumour model
Vascular.
MCP-1 -CCR2 implicated in macrophage infiltration and foam cell 
accumulation in atherosclerosis MCP-1 _/‘ mice have 65-85% less 
arterial deposition in hypercholesterolaemia models (Gosling et al, 
1999). See text for further discussion.
Figure...The Role of Chemokines in Human Disease. Examples of disease states in which chemokines play a role in 
pathogenesis, including cardiovascular disease, allergic inflammatory disease, transplantation, neuroinflammation, cancer 
and infection.
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been assigned to 17q11.2-12 (Rollins et al, 1991), the locus to which, MCP-2, -3 and 
4 have since been mapped.
The monomeric structure of MCP-1 consists of an N-terminal loop and a (3-sheet 
overlaid by an a-helix at the C-terminal tail (Lubkowski et al, 1997). Originally isolated 
from the culture supernatants of human malignant tumour cells lines, MCP-1 was 
thought to be a tumour-derived chemotactic factor for monocytes, but has since been 
shown to attract T and B lymphocytes, NK cells, and mast cells. As well as 
leukocytes, MCP-1 has been reported to attract and activate fibroblasts (Gharaee- 
Kermani et al, 1996), smooth muscle cells (Shecter et al, 1997), astrocytes (Hessen 
et al, 1996), and cells within the hepatic system, such as stellate cells (Marra et al, 
1999;.
MCP-1 mediates its cellular effects primarily through its binding to CCR2, which 
exists in A and B forms that arise via alternative splicing of the carboxyl-terminal tail. 
Engagement of the CCR2B splice variant, in particular, has been reported to 
stimulate a number of signalling pathways in primary cells and cultured cell models 
(Turner et al, 1998; Mellado et al, 2001). A wide variety of cells, including 
monocytes, fibroblasts, vascular endothelial and smooth muscle cells produce MCP- 
1 in response to a number of inflammatory mediators These include platelet-derived 
growth factor (PDGF), tumour necrosis factor-a (TNF-a) and lipopolysaccharide 
(LPS) (Ping et al, 1996; Valente et al, 1998). In addition, due to the growing 
evidence that MCP-1 plays a role in atherogenesis, two well-documented 
atherogenic stimuli such as oxidised low density lipoproteins (Berliner et al, 1990) 
and fluid sheer stress (Shyy et al, 1994) directly induce MCP-1 expression.
Induced expression of MCP-1 by these mediators is thought to be heavily dependent 
on transcriptional regulation by NF-kB. To date, several signalling pathways have 
been shown to mediate NFkB activation, recruitment of transcriptional complexes 
and the subsequent production of MCP-1 (Alsonso et al, 1999; Goeber et al, 2001).
MCP-1 has been considered as an important cytokine in mediating monocyte tissue 
infiltration in a variety of inflammatory diseases. These include atherosclerosis 
(discussed later), alveolitis, idiopathic pulmonary fibrosis, viral meningitis, glomerular 
nephritis, ovarian carcinoma and human breast cancer (Koch et a l , 1992; Ransohoff 
et al, 1993; Luster, 1998; Ueno et al, 2000). Given the role of MCP-1 under 
pathophysiological conditions, therapeutic strategies directed at counteracting MCP-1
13
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are flourishing within the pharmaceutical world. For example, anti-MCP-1 gene 
therapy and strategies employing antagonists of MCP-1 have already been shown to 
have comprehensive inhibition of vascular remodelling and tumour growth in 
atherosclerosis and cancer, respectively (Salcedo et al, 2000; Egashira et al, 2001),
MCP-2, MCP-3 and MCP-4
Following the characterisation of MCP-1, subsequent years brought about the 
expansion of the MCP family. To date, there are four human members of this 
chemokine family (MCP-1 ,-2,-3 and -4), all with similar structural and functional 
characteristics, and immune cell targets. As far as MCP-2, -3 and -4 are concerned, 
information regarding their exact function is just beginning to be elucidated. MCP-1 
provides a suitable prototypical model for investigation into the role of other MCP 
family members in the immune response. (Van Damme, et al, 1992J. Sharing similar 
characteristics to that of MCP-3, MCP-2 recruits and activates a number of 
inflammatory cells, including monocytes, T lymphocytes, NK cells, basophils, mast 
cells and eosinophils, however, in contrast to MCP-3 it does not serve to activate 
eosinophils (Dahinden et al, 1994). Its ability to target a wide range of cells may be 
owed to it binding specificity and functional responses through receptors other than 
CCR2.
MCP-3 is a particularly interesting CC chemokine which was originally purified from 
osteosarcoma cell cultures, and was subsequently cloned in 1993 (Opendaker et a l . 
1993). Like MCP-2, it is a chemokine that is structurally and functionally related to 
MCP-1 (Sozzani et al, 1994), and the leukocyte receptors mediating MCP-3 
responses are thought to be fully defined. However, it is one of the most broad acting 
chemokines, potently inducing chemotaxis of monocytes, basophils, eosinophils and 
lymphocytes, as well as degranulation of basophils eosinophils and monocytes 
(Combadiere et al, 1995).
In 1997, Berkhout et al, described the characterisation of a novel human CC 
chemokine and tentatively named it monocyte chemotactic peptide-4 (MCP-4). This 
chemokine showed a high level of sequence homology with human MCP-1. Using 
chemokine binding studies as well as functional response data, the receptors 
involved in MCP-4 binding and signalling have since been identified as CCR2b, 
CCR3 and CCR9/D6 (Stellato ef al, 1997; Nibbs et al, 1997). ). Like MCP-1, 
expression of MCP-4 has been demonstrated in human atherosclerotic lesions and is
14
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known to induce monocyte chemotaxis in carotid and coronary arteries (Berkhout et 
al, 1997).
Table 1.2 The MCP chemokine family.





MCP-2 60% to MCP-1 and 3 






Antagonist for CD4/CCR5 HIV entry 
(Gong etal, 1997)





M. T. Bas. 
Eo.
Multiple sclerosis (McManus et al
1998). Coreceptor for HIV (Blanpain,
1999). Irritable bowel disease 
(Helwig, 2000)
MCP-4 62% MCP-1 CCR2, CCR3.D6 M, T, B,
Eo.
Atherosclerosis (Berkhout et al, 
1997). Asthma (Taha et al, 2001) 
Allergic Rhinitis (Kaplan, 2001)
(See page 9 for legend)
1.3 Chemokine Receptors
In 1990, the cloning of human formyl-peptide receptor was a significant milestone in 
the efforts to characterise chemokine receptors. Through subsequent sequence 
analysis and the deduction of three-dimensional structures, high-resolution images of 
many other receptors are now being revealed. Today, 18 different chemokine 
receptors are known with over 30 chemokines characterised (See Table 1.1).
Figure 1.4. Structure of a generic CC chemokine receptor.
Figure 1.4. Amino 
acid composition o 
CCR5 is shown her 
to depict the typica 








All of the receptors identified thus far are members of the seven-transmembrane 
spanning (7-TMS), G-protein-coupled (GPCR) family. Figure 1.4 shows a schematic 
representation of a generic chemokine receptor. Although showing similarities to 
many other 7-TMS receptors, chemokine receptors have exclusive structure 
signatures such as the DRYLAIV in the second intracellular loop. The major features 
of chemokine receptors are as outlined: They consist of approximately 350 amino 
acids; a short extracellular N-terminal tail (acidic) that contains glycosylation sites; 
an intracellular C-terminus which holds serine and threonine residues for signal 
regulation; seven a-helical transmembrane domains (3 intracellular and 3 
extracellular connecting loops); lightly conserved cysteines between loops 1 and 2 
connected by disulphide bridge (critical for general conformation of the molecule); G 
proteins coupled through C-terminus and possibly through the third intracellular loop 
(Murdoch and Finn, 2001). These receptors are, for the most part, able to couple to 
multiple G-protein isoforms, and it is this differential coupling to G proteins (and other 
downstream effectors) which confers a chemokines ability to elicit diverse 
physiological responses.
Chemokine receptor-coupling to G-proteins and 'Classical' Signalling Cascades. 
GPCRs act as specific detectors for extracellular signals to be transduced into the 
stimulation of G proteins. Instead of directly acting on the effector proteins, the 
receptor uses G proteins as an interface to provide an extra step for signal 
amplification. Thus, these receptors can stimulate multiple G proteins that, in turn, 
regulate multiple effector proteins.
As for all 7TM receptors, ligand binding shifts the equilibrium between active and 
inactive receptor conformations in favour of the active one, with consequent 
exchange of GDP for GTP. Activation of the G protein by GTP not only dissociates 
the G-protein subunits, but also uncouples the G protein from the receptor, which 
renders the latter with little affinity for the agonist (For review see Hamm, 1998). G 
proteins are made up of a, p and y subunits, with the a-subunits being the best 
characterised. Although there are multiple gene products encoding each a-subunit, 




Table 1.3. G protein a subunits
Class Members Toxin sensitivity Signal
Gs as, aotf CT TcAMP TCa2+
G| <Xi1, PTX IcAMP
00(2, aj3, PTX AVoltage
a0 - IC a2+
<*t1, at2. agust IcGMP
az IcGMP
Gq aq, an, a14, a15, a16 - Tip3, DAG
G12 ai2. a13 -
Table 1.3. G Protein sub-units. Several of the a subunits can be modified by ADP 
ribosylation; pertussis toxin (PTX) and cholera toxin (CT). Abbr. AC, adenyl cyclase; cGMP- 
PDE, cGMP-dependent phosphodiesterase; PLC, phosphatidylinositol-specific phospholipase 
C; DAG, diacylglycerol.
Upon GTP binding to the a subunit, the aGTP and the py subunits dissociate, and in 
this new active conformation, the Ga subunit can interact with effectors with 20-100- 
fold higher affinity than in their GDP bound form (Neer et al, 1995). The four major 
classes of Ga subunits have well known cellular targets, and with the advent of the 
yeast two-hybrid screening technology, molecular studies have uncovered new 
targets. For example, GAIP, (a Ga-interacting protein and a member of the RGS 
family of GTPase-activating proteins) was identified by this technique, and more 
recently, nucleobindin was found as a putative target of a-subunits (Lin et al, 1998). 
GPCR-mediated signal transduction, however, is not exclusive to a-subunit 
activation. Let us now consider the role of Gpy subunits;
Once Ga has dissociated from Gpy, the liberated Py is an activator of a multitude of 
proteins, and the list continues to increase (Clapham and Neer, 1997). The most 
clearly defined effects have been on classical second messengers such as 
phospholipase C-p2) G-protein-responsive ion channels and; the Rho family of 
GTPases. Over the past 5 years, more interest has been generated around the py- 
mediated activation of PI 3-kinase isoforms, and Gpy-stimulation of the MAP kinase 
pathway. It is quite apparent that these subunits are heavily influential on the control 
of both of these important signalling cascades. Given this rich and flourishing list of 




Chemokine Receptors and G proteins
There is considerable heterogeneity of chemokine receptors (and their isoforms) in 
their coupling to G protein subunits to initiate signalling pathways. Although it is 
considered that chemotaxis is dependent on coupling to the pertussis toxin sensitive 
Gai, it is becoming increasing clear that many chemokines demonstrate a limited 
heterogeneity (Kostensis etal, 1999).
In terms of migration, the Gai subunit per se does not appear necessary. The 
essential step is the release of (fy subunits from the Grcoupled receptor. Only (3y- 
subunits released from Grcoupled receptors have been shown to mediate 
chemotaxis, and not those from Gs or Gq. This has been further investigated by an 
elegant study by Neptune et al (1997), using receptors that do not bind chemokines 
or induce cell movement. These receptors (e.g. opioid) stimulated chemotaxis via Gj 
proteins when expressed on migration-competent cells. In contrast, neither Gs nor 
Gq-coupled receptors stimulated chemotaxis even when expressed in the same 
migration competent cells. These findings have been further supported by cellular 
distribution experiments using GFP-tagged py-subunits in Discoideum (Jin et al,
2000). Taken together these observations demonstrate that the release of py is a 
crucial step in chemotaxis, but accompaniment by other signals generated by 
chemokine receptor activation is required.
The ability of chemokine receptors to couple to these multiple G-protein isoforms is, 
in many cases, facilitated by the DRYLAIVH motif in the second intracellular loop 
(Wu et al, 1993),. In addition, structural and mutational studies have implied that 
receptor-G-protein interactions are modulated by other intracellular domains 
including the second and third intracellular loops (Samson et al, 1997; Alkhatib et al, 
1997; Zhou et al, 2001) and the cytoplasmic tail. Many strategies employing 
recombinant DNA techniques have been used to elucidate the structure-function 
relationship of chemokine receptors. Construction of hybrid chimeric receptors, are a 
useful starting point for identifying the domains involved in ligand binding and 
signalling. Site-directed mutagenesis may be used to further delineate functional 
domains through point specific substitutions or deletions (Monteclaro et al, 1997)
It is well established that for some GPCRs, such as the (3-adrenergic receptor, 
palmitoylation of cysteine residues in their cytoplasmic tails can modulate their 
biological activities. Palmitoylation of GPCRs has been shown to affect different
18
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functions of the receptors, such as membrane targeting, signalling properties and 
recycling. Although it is widely accepted that most (but not all) chemokine receptors 
display cysteines in their cytoplasmic tails, it is only in that last year that 
palmitoylation has a role in chemokine receptor function. Blanpain et al (2001) have 
demonstrated that this biochemical modification of cysteine residues is indeed 
necessary to allow efficient trafficking of CC-chemokine receptor 5 (CCR5). Whether 
these functions can be generalised to the palmitoylation of other chemokine 
receptors on other leukocytes remains to be determined.
CC chemokine receptor 2 (CCR2)
Two independent groups simultaneously cloned the MCP-1 receptor, CCR2. CCR2B 
was identified by Yamagami et al, who showed that it encodes a protein of 360 amino 
acids and shares a high degree of similarity (56%) with CCR1. Cloning by Charo and 
co-workers culminated in the production of two positive clones corresponding to two 
splice variants of CCR2: CCR2A and CCR2B. Both isoforms have identical 5’ 
untranslated and transmembrane regions, but have dissimilarities in the alternatively 
spliced carboy-terminus (Charo etal, 1994). This alternative splicing renders CCR2B 
with 36% homology to the corresponding region of CCR1, however the carboxyl tail 
of CCR2A bears no similarities to any other known chemokine receptor.
Despite years of intensive research, the process by which CCR2 is activated by its 
ligands remains a matter of contention. More detailed analyses of the ligand binding 
domains of CXCR1 and CXCR2 have suggested that multiple regions of the receptor 
are required to initiate functional interaction. Similarly, several groups have shown 
that the interaction of MCP-1 with CCR2 involves multiple domains. In particular, the 
first extracellular loop is thought to contain critical microdomains for ligand binding 
(Han et al, 1999) which is in agreement with a hypothetical model that predicts a two- 
step mechanism for CCR2 activation (Figure 1.5). In this model, MCP-1 binds first to 
the amino terminal tail with high affinity before it interacts in the second step (with 
relatively low affinity) to distal extracellular domains (Monteclaro and Charo, 1996). 
As a general rule, the N-terminus and extracellular loops of these receptors have 
been implicated in peptide agonist interactions, and similarly, the C-terminus and the 
intracellular domains co-operate to bind G proteins and other downstream effectors 
(Bockaert and Pin, 1999).
A limited heterogeneity is demonstrated in the coupling of CCR2 to G proteins. For 
example, although CCR2A and CCR2B can couple to the Gj-Gpy-PLCp2, these
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isoforms exhibit an interesting specificity in their coupling to the a subunits of the Gq 
class: CCR2B couples to both Goc-i6 and Ga14) whereas CCR2A cannot couple to 
either (Kuang et al, 1996). Similar observations are seen in the coupling of SDF-1 
and RANTES to both pertussis toxin sensitive Gj (Hesselgesser et al, 1998; Bacon et 
al, 1995) and pertussis toxin-insensitive Gq members of the G protein family (Bleul et 
al, 1996).
As suggested for other chemokine receptors, it has also been proposed that CCR2B 
undergoes homo- and hetero-dimerisation on ligand binding. A number of different 
approaches have been used to demonstrate how a complex of at least two receptors 
are required to induce a functional response. Oligodimerisation in the CCR2 model 
has been clearly demonstrated, and is thought to induce tyrosine phosphorylation 
leading to JAK kinase activation, in addition to possible recruitment of Src family 
kinases, and STAT transcription factors (Mellado et al, 1998).








The hypothetical ‘two-step, two-site’ model of CCR2 activation. MCP-1 receptor 
activation proposed by Monteclaro and Charo (1997). Initially, the MCP-1 binds with high 
affinity to 30-35 critical residues at the N-terminal extension of CCR2. The ‘pseudo-tethered’ 




Hetero-dimerisation between chemokine receptors has also shown to have functional 
relevance in agreement with the observations of opioid receptors. There is some 
biochemical and pharmacological evidence to show that hetero-dimerisation of 
GPCRs causes synergistic agonist binding and potentiates signalling. With respect 
to CCR2, hetero-dimerisation not only has a functional significance, but may also 
provide aetiological significance in diseases associated with this receptor.
A polymorphism reported for the CCR2 receptor, whereby the Val64 is replaced by 
lie (CCR2V64I) is associated with a 2-4 year delay in progression to acquired 
immunodeficiency syndrome (AIDS) (Lee et al, 1998). In comparison to other 
chemokine receptors, relatively few viral strains are known to use CCR2 as a 
coreceptor to infect cells. Other groups have shown that the mechanism underlying 
this protective effect may be the ability of the mutant CCR2Val64 to hetero-dimerise 
with CCR5 and/or CXCR4 (Mellado et al, 1999). More recently, this group have 
shown that hetero-dimerisation of CCR2 not only induces more efficient biological 
responses in response to MCP-1, but associates with specific signalling pathways, 
such as recruitment of Gq/n, a pertussis toxin insensitive G protein.
CCR2: A Key Player in Atherosclerosis
The chronic inflammatory response that typifies atherosclerosis comprises the 
recruitment of myeloid cells and the transmigration, development of low-density 
lipoprotein (LDL)-laden macrophages and T cells that contribute to the formation 
atherosclerotic lesions. For years, MCP-1 has been implicated in monocyte 
extravasation and plaque formation since high levels are consistently found in 
macrophage-rich areas of atherosclerotic vasculature (Nelken et al, 1991). The most 
confounding evidence has come from in vivo studies using MCP-1-deficient mice 
which overproduce apolipoprotein (ApoB/MCP-1'7'), and are therefore susceptible to 
atherosclerosis (Gosling et al, 1999). These mice were protected from plaque 
formation even when fed on a high-fat diet, and this is highly suggestive that MCP-1 
expression is crucial to the development of atherosclerotic plaques. Furthermore, 
mice that were defective in both MCP-1 and LDL receptors had over 80% less 
deposition of lipids in their arteries compared to the control mice. (Gu et al, 1998) 
These genetic data were further supported by studies using CCR2 knockout mice 
predisposed to atherosclerosis (ApoE/CCR2'/ ). Interestingly, the double knockout 
mice had 50% fewer lesions compared to the controls, indicating that CCR2 is the 
key receptor involved in the pathogenesis of this disease (Boring et al, 1998). 
However, it should be noted that lesion formation is not completely abrogated in
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these models, and so, another recruiting agent is thought to be in operation. (For 
review of in vivo studies into the recruitment properties of MCP-1/CCR2 in 
atherosclerosis see Peters and Charo, 2001).
CCR11 -  An alternative to CCR2?
The orphan receptor PPR1 was originally isolated from bovine papillary tissue 
although was found to have striking structural similarities to CC chemokine receptor 
(Matsuoka et al, 1993). Further analysis demonstrated that the human homologue of 
PPR1 did in fact bind members of the MCP family (MCP-1, -2, -3, -4 and eotaxin) 
with high affinity and also mediated functional responses to MCP-1, -2 and -4. PPR1 
has since been designated CCR11 -  a functional receptor to the MCP-1 family. 
(Schweickart et al, 2000). The characterisation of this novel receptor opened up a 
new concept in the MCP research community.
Unlike other chemokine receptors, CCR11 is poorly expressed on lymphoid or 
myeloid cells, but shows patterns of expression in cells of vascular tissues. Given 
that MCP-1 and CCR2 are associated with atherosclerosis development, it is 
reasonable to assume that this may be accompanied by CCR11 -mediated events. 
The result of knockout studies whereby gene mutations are not lethal and result in 
relatively mild phenotypes may be explained by the complex redundancy of MCP 
chemokines in the vascular environment.
1.4 Signalling from GPCRs
The phosphoinositide-specific phospholipases (PLCs) play important roles in cellular 
metabolism including the biosynthesis and degradation of membrane lipids. The 
catalysis of minor lipid phosphatidyllnositol(4,5)P2 by a PLC is one of the first key 
events by which more than 100 signalling effectors are known to regulate their target 
cells. The hydrolysis culminates in two important secondary messengers; 
Diacylglycerol (DAG) and inositol-1,4,5-trisphopshate (lnsP3). Like the other 
phospholipases, PLC exists in multiple isoforms; PLC-p, PLC-y and PLC-8 (for review 
see Rhee and Bae, 1997). Of these isoforms, only PLC-p appears to be sensitive to 
GPCR-activation.
Stimulation rapidly activates PLC-fc and PLC-fc isoenzymes, which can occur 
through the GTP-bound a-subunits of the Gq class of heterotrimeric G proteins or by
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the Gpy subunits (Exton et al, 1997; Zhang and Neer et al, 2001). The PLC-p 
enzymes also exhibit differential sensitivities to G protein subunits, and this may 
contribute to the diversity in the nature and magnitude of the enzyme responses 
observed. A number of recent studies have provided an idea of domain organisation 
of PLCp2 and have been able to characterise structure, catalysis and cellular 
localisation of this enzyme (reviewed in Katan, 1998). All of the ten mammalian PLC 
isoenzymes identified to date are; 1) modular proteins, 2) contain a pleckstrin 
homology (PH) domain, and 3) a catalytic domain and a C2 domain.
Calcium signalling
The PLC product, lnsP3, subsequently binds to receptors on intracellular calcium 
stores, in particular the endoplasmic reticulum, and induces calcium mobilisation. 
This pathway has commonly been used to test the responses of ligands (e.g. 
chemokines, hormones) to their receptors (Baggiolini et al, 1997). Increases of 
[Ca2+] regulate a diverse range of cellular processes ranging from fertilisation to cell 
death (reviewed in Berridge et al, 1999). Calcium ions are utilised as intracellular 
signalling molecules to control many biological processes and these signals are 
conveyed by calcium sensors such as calmodulin (CAM) and troponin C (TnC). 
These proteins are responsible for detecting the Ca2+ rise and transducing the 
information into specific cellular responses.
Protein Kinase C
In hand with lnsP3, the other product of Ptdlns(4,5)P2 hydrolysis by PLC is 
diacylglycerol (DAG), which can activate particular isotypes of protein kinase C 
(PKC). PKC, a major target for tumour promoting phorbol esters, and has been 
implicated as having a major role in both short term and long term regulation of 
cellular responses including changes in cell morphology, ion fluxes, differentiation, 
and proliferation (Exton, 1997). Although PKC is recognised as an important enzyme 
in many signalling processes, the downstream effects remain poorly defined. The 
present family of 11 PKC isotypes (a, pi, pll, y, 8, s, 0, xlX and p) are grouped on 
the basis their structural and functional considerations (Figure 1.6). Most PKC 
isotypes display typical DAG (or phorbol ester) dependence for their kinase activity, 
with only the atypical isotypes (aPKC) being insensitive.
PKC is regulated by two sequential, and equally important mechanisms: (1) 
phosphorylation triggered by the recently discovered 3-phosphoinositide-dependent
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kinase (PDK)-1 and; (2) binding to the lipid second messenger DAG (Le Good et al, 
1998; Chou et al, 1998; Parekh et al, 2000). Both of these mechanisms are 
important in regulating the structure, subcellular localisation, and function of PKC 
(Dempsey et al, 2000). Activation of PKC isoenzymes is stimulated by almost every 
cell surface receptor and is therefore not a characteristic event exclusive to GPCR- 
induced signal transduction. However, PKC activation is required for biological 
functions triggered by GPCRs, such as respiratory burst in neutrophiis and ceil 
migration (Li et al, 2000) and is involved in receptor phosphorylation and consequent 





Figure 1.6 PKC Signal transduction pathway exhibits heterogeneity
Isoenzymes can be divided into subgroups based on structure and cofactor requirements: 
conventional (a, ft, pH, y), novel (8, e, r\, 0), atypical (£, i) and the recently described (p, v).
Phospholipase D
Phospholipase D (PLD) is now recognised as a vital component of signal 
transduction pathways, vesicular trafficking (Jones et al, 1999; Exton, 1999), and cell 
transformation (Ohguchi et al, 1999). PLD is a ubiquitous enzyme that hydrolyses 
membrane phospholipids especially phosphatidylcholine (PC) to generate 
phosphatidic acid (PA) and choline. Choline is not thought to serve as a second 
messenger, since it remains in high concentrations in resting cells (McPhail, 1999). 
PA, however, has been implicated as a biologically active molecule and can be 
further metabolised by PA-phosphohydrolase to form DAG, a protein kinase C 
activator. PLD attacks the phospholipid substrate to generate a transient 
phosphatidyl-PLD intermediate. With water as an acceptor, PA is generated; 
however, in the presence of a primary alcohol PLD preferentially catalyses a unique
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transphosphatidylation reaction generating phosphatidyl-alcohol (Figure 1.7). The 
production of the phosphatidyl-alcohol has been extremely useful for the detection of 
PLD activation since unlike PA (which can also be produced by DAG kinase and by 
acylation of glycerol-3-phosphate) a phosphatidyl-alcohol is uniquely formed by PLD. 
Unlike PA that can be further metabolised to DAG and lyso-PA, a phosphatidyl- 
alcohol remains metabolically stable. (Liscovitch et al, 1999).
Figure 1.7 Product of PLD catalysis depends on acceptor 
molecules







A growing body of evidence is now emerging that is beginning to establish potential 
links between phosphatidylinositol 3-kinase (PI3K) and PLD. This has risen form the 
observation that at least three Ca2+-dependent PLD isoenzymes may exist with 
specificity for Ptdlns(3,4,5)P3) the major lipid product of PI3K (Ching et al 1999J. 
Also, activation of small GTP-binding protein, Ras, via PI3K is thought to lead to the 
activation of the Ras effector molecule Ral, which itself has been implicated in PLD 
activation (Jiang et al, 1995). The most interesting link is that emerging between 
PI3K and members of the ARF family of proteins (Frohman et al, 1996; De Camilli et 
al, 1996). ARFs (consisting of ARF1-6) cycle between inactive GDP- and active 
GTP- states which are regulated by ARF-GEFs (ARF-guanine nucleotide exchange 
factors), and ARF GTPase activating proteins (ARF-GAPs).
It is the family of ARF-GEFs (including GRP-1, ARNO and cytohesin-1) and their 
interactions with PI3K that has generated such interest. ARF-GEFs contain a PH 
domain that binds to Ptdlns (3,4,5)P3 in preference to other phosphoinositide lipids 
(Ching et al, 1999), and facilitate its own translocation to the cell membrane. The 
use advent of green fluorescent protein (GFP) imaging of ARF-GEF constructs has 
helped to characterise the PI3K-dependent regulation of ARFs and subsequent PLD 
activation (Venkateswarlu eta l, 1998, Hmama et al, 1999).
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1.5 Phosphatidvlinositol 3-kinase- Dependent Signalling Cascades 
The PI3-kinase family
Membrane lipids do not only have a structural role in the mammalian cell, but are 
also implicated in receptor stimulated signalling. The 3-phosphorylated inositol lipids 
assume roles as second messengers by interacting with a multitude of cellular 
proteins. The generation of these lipids and their subsequent impact of signalling 
pathways influence many fundamental cellular activities. The term 'PI3-kinase' is 
now applied to a rapidly growing family of proteins that catalyse the conversion of 
Ptdlns, Ptdlns(4)P and Ptdlns(4,5)P2 to 3-phosphorylated lipids, Ptdlns(3)P, 
Ptdlns(3,4)P2 and Ptdlns(3,4,5)P3, respectively, by phosphorylating the D-3 position 
of the inositol ring (Figure 1.8). Ptdlns(3)P is constitutively present in eukaryotic 
cells, and its levels are unaltered upon stimulation. Ptdlns(3,4)P2 and 
Ptdlns(3,4,5)P3, on the other hand, are almost absent from resting cells, but cellular 
stimulation with a variety of ligands results in a marked rise in intracellular 
concentration. This is highly indicative of a likely second messenger function 
(reviewed in Stephens etal, 1993).
The multiple isoforms of PI3Ks can be divided into three classes on the basis of their 
in vitro substrate specificity, structure, and likely mode of regulation. All PI3K 
catalytic subunits share a homologous region that consists of a catalytic core domain 
(HR1; homologous region 1) linked to HR2 (know as the PI kinase homology domain) 
and a C2 domain.
The Class I PI3-Ks
Class I PI3Ks are heterodimers consisting of a catalytic subunit and a regulatory 
subunit. In vitro these PI3Ks phosphorylate and utilise Ptdlns, Ptdlns(4)P, and 
Ptdlns(4,5)P2 as substrates. However, in intact cells, Ptdlns(4,5)P2 appears to be the 
substrate of choice. This class of enzymes can further be divided into class 1A and 
class 1B, which signal downstream of tyrosine kinases and G protein-coupled 
receptors, respectively. All mammalian PI3Ks from this class interact with active 
GTP-bound Ras, although the role of this interaction in PI3K signalling is not 
understood. Numerous studies have shown that all members of this class form 




Figure 1.8 Structure of Phosphatidylinositol and the cycle of phospholipid 
generation by the action of PI 3-kinases
A) Structure of PI
Fatty Acyl Side Chains Inositol head grou
B) Synthesis of D-3 phosphorylated 
lipids
Ptdlns(3,4)P3 4-PTPase Ptdlns(3,4,5)P3 5-PTPase
Ptdlns(3)P Ptdlns(3,4)P2 Ptdlns(3,4,5)P





<   1 <
Ptdlns  ► Ptdlns(4)P
Ptdlns (4,5)P2 5-PTPase
 ► Ptdlns(4,5)P
Ptdlns 4-kinase Ptdlns(4)P 5-kinase
Figure 1.8. A) The positions 3, 4, 5 indicated in red signify those which can receive a 
phosphate group, however, only position 3 phosphorylation occurs through PI3Ks. The enzyme 
activity of PI3K phosphorylates the 3’-hydroxyl group on the inositol ring of Ptdlns (or indeed 
that of Ptdlns(4)P and Ptdlns(4,5)P2) by the transfer of the terminal phosphate group from ATP. 
B) The tightly regulated cycling of D-3 phosphoinositide lipids under the control of PI 3-kinases, 




Class 1A PI3Ks are 100-130 kDa proteins that interact with adaptor subunits 
containing Src homology-2 (SH2) domains. Activation of tyrosine kinases in 
receptors and receptor-associated adaptors results in the generation of 
phosphorylated tyrosine residues. It is to these residues, preferably in a Y(P)xxM 
motif (where x is any amino acid), that the afore mentioned SH2 domains on the 
adaptor subunits are likeiy to bind. This phosphotyrosine binding is thought to 
facilitate the translocation of the PI3K from the cytosol to the membranes, ensuring 
proximity to their lipid substrates and small molecular weight G-proteins.
Under resting conditions, p85 serves to stabilise p110 protein and inhibit kinase 
activity. This inhibitory effect is alleviated by binding of SH2 domains of p85 to 
tyrosine phosphorylated peptide, receptors or linker molecules (Cuevas et al. 2001). 
Mechanisms for the recruitment of PI3K not involving tyrosine phosphorylation events 
have also been reported (Prasad et al, 1993). Most p85 gene products also include 
a Src-homology-3 (SH3) domain, two proline rich domains and a break point cluster 
(BCR)-homology domain (BH) all of which are thought to be implicated protein- 
protein interactions (Wymann and Pirola, 1998).
To date, eight different adaptor subunits for class 1A catalytic subunits have been 
described (seven in mammals and one in Drosophila) which are generated by 
expression and alternative splicing of three separate genes, namely p85a, p85p and 
p55y. All of which make functional complexes with the p110 catalytic subunit. 
Mammals have three class 1A p110 isoforms, p110a, p and 8, all encoded by 
different genes. p110a and p are ubiquitously expressed in mammalian tissue, in 
contrast to p1105 that is mainly found in leukocytes (Vanhaesebroeck et al. 1997). 
So far, there is no evidence of preferential coupling between any of PI3K adaptor 
molecules and p110 catalytic subunits, however, it is reasonable to assume that 
differences in function or regulation may exist due to tissue specificity.
At least one of these class1A PI3K isoforms is expressed in all of the mammalian cell 
types studied, and engagement of every receptor known to induce tyrosine kinase 
activity is shown to activate class 1A PI3K This activity can be induced by receptors 
with intrinsic tyrosine kinase activity or non-receptor tyrosine kinases, such as Src- 
family kinases (reviewed in wymann and Pirola, 1998).
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The Class 1B PI3Ks
Several years ago, it was shown that haematopoietic cells possess a PI3K that can 
be directly stimulated by Gpy heterodimers. This distinct lipid kinase, now referred to 
as PI3-kinase-y, is the only characterised member of the class 1B G protein-activated 
PI3K, and consists of a unique 101kDa regulatory subunit and a distinct 110kDa 
called p110y. Unlike the class 1A PI3Ks, the p110y subunit does not have a site that 
binds to the regulatory p85, but instead a Ras-GAP homology region, which may fold 
to form a PH domain, that contributes to form a common G(fy effector region 
(Stoyanov et al, 1995). Direct activation of the p101/p110y PI3K is then mediated by 
the Gpy subunit. Although several reports show that the activation of p110y are 
substantially amplified by the presence of p101, some groups suggest that p110y 
alone can be catalytically activated by Gpy and have clear biological effects 
(Stephens et al, 1994). Therefore, the function of the p101 non-catalytic subunit of 
PI3K-y has yet to be identified.
The physiological roles of PI3Ky have been clearly defined particularly in the context 
of linking GPCR stimulation to the formation of Ptdlns(3,4,5)P3 and the subsequent 
activation of other downstream effectors such as PKB, ribosomal protein S6 kinase, 
and MAPKs. Several studies based on the generation of p110y null mice have shown 
this enzymes' impact on cellular signalling to be crucial for several biological 
inflammatory responses such as thymocyte development, T cell activation, neutrophil 
migration and oxidative burst (Okada etal, 1994, Sasakdi etal, 2000).
The dynamic nature of class I PI3K signalling seem to be achieved by a second 
enzymatic function, i.e., protein-serine kinase activity. Bondeva et al, 1998 reported 
that cellular signalling bifurcates at the level of PI3Ky. Whereas 
phosphatidylinositides target PKB through the lipid kinase activity of PI3K-y, the 
protein kinase ability of this enzyme concurrently phosphorylates the extracellular 
signal regulated kinase/mitogen-activated protein kinase pathway (ERK/MAPK). In 
this respect, reports have suggested that the p101 subunit was critical for supporting 
p110y-induced PKB and c-Jun amino terminal kinase activation (JNK), but had little 
consequence on the ERK/MAPK activation. This is highly suggestive that p101 may 




Class II PI3K include PI3K-C2a (mcpk, p170), PI3K-C20 (HsC2-PI3K) and PI3K-C2y, 
and are distinguished from other PI3K isoenzymes by the presence of two tandem 
domains at their carboxyl terminus: the Phox (PX) and the C2 domains. The PI3K- 
C2a PX domain itself has been shown to associate selectively with liposomes 
containing Ptdlns(4,5)P2 (Xu et al., 2001). The second important feature is the C2 
domain - a phospholipid-binding molecule that can confer a Ca2+ sensitivity. The role 
of this motif is also not understood, although the diversity in biochemical function 
mediated by C2 domains has been clearly demonstrated. C2 domains of 
synaptotagmin, protein kinase C and phospholipase C can bind a variety of ligands, 
including Ca2+, phospholipids, inositol polyphosphates and intracellular proteins 
(Ponting and Parker, 1996).
The nature of receptor-linked activation pathways to these isoenzymes is only 
recently becoming elucidated. PI3K-C2a plays a signalling role downstream of both 
the receptor for the CC chemokine MCP-1 (Turner et al, 1998) and the insulin 
receptor (Brown et al, 1999), and engagement of epidermal growth factor and 
platelet-derived growth factor receptors result in activation of both PI3K-C2a and 
PI3K-C2P (Arcaro et al, 2001). The observation that PI3K-C2a is concentrated in the 
trans-golgi-network and is present in clathrin-coated vesicles also suggests that this 
PI3K may play a role in regulating adaptor protein function (Domin et al, 2000)
Studies of the murine (Virbasius et al, 1996) and human enzymes (Domin et al ,
1997) show their in vitro substrate specificity is restricted to PI and PI(4)P, and that 
they cannot utilise PI(4,5)P2. However, it should be noted that PI3K-C2a might have 
a different substrate specificity in intact cells to that observed under in vitro 
conditions. Interesting, of all the mammalian enzymes, PI3K-C2a remains the most 
refractory to PI3K inhibitor, wortmannin (Domin and Waterfield, 1997).
Class III PI3Ks
The classes III PI3Ks are homologous to the Vps34p, the only PI3K identified in 
yeast. These enzymes are restricted in their substrate specificity in that they only 
phosphorylate Ptdlns, and are probably responsible for the majority of Ptd(3)P in 
cells. Since the cellular levels remain constant, and are not altered upon cellular 
stimulation. It is assumed that the involvement of class III PI3K in intracellular 
trafficking is not a product of cellular stimulation (Reviewed in Odorizzi et al, 2000).
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1.5.2 The Phosphoinositide Lipids Binding Molecules
It is generally assumed PI3K exerts its biological effects by promoting the localisation 
or activity of other downstream molecules. This has been further supported by the 
characterisation of protein motifs that are known to specifically bind lipids. To focus 
the discussion of 3-PI targets, we now consider three structurally distinct Pl-binding 
domains (FYVE, PX, and Pleckstrin homology) for which the structure and nature of 
interaction has been defined at the molecular level.
Pleckstrin Homology Domains
Pleckstrin homology (PH) domains are globular protein domains of around 100 amino 
acids that can bind phospholipids. PH domains and the structurally related 
phosphotyrosyl binding (PTB) domains are present in many signalling proteins, such 
as kinases, phospholipases, and adaptor proteins. The core PH domain structure is 
made up of two p-sheets (of four and three anti-parallel p-strands), that is capped on 
one side by a C-terminal a-helix. The inositol head group of the ligand becomes 
sandwiched between the loops at the end of the barrel distal from the C-terminal a- 
helix (Lemmon and Ferguson, 2000). The relevance of phosphoinositide binding to 
these domains is unclear, however, several of these motifs have now been shown to 
bind to Ptdlns(4,5)P2, lns(1,4,5)P3 and products of PI3-K, such as Ptdlns(3,4)P2 and 
Ptdlns(3,4,5)P3 (Rameh et al, 1995, Saito et al, 2001). The PH domains of the serine 
threonine kinase PKB and phosphoinositide-dependent kinase-1 (PDK1), guanine 
nucleotide exchange factors (GEFs), Bruton's tyrosine kinase (Btk) family kinases 
and phospholipase C provide examples of this.
A sequence motif for PI3-K product binding by PH domains
Consensus (j>xKx Gx *K* x xRxRxF
A R K L
S
P
In the above consensus sequence represents an amino acid with a hydrophobic side 




Table 1.4 Predicted 3’ Phosphoinositide binding preferences. PH domain- 
containing proteins








Transient recruitment to Longer-lived membrane association
the membrane
The FYVE Domain
In 1998, several groups reported the identification of a PI(3)P-binding molecule - the 
FYVE domain - that is found in various proteins including some that are implicated in 
endosomal function. The FYVE domain of human early endosome autoantigen 1 
(EEA1) was first identified as a motif responsible for binding exclusively to Ptd(3)lnsP 
(Patki et al, 1998), and now more than 30 mammalian protein containing this motif 
have been identified. Instead of a targeting role, it seems that the FYVE domains 
may execute a regulatory role on the functional activities of several proteins, possibly 
through conformational changes upon their interaction with Ptdlns(3)P (Xu et al,
2001).
The Phox Domain
The Phox Homology (PX) domain, a 125 residue module, has been observed in 
numerous human and yeast proteins including kinesins, phospholipases PI3Ks and 
SNAREs (Cheever et al., 2001). The recent establishment that the PX domain 
interacts with Ptdlns(3)P and other phosphoinositides suggests another mechanism 
by which phosphoinositides regulate cellular events. Most proteins that contain the 
PX domain are involved in membrane trafficking (e.g. PLD) cytoskeletal organisation 






function of this domain remains unclear. The conservation of key structural and 
binding site residues across the diverse PX family does, however, indicate a shared 
fold and phosphatidylinositol recognition function.
1.5.3 Downstream Effectors of PI3K.
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Figure 1.10. The cellular effects of PI3-Kinase. Summary of the best-characterised
pathways initiated by the major lipid products of PI 3-kinase. Asterisked proteins have a PH 




How D-3 lipids transduce the effects of agonists of PI3K was unclear until the recent 
discovery that several protein kinases become activated upon exposure to these 
molecules. Some 15 years after the identification of the AKT8 retrovirus the cellular 
homologue of v-Akt was cloned by several groups and found to be a 57kD a protein 
serine threonine kinase, currently referred to as Akt or protein kinase B (PKB) (Coffer 
and Woodgett, 1991). Analysis of the PKB sequence reveals a multi-domain protein, 
and includes an N-terminal PH domain assumed to be responsible for binding PI-3P 
lipids (Haslam etal, 1993).
Although there is still debate about the precise role and nature of PI-3P lipids in the 
activation of PKB, it is clear that most growth factor/cytokine-signalling pathways 
require PI-3P lipid formation for PKB activation. Activation of PKB is accompanied 
by phosphorylation, and this appears to be the required step in its induction. This 
may occur by transphosphorylation by other kinases or by autophosphorylation 
following activation. For PKBa, the issue has been resolved by the identification of 
two crucial phosphorylation sites; Thr308 and Ser473, and this suggests that there is 
dual regulation. Sufficient levels of PI-3P lipids promote the recruitment of all the 
required machinery to the plasma membrane, thus, placing the PKB multimer in the 
correct proximity for interactions with 'third party' kinases. The enzymes specifically 
identified for the phosphorylation Thr308 and Ser473 were tentatively named 
Ptdlns(3,4,5)P3-dependent kinase-1 and -2 (PDK-1 and 2), respectively, and were 
thought likely to be regulated in an analogous manner since phosphorylation of the 
two sites on PKB is tightly co-ordinated (for review see Coffer et al, 1998; Lawlor and 
Alessi, 2001).
Recent work indicates that PDK2 may in fact be a ‘modified’ PDK1 since the kinase 
domain of PDK-1 was found to bind to carboxy-terminal residues of PKC-related 
kinase-2 (PRK2), termed the ‘PDK-1 interacting fragment’ (PIF). The interaction has 
been shown to occur through a 24-amino acid fragment of PIF that encompasses the 
hydrophobic motif of PRK2 and binds to a pocket on the kinase domain of PDK1 -the 
‘PIF-binding pocket’ (Biondi et al, 2001). In the presence of PIF, PDK-1 and 
Ptdlns(3,4,5)P3, PKB was shown to be phosphorylated at Thr308 and Ser473 
(Balendran et al, 1999). In the light of this research, it is unclear whether the activity 
of PKB comprises PDK1 complexed to a ‘PIF-like’ protein and/or PDK1 complexed to 
a distinct PDK2. It has since been suggested that following phosphorylation of PKB 
at Thr308, PKB autophosphorylates itself at Ser473. However, the finding that Ser473 is
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phosphorylated in PDK1-deficient ES cells in the absence of Thr308 argues against 
this possibility (Williams et al, 2000).
Amino acid sequences very similar to those surrounding Thr308 and Ser473 in PKB 
are conserved in all members of the ‘AGC’ Ser/Thr kinases. This group of enzymes 
includes PKA, PKG, PKC, and PKB isoforms, in addition to P70S6K, p90-ribosomal 
kinase, and the serum- and glucocorticoid-induced protein kinase (SGK). These 
enzymes mediate many of the cellular effects of extracellular agonists by 
phosphorylating key regulatory proteins, and like PKB, are modulated by PDK-1 
phosphorylation (Vanhaesebroeck and Waterfield, 1999).
Activated PKB promotes cell survival by phosphorylating and inactivating several 
apoptosis-mediating proteins such as BAD, caspase-9 and forkhead transcription 
factor (Brunet et al, 1999). Until recently, the molecular mechanisms of induction of 
apoptosis have been ill understood. However, the use of PI3K inhibitors has 
implicated this pathway in the balance between cell survival and apoptosis (Yoa and 
Cooper, 1995; Burgering and Coffer, 1995). Such studies have led to the 
investigation of the role of PKB in the regulation of these processes. Several groups 
also have provided the link between PKB and intracellular glucose transport, 
glycolysis, protein synthesis, and perhaps most interestingly, the synthesis of 
glycogen via GSK-3 (Sheppard et al, 1996).
Glycogen synthase kinase-3
The principle substrate of PKB is glycogen synthase kinase a/p (GSK-3) which was 
initially identified as the enzyme that regulates glycogen synthesis in response to 
insulin (Cross et al, 1995). Initially GSK-3 was shown to phosphorylate sites in 
glycogen synthase, which are specifically dephosphorylated when insulin induces 
synthase activation that ultimately leads to glycogen synthesis. A more general role 
for GSK-3 is suggested in its growing number of substrates, including several 
transcription factors and translation initiation factors. In addition, GSK-3 has been 
implicated in the regulation of cell fate in Dictyostelium (Harwood et al, 1995) and is a 
component of the Wnt signalling pathway required for Drosophila (Sigfried et al,
1992) and Xenopus development (Dominguez et al, 1995). Thus, GSK-3 appears to 
play multiple roles in cell regulation.
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Several pathways have been proposed to regulate GSK-3 phosphorylation (including 
growth factor-induced PKC activation, p90Rsk activation, and p70S6-kinase), 
however, the pathway regulated by PI3K-dependent PKB remains the best 
characterised (Weeren etal, 1998). Although GSK-3 can be directly phosphorylated 
and inactivated by PKB, it must be remembered that GSK-3 can also be activated 
independently of this PKB, (for instance, through the Wnt pathway) (Miller and Moon, 
1996).
1.5.4 Approaches to Assess the Functional Significance of PI3-kinase 
Pharmacological Approaches
The availability of inhibitors has provided a useful pharmacological approach with 
which to assess the functional relevance of PI3K activation to cellular signalling. The 
fungal metabolite Wortmannin first received widespread attention as an inhibitor of 
the agonist-induced respiratory burst in neutrophils (Baggiolini et al, 1987). It was 
subsequently found to inhibit other pathways including PLC and PLD (Bonser et al,
1993), and pleckstrin phosphorylation in platelets (Yatomi et al, 1992). However, at 
nanomolar concentrations (<100nM) wortmannin is a potent inhibitor of PI3K and has 
been used extensively to illustrate the role of this enzyme in signal transduction 
processes. Several groups have since identified the critical residues required for the 
action of this inhibitor and have shown that wortmannin covalently modifies the Lys- 
802 on the p110a subunit of PI3K, the key residue involved in the phosphate transfer 
reaction (Wymann et al. 1996).
It is clear, however, that various isoforms of PI3K exhibit different sensitivities to 
wortmannin. The p85/p110 heterodimer is very sensitive, demonstrating an IC50 of 
just 10nM, as is the Ptdlns-specific PI3K kinase. In contrast, much higher 
concentrations (IC50 - 46nM) are needed to inhibit the activation of PI3K-y 
(Wolscholski et al, 1994. Stephen et al, 1994). Other PI3K isoforms such as PI3K- 
C2a are appear relatively insensitive to treatment with wortmannin (Turner et al,
1998).
Recent studies have highlighted the limitations of interpreting results using such 
inhibitors. These relate to the demonstration that wortmannin (at concentrations 
normally used to inhibit PI3K) has the ability to block the action of at least two other 
enzymes, namely Ptdlns 4-kinase and PLA2 (Cross et al, 1995). Such effects may 
have profound disruption on several other pathways, and have possible effects on
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biochemical and functional assays. Nevertheless, many of the results obtained using 
wortmannin have been reproduced using the structurally unrelated PI3K inhibitor, 
LY290042, and strongly suggest that that the actions of wortmannin are specifically 
due to PI3K inhibition.
Molecuiar Approaches
With the advances in modern molecular technology, more elegant alternatives to 
pharmacological agents been developed. Dhand et a/, were one of the first groups to 
construct a dominant negative construct of a PI3K isoform. A p85 deletion mutant 
(Ap85) lacking the inter-SH2 region prevents the interaction between catalytic and 
regulatory subunits, and renders the enzyme inactive. When expressed in excess of 
endogenous PI3K, this construct behaves as a dominant negative (Hara et al, 1994; 
Dhand et al, 1994). Numerous groups have demonstrated this as a useful tool for 
observing the role of PI3K in receptor-mediated responses, such as IL-3-stimulated 
signal transduction in BaF cells (Craddock et al, 1999, 2001) and EGF-stimulated 
DNA synthesis in hepatocytes (Kong et al. 2000).
Constitutively active PI3Ks have also been developed. In these constructs, the p110 
catalytic subunit is a chimera that is covalently linked to the p85 subunit via the inter- 
SH2 domain. The constitutively active mutant has been shown to activate a number 
of pathways such as the p70S6-kinase and Ras/MAPK (Weng et al, 1995) and has 
clearly demonstrated the interaction of PI3K with GLUT4 in glucose transport (Fevert 
etal, 1998).
Genetic Modification
The biological roles of PI3K isoforms are beginning to be elucidated by gene 
targeting: mice lacking p110y are viable and fertile but have diminished neutrophil 
and lymphocyte function (Sasaki et al, 2000; Hirsh et al, 2000). Conversely, mice 
lacking p85a are not viable, and studies using P85CI''' stem cells have shown that 
p85‘;‘ B cells are functionally deficient whereas P85'7' T lymphocytes are completely 
normal (Fruman et al, 1999). Mast cells lacking p85a have a defect in stem cell 




Table 1.5 Inhibition of PI3K in functional settings
Method Example Advantage Disadvantage
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Can be manipulated 
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turned on or off.
Effects from 
transfection procedure
1.5.5 Lipid Phosphatases - Negative Regulators of PI 3-Kinases
Considering the impact of PI3K on many cellular functions, it stands to reason that 
there should be an effective mechanism to restrain the levels of lipid products and 
maintain the biochemical milieu of the cell. Tight control of the levels of PI 3-K 
products, namely Ptdlns(3)P, Ptdlns(3,4)P2, and Ptdlns(3,4,5)P3, is required for 
signal regulation, and is achieved, in most part, by two important phosphatases 
(Figure 1.11). For the sake of simplicity, let us just consider the fate of 
Ptdlns(3,4,5)P3, and its Ptdlns(3,4,5)P3-driven effector pathways: There are two
characterised routes for its degradation. The first involves the degradation to 
Ptdlns(4,5)P2 by 3-phosphatase, PTEN. The second achieved through SH2- 
domain-containing inositol polyphosphate 5-phosphatase (SHIP), that catalyses the 
conversion of Ptdlns(3,4,5)P3 to Ptdlns (3,4)P2 (for reviews; Cantley and Neel, 1999; 




Ptdlns(3)P <----- ► Ptdlns(3,4)P2 Ptdlns(3,4,5,)P3
//  PI3K //  PI3K A m
Ptdlns < -------- -► Ptdlns(4)P < ------ ----- ► Ptdlns(4,5)P2
Figure 1.11 Regulation of PI3K products by lipid phosphatases. Selective 3 - and 5 -
phosphatases, PTEN and SHIP, regulate the state of phosphorylation of the phosphoinositide 
lipids. Ptdlns, Ptdlns(4)P and Ptdlns(4,5)P2 can potentially serve as substrates for different 
PI3Ks. SHIP and PTEN rapidly degrade the 3’ -phosphorylated lipid products of PI3K. This 
negative regulation helps to maintain equilibrium within the intracellular lipid pool.
PTEN (phosphatase and tensin homologue deleted on chromosome ten) acts as a 
tumour suppressor and its gene is mutated in a multitude of human cancers. Several 
papers, including those by Susuki et al (1998), now establish a link between 
PI3K/AKT pathway and cancers via defects in PTEN (Di Christofan et al, 1998). 
Cells lacking PTEN have elevated levels of Ptdlns(3,4)P2 and Ptdlns(3,4,5)P3 and 
constitutively active PI3K. It is becoming increasingly clear from PTEN knockout 
models that defects in 3-phosphatase-driven regulation of the PI3K has dramatic 
effects on the apoptotic and growth regulation, integrin signalling, and cytoskeletal 
organisation (Tamura et al, 1999).
Similarly, an effective negative feedback mechanism is achieved through the 
activation of SHIP. The regulatory effects of SHIP are mediated by the 
dephosphorylation of inositol lipids on the D-3 position, and in this case 
Ptdlns(3,4,5)P3 would be converted back to Ptdlns(4,5)P2. As with PTEN, loss of 
SHIP function results in an impaired and unbalanced immune response. Mast cells 
from SHIP'" animals exhibit greater PKB phosphorylation (as measured by Ser/Thr 
phosphorylation, and GSK-3 phosphorylation), and levels remain high for extended 
times following stimulation (Liu et al, 1999). These knockouts also show a resistance 
to apoptotic signals, which is consistent with the function of PKB in this process.
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1.6 The Mitogen-Activated Kinase Pathway 
The Ras/Raf/ERK pathway
Much progress has been made with respect to the identification of signal transduction 
pathways involved in gene expression. Of great significance are the so-called 
mitogen-activated protein kinase (MAPK) proteins. Activation of the different MAPK 
signalling pathways ultimately results in the direct or indirect phosphorylation and 
activation of various transcription factors and alterations in gene expression. The 
MAP kinases represent a point of convergence for cell surface signals regulating cell 
growth and division. These enzymes comprise a family of serine/threonine kinases, 
which include (1) The extracellular signal-regulated kinases (ERKs): ERK1 and 
ERK2; and, (2) The stress-activated protein kinases; the Jun N-terminal kinase (JNK) 
and p38. MAP kinases are apparently regulated by highly conserved upstream 
protein kinases that receive signals from effectors acting at the plasma membrane. 
Extensive investigation demonstrates that in the mammalian ERK1/2 pathway, 
through interaction with Raf proteins, Ras can activate the dual functioning 
threonine/tyrosine kinases, MAP/ERK kinases (MEK 1/2), which go on to 
phosphorylate ERK-1/2 (Downward, 1998). Whereas both Raf-independent and 
Ras-independent signalling has been reported (Gangarosa et al, 1997, Takeda et al,
1999), the Ras/Raf/MEK/ERK pathway provides a common route by which growth 
factor receptor signals converge activate transcription factors such as AP1.
Stress-Activated Protein Kinases
The 'stress-activated' MAPKs include the Big MAPK (BMK/ERK5), the p38 MAPKs 
and the JNK MAPKs which also phosphorylate transcription factors. The JNKs were 
first identified on the basis of its capacity to bind to the c-Jun trans-activation domain 
(Hibi et al, 1993). There are two well-characterised proteins, JNK1 (46kDa) and 
JNK2 (55kDa) which are distant relatives of the MAP kinases. Many substrates are 
phosphorylated by the JNKs including c-Jun, ATF2, Elk-1 and NFAT that help to 
regulate gene expression in response to cytokines, growth factors, and other cellular 
stresses. The activity of JNKs is stimulated by UV radiation, hyperosmolarity and 
inflammatory cytokines (Review: Harper and LoGrasso, 2001), which is suggestive 
that the JNK pathway is activated in cellular response to stress. It is interesting how 
such diverse stress signals appear to activate a common pathway, and given the 
diverse roles of JNKs (e.g. modulators of T cell activation or neuronal apoptosis), the 
search for a critical target in this pathway has generated much attention.
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P38 is most strongly activated by proinflammatory cytokines and environmental 
stresses. It is regulated by the upstream kinases MKK3, MKK6 and MKK4, and has 
been shown to activate a number of downstream substrates including transcription 
factors ATF2 and PHAS-I and kinases such as Mnk1 and the recently cloned p38- 
related/activated protein kinase (PRAK) (New et al, 1998). A seemingly endless 
number of extracellular stimuli have been shown to activate the p38 pathway in many 
systems, and its relative role in cellular function has been made clearer with the use 
of Glaxo-SmithKline inhibitors, SB203580 and SB202190. The biological 
consequence of p38 activation may vary under different conditions, although there is 
a multitude of evidence that it has anti-mitogenic activity. 1) p38 is most strongly 
activated by proinflammatory cytokines. 2) It has been show to inhibit cyclin D1 
expression - a direct modulator of cellular proliferation, and 3) The p38 pathway 
activates heat shock protein-27 (Hsp27) in vivo which itself can inhibit cell 
proliferation (Chen et al, 2000).
1.6 The Ras Superfamilv
The Ras Superfamily of small GTPases encompasses five subfamilies. There are: 
Rho-, ARF-, Rab-, Ran- and the Ras family itself, which together comprise more than 
50 members. Small GTPases serve as crucial molecular switches in the regulation 
of intracellular signalling pathways (Exton, 1998). GTPases control biochemical 
events by cycling from the inactive GDP-bound state to active GTP-bound forms. 
This cycling is regulated by the opposing activities of guanine nucleotide exchange 
factors (GNEFs) and GTPase activating proteins (s) (Vojtek et al, 1998).
GNEFs (e.g. SOS, Vav) catalyse the activation of GTPases such as Ras by 
promoting the formation of active GTP-bound Ras, whereas GAPs (e.g. p120 GAP) 
accelerate the normally slow intrinsic GTPase activity of Ras to promote the 
formation of inactive GDP-bound Ras. The activated GTPase interact with specific 
target proteins that act as effectors to regulate downstream signalling cascades. See 
Figure 1.12.
Investigation into the roles of these proteins has been made easier with the use of 
dominant negative mutants, pharmacological inhibitors (e.g. farnesyltransferase 
inhibitors), and toxins. These bacterial products include the Clostridium sordelli lethal 
toxin (LT) - a high molecular weight toxin that covalently modifies small GTPases 
and has been used in several studies to highlight the contribution of Ras, Rap and 







Figure 1.12 The GTPase cycle .Schematic view of the factors that regulate Ras. Proteins 
from the Ras family cycle between the active GTP-bound state and the inactive GDP-bound 
state. Guanine nucleotide exchange factors (GNEFs) catalyse the activation of Ras through 
promoting the dissociation of GDP, thus, allowing Ras to interact with target proteins to 
induce co-ordinated signals. Ras remains in this active state until the bound GTP is 
hydrolysed to GDP, a process accelerated by GTPase activating proteins (GAPs).
Rho GTPases
The Rho GTPase subfamily, which consists of the closely related proteins Rho, Rac 
and Cdc42, has been implicated in the regulation of a diverse range of cellular 
functions (Reviewed in Mackay and Hall, 1998; Reif and Cantrell, 1998). Many 
studies have established that Rho GTPases control cytoskeletal dynamics in many 
cell systems. Cdc42 induces the polymerisation of actin in neutrophils extracts 
(Benard et al, 1999), and Rho, Rac and Cdc42 have been implicated in the 
chemotactic response to chemokines in leukocytes, as well as its involvement in the 
phagocytic process (Del Pozo et al, 1999). Moreover, Rho, Rac and Cdc42 have 
been identified as key players in several leukocyte signalling pathways, such as in 
the activation of phospholipase D (Hammond et al, 1997) and PI3K (Parker, 1995). 




p85/p110 heterodimer (Tolias et al, 1995). Conversely, the cytoskeletal 
reorganisation induced by PI3Ky overexpression was entirely dependent on Rac, but 
not Cdc42 (Metjian et al, 1998).
As well as cytoskeletal reorganisation, Rho proteins appear to trigger changes in 
gene transcription via the MAPK pathway (Figure 1.13). Several reports have 
implicated that both the JNK and Rac and Cdc42 can activate p38 MAP kinase 
cascades. This suggests an analogous role to that played by Ras in the MAPK 
pathway. We are still a long way from the biochemical description of the pathways 
linking active Rho proteins to cellular responses. However, the spectrum of their 
regulatory role is becoming wider. Already, Rho, Rac, Cdc42 have been implicated 
in cell movement, cytokinesis, axonal guidance, and morphogenetic processes 






















Fig 1.3. The role of Ras and Rho GTPases in gene transcription.
Ras is known to regulate the ERK pathway by directly activating Raf MAP kinase 
kinase kinase (MKKK). The regulation of JNK and p38 cascades and the 
subsequent activation of transcription factors appears to be more complex than 
that of the ERK pathway. Rac and Cdc42 can activate JNK and p38 MAP kinase 
pathways, although the mechanism is unclear. To date, eight MAP kinase kinase 
kinases have been described which are capable of activating JNK/p38, of these 




The Ras family comprises H-Ras, K-Ras4A, K-Ras 4B, N-Ras, and other 
homologous proteins such as R-Ras, TC21, Rap and Ral. Ras proteins are proto­
oncogene products that appear to be critical to signalling pathways spanning from 
the cell surface to the control of proliferation, differentiation or apoptosis (Rebollo and 
Martinez-A, 1999). Mutations in Ras at amino acids 12, 13 or 61 make Ras 
insensitive to GAPs, thus constitutively active. These mutations are extremely 
common in many human cancers, with an estimated 30% of all human tumours being 
due to the oncogenically activated Ras (Rommel and Hafen, 1998; Vojtek and Der,
1998).
Unking GPCRs and Gfiy to Ras.
There is a wealth of information documenting the Ras-MAPK pathways that are 
initiated by ligand-bound receptor tyrosine kinases (RTKs). Following the 
autophosphorylation and tyrosine phosphorylation of adaptor proteins like She and 
Grb2 guanine nucleotide exchange factors for Ras are recruited to a membrane- 
localised complex. More recently, the importance of GPCRs in both normal and 
aberrant growth control has become more evident, thus highlighting their key role in 
conveying mitogenic signals to the nucleus (Figure 1.14).
The inhibitory effect of genistein on LPA-induced MAPK activation was the first 
indication that tyrosine kinases may be involved the activation of MAPK by GPCRs 
(Hordijk et al, 1994). Additionally, many groups have demonstrated the rapid 
tyrosine phosphorylation of the SH2-containing protein (She) band and the 
subsequent formation of Shc-GRB2 complexes. This is a reaction in which several 
tyrosine kinases have been implicated, such as Fyn Lyn and Yes and the more 
distantly related Syk and Pyk2. The subsequent association of She with GRb2 
serves to direct the guanine nucleotide exchanger, SOS, to the plasma membrane 
and into proximity with Ras (Wan et al, 1996).
For those GPCRs coupled to pertussis toxin (PTX)-sensitive G|, such as 
lysophosphatidic acid (LPA), the pathway is initiated by the dissociation of the Py 
subunits from the G protein complex (Heldin et al, 1999). This observation prompted 
the search for molecules acting downstream of Gpy, and in many conditions, it was 
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Studies based on co-expression of G(3y along with dominant negative mutants of Ras 
commonly resulted in the diminished activation of MAPK. (Della Rocca et al, 1997). 
Taken together, it was proposed that signalling from the GPCR to MAPK quite often 
functioned on Ras-dependent pathway.
The involvement of PI3K in the Ras/MAPK cascade has also been intensely 
investigated. Several groups have shown that by inhibiting PI3K, MAPK activation by 
GPCRs can be abrogated. For instance, PI3Ky was found to function downstream of 
Gpy but upstream of Src-like kinases -  a potential mechanism whereby GPCRs 
modulate non-receptor tyrosine kinases (Hawes et al, 1996). Interestingly, there is 
now some evidence to suggest that there could well be Ras-independent routes for 
MAPK activation. Moreover, these pathways could potentially involve PI3Ky. The 
molecular mechanisms by which this occurs are not well understood. One possible 
explanation for the PI3Ky-mediated, Ras-independent pathway may involve the 
atypical £ isoform of PKC (Takeda et al, 1999). This is further supported by the 
observation that direct stimulation of PKC by phorbol esters can activate MAPK in a 
Ras-dependent or Ras-independent manner.
It can be concluded here that multiple molecules are involved in the activation of 
MAPKs by GPCRs. The conflicting results obtained by several groups may be 
explained by the restricted tissue distribution of these molecules. The relative 
biochemical routes utilised to link GPCRs to the MAPK pathway may depend heavily 
on the repertoire of signalling molecules available in each a particular cell type.
Downstream Effectors of Ras
Ras mediates it effects on cellular proliferation primarily through the activation of a 
cascade of kinases. As previously discussed, the best-characterised downstream 
effector molecule of Ras is Raf (c-Raf-1, A-Raf and B-Raf), a serine/threonine kinase 
that links Ras to the MAP kinase cascade. The binding of Ras to Raf requires active, 
GTP-bound Ras, which is thought to occur via two distinct amino-terminal regions of 
Raf-1 (Vojdek and Der, 1998). It appears that Ras promotes not only membrane 
translocation of Raf, but may also facilitate the events leading up to its activation. In 
addition, other components appear to contribute to Raf-1 activation including 14-3-3 
proteins, hsp90 and serine/threonine kinases indicating that the Ras-Raf connection 
is via a multicomplex of which the specific interactions remain to be determined.
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Although extensive research has clearly implicated the involvement of PI3K in the 
Ras/Raf/MAPK cascade, it may also represent a direct target of active Ras in other 
pathways. PI3K has been shown to become activated by direct interaction of the 
catalytic sub-unit with Ras-GTP in vitro and in vivo (Kodaki et al, 1994). Several 
studies have demonstrated that levels of the phospholipid products of PI3K are 
elevated by the co-expression of active Ras and PI3K, while in the presence of Ras 
inhibitors; their production in response to stimulation is reduced. Furthermore, 
mutational studies in Ras imply a degree of co-operation between the Raf and PI3K 
pathways, in that they synergise strongly in transformation in the absence of Ras, 
indicating some biological responses initiated by Ras require the activity of both PI3K 
and Raf.
In addition to Raf and PI3K, other potential effectors of active Ras are the small G- 
proteins Ral and Rho. Until recently, the physiological relevance of their interaction 
with Ras was unknown. However, RalGDS has been found to interact with Ras and 
to function as an effector target in Ras signalling pathways, inducing cellular 
transformation in parallel with activation of the Raf/MAP kinase cascade (Reviewed 
in Wolthuis and Bos, 1999). Ral-A has been shown to be involved in tyrosine-kinase 
mediated activation of PLD, suggesting that the Ras-Ral pathway is linked to the 
regulation of phospholipid metabolism (Wang, 1999). Although Rho function has 
been shown to be required for Ras- mediated DNA synthesis, the available data 
regarding Rho as a Ras effector is limited.
1.7 A New Dimension in GPCR signalling - Chemokines
Despite the rapid advances in characterising new chemokines and their cognate 
receptors, the biochemical events leading to cell migration towards a chemotactic 
gradient remain ill understood. It is agreed that cell movement depends on multitude 
of tightly orchestrated cellular processes such cytoskeletal reorganisation, alterations 
in integrin affinity and integrin cycling. The signalling cascades pertaining to these 
events are only just beginning to emerge, and these observations are, in many cases 
comparable to those observed in other GPCR systems.
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Stimulation of chemotaxis requires the functional coupling of the receptor to G 
proteins. It is here that chemokine-stimulated signal transduction is initiated. On the 
whole, chemokine receptors are usually coupled to Gai proteins that render cellular 
responses sensitive to pertussis toxin treatment. However, SDF-1, and RANTES 
induce coupling to pathways that are both sensitive (Gj) and insensitive (Gq) to 
pertussis toxin (Bacon et al, 1995; Bleul et al, 1996). Interestingly, splice variants of 
MCP-1 receptor, CCR2, exhibits a unique specificity in its coupling to the a subunits 
of the Gq class of G proteins
Appropriate stimulation of a chemokine receptors rapidly activates PLC-fc and PLC- 
p3 isoenzymes which ultimately leads to lnsP3 generation and a transient rise in 
calcium concentration. The activation of the PLC-p isoforms by Gpy subunits is well- 
established (Schall and Bacon, 1994; Baggiolini, 1997). In PLC-P2/3 knockout mice, 
chemokine-stimulated calcium transients are completely abrogated (Li et al, 2000) -  
another confirmation that these are the isoforms of choice in chemokine-activated 
leukocytes.
Another well-documented effector of py subunits is the G protein-specific PI3K, 
PI3Ky, and studies from gene-targeted mice have demonstrated its relative 
contribution in chemokine-mediated cell function. PI3Ky knockouts have severely 
impaired ability in chemokine signalling, which is good indication that this isoform is 
an essential element in pathways downstream of some GPCRs.
The recently reported activation of the Src-family kinases by Ga subunits and RGS 
(regulators of G protein signalling) has refreshed an interest in subunit-regulated 
signalling (Morris and Malbon, 1999). Although we are awaiting direct confirmation 
from chemokine systems, Gar mediated signalling downstream of these receptors is 
assumed from inference and indirect evidence. There is considerable structural 
similarities between the kinase domain (SH1) among Src-family enzymes, so it 
reasonable to assume that Gai subunits could also activate other Src-related kinases 
with leukocytes, such as Fgr, Lck or Lyn (Ganju et al, 1998; Blaukat et al, 1999; 
Wang et al, 2000). This would not only account for the linkage of chemokine 
receptors to the Ras-MAPK cascade via the “classical” tyrosine kinase pathway, but 
may also explain the activation of Focal adhesion kinase (FAK) and Pyk-2 by 
chemokines (Wang etal, 2000; Y Sotsios, unpublished data, Yamasaki etal, 2001).
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Fig 1.15 Chemokine signalling ensuing receptor ligation Receptor ligation instigates the 
release of Py subunits from G ar  and Gr coupled receptors. Gpy rapidly activate PLC and 
consequently hydrolyses Ptdlns(4,5)P2 to form DAG, and release calcium from intracellular 
stores through generation of IP3. GPCRs have been reported to activate MAPK through py- 
activated PI3Ky in both PKC^-dependent and -independent means. Activation of Pyk2 by By 
subunits is through an indirect mechanism -  quite possibly via a py-mediated rise in [Ca +] 
and PKC activation leading to a transient association between Pyk2 and Src (Blaukat et al, 
1999). In contrast, Gai could stimulate phosphorylation of Src-family kinases directly, and 
activate MAPK via the “classical” (Shc/Grb2/SOS) pathway. Activation of both Class I PI3Ks 
(p85/p110 and PI3Ky) may lead to protracted Ptdlns(3,4,5)P3 accumulation and subsequent 
phosphorylation of PKB. This scheme, which is not complete, highlights the key effectors 
following stimulation of a hypothetical generic chemokine receptor. For simplicity, the 
potential signalling events between the pathways are omitted -  see text for detailed account.
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Pi3-kinase: A Role in Chemokine Signal Transduction?
The very first report that PI3K was involved in chemokine-stimulated cells was that 
the polarisation and chemotaxis of T cells mediated by RANTES/CCR5 could be 
abrogated with pharmacological inhibitors of the enzyme (Turner et al, 1995). This 
has been reiterated for other CC chemokines such as MCP-1 and IP-10, as well as 
CXC (e.g. SDF) (Turner et al 1998; Bonacchi et a/; 2001). It is clear that production 
and degradation of 3-phosphorylated lipids is an important event in developing 
signalling gradients and subsequent cell migration (reviewed in Sotsios and Ward 
2000; Curnock et al, 2002). Both Class U / b  and Class II PI3-kinases have been 
implicated in biochemical and functional roles in several chemokine systems, but the 
precise role of each isoform are not completely understood. The diversity of 
chemokine receptors to couple to different G proteins and PI3K isoforms, is perhaps 
a means in which these receptors can simultaneously exert control over a number of 
functional events (e.g. polarisation, superoxide release, lamellipodia formation) as 
well as transcriptional and post-translational control of the cell.
Phospholipase D - a  mediator in Chemokine Signalling?
As previously discussed, several studies have reported phospholipase D (PLD) to be 
activated by several GPCRs including IL-8 and RANTES chemokine receptors 
(Bacon et al, 1995,1999). The possible involvement of PI3K and ARF proteins -  
has implications for our understanding of PLD regulation and actin polymerisation by 
chemokines. So, given the evidence, it is fair to assume that chemokines induce 
migration through its regulation of actin polymerisation. This is achieved (in part) 
through Ptdlns(3,4,5)P3-modulation of ADP-ribosylation factors (ARFs), such as 
ARF-6, which subsequently leads to activation of PLD. This is of particular interest 









Figure 1.16 Chemokine-induced activation of PLD is facilitated by PI3K and ARF 
proteins. Ptdlns(3,4,5)P3 is increased in response to chemokine stimulation via PI3Ky (or 
p85/p110 heterodimer) and promotes recruitment of PH domain containing ARF-GEFs (e.g. 
ARNO) to the cell membrane. Here, the ARF-6 is cycled into its active GTP-bound state and 
subsequently activates PLD. The resultant accumulation of phosphatidic acid is thought to 
mediate cytoskeletal reorganisation and shape change -  structural pre-requisites for cell 
migration. See text.
The Ras superfamily -  Molecular Switches for chemokine signalling
The structural reorganisation of the cytoskeleton including compartmentalisation and 
cell polarisation is a prerequisite for chemotaxis. Members of the Rho family of 
GTPases, namely Rho, Rac and Cdc42 are pivotal in deploying such events,. For 
this reason, much interest has focussed on the role that these GTPases play in both 
cell migration and its involvement in the PI3K signalling system (Metjian et al, 1998; 
MacKay and Hall, 1998; Jimenez et al, 2000).
A role for Cdc42 in chemotaxis has been demonstrated using CSF-1-stimulated 
macrophages injected with the dominant negative N17Cdc42 (Allen et al, 1998; 
Haddad et al, 2001). Moreover, in leukaemic T cell lines, these mutants display a 
much more inhibitory effect towards a chemotactic gradient than dominant negative 
mutants of RhoA and Rac (Del Pozo et al, 1999). It appears that Cdc42 and its 
interaction with downstream effectors, such as Wiskott-Aldrich syndrome protein 




Ras is a versatile intracellular switch that has been implicated in only a small number 
of pathways activated by chemokines. Both MCP-1 and SDF-1 can activate Ras in 
THP-1 and Jurkat cells respectively (unpublished observations) whilst IL-8 has been 
demonstrated to activate Ras in neutrophils. The mechanisms by which Ras is 
activated are not well understood, although stimulation of other GPCRs results in 
tyrosine phosphorylation events that ultimately lead to recruitment and activation of 
Ras. In most cases, chemokine-stimulated Ras activation has been studied in the 
context its interaction with the PI3-kinase and MAPK pathways.
Chemokines Stimulate the MAPK cascade
A role for the MAPK cascade in cell motility has been recognised for a number of 
years. Amoeboid chemotaxis of fibronectin-stimulated fibroblasts was one of the first 
indications that ERK was involved in this process. Given the surge of interest over 
the past 5 years in chemokine signalling events, characterisation of the chemokine- 
induced MAPK (including ERK, p38 and JNK) activation has been well documented. 
This has been mainly achieved by the inhibition of ERK activation with MAP kinase 
(MEK) inhibitors such as PD98059 that has abrogated chemotaxis in response to 
several chemokines. Such experiments have shown that ERK activation is necessary 
for SDF-1 and MIP-3a induced migration (Sullivan et al, 1999; Tilton et al, 2000). 




Given the recent surge of interest in leukocyte m igration in response to 
chemokine stimulation, here I attempt to investigate the intracellular signalling 
events underlying this process. Although the role of pivotal enzymes such as 
PI3-kinase and MAPK, and their regulation has been characterised in a 
number systems, their role in cell migration remains poorly understood. In 
this thesis, the objective is to assess the ability of M CP-1, MCP-2, MCP-3 and 
MCP-4 to stimulate signal transduction in the monocytic cell line, THP-1, and 
to characterise the nature of these interactions. Once a clear biochemical 
profile has been achieved, I aim to link these events functional output
Insofar as resources and time permits, this study aims to:
4- Compare and contrast the signal transduction profiles of MCP-2, -3 
and -4 , to that of the more extensively characterised M CP-1.
4- Assess the role of PI3-K in other MCP-induced signalling pathways and 
the subsequent consequences on cell migration.
Demonstrate any differences in activation, kinetic profile and functional 
significance of the various PI3K isoforms.
^  Attem pt to extrapolate these data to other chemokine systems and 
suggest how the exploitation of molecular targets could be applied to the 
pathophysiology of atherosclerosis and other inflammatory disorders.
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Figure 3.1 RT-PCR analysis of CC chemokine receptor expression.
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Figure 3.1 RT-PCR analysis of CC chemokine receptor expression 1 ug of DNAase l-treated mRNA was 
used per reaction and identical reactions were carried out for each cell line. PCR was performed for 30 cycles 
and the oligonucleotide primers used are under ‘Materials and Methods’. In A, THP-1 cells from different 
passage numbers (1-20 and 30+), and over were screened for the CC chemokine receptors CCR1, -2, -3, -4, 
and 5. As a negative control (B), both cell lines were screened for GAPDH CCR1, -2, and -3 in the absence of 
reverse transcriptase. (C). Peripheral blood mononuclear cells and the U937 cell line was used as a positive 
control for CCR1, -2, -3 and 4. 10pl from the final reaction mixture was electrophoresed on a 2% agarose, 1 
xTAE at 150V for 90 min and the DNA visualised by ethidium bromide staining of the gel. The sizes of the DNA 
molecular weight markers (base pairs) are shown in the lanes next to the samples.
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Figure 3.2 Surface expression of CCR2 on unstimulated THP-1 cells.
8 -.
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Figure 3.2 Surface expression of CCR2 on unstimulated THP-1 cells 1 x 105 THP-1 
cells per point were analysed for surface expression of CCR2, with FITC-conjugated 
mouse lgG2B anti-human antibodies (transparent histogram), or isotype matched control 
antibodies (black histogram). The cells were analysed on a Becton Dickinson FACS 
Vantage as described in ‘Materials and Methods’. The expression profile shown is from 
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Figure 3.3 Detection of Intracellular [Ca2+] in THP-1 cells.
2 x106 cells were loaded with Fura-2AM and assayed at 37°C in 
a continuously stirring cuvette in a Photon Technologies 
fluorimeter(nm), (340 n m { y ;  380nm {?tem}), with fluorescence 
emission recorded every 100 ms for at least 180 s. All 
experiments were conducted in the presence of extracellular 
calcium as indicated under “Materials and Methods” unless 
otherwise stated. MCP-1 was added at the times indicated (^ ). 
In A, MCP-1 was added to final concentrations of 1, 10 and 
100nM. Graph represents three separate stimulations 
superimposed onto one axis. B. Cells were stimulated with 
100nM MCP-1 in the absence of extracellular calcium. C. As 
a positive indicator of calcium mobilisation, cells were 
stimulated with ATP (3|iM). Traces are in M [Ca2+] from one 
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Figure 3.4 Comparison of MCP-1, -2, -3, and -4-lnduced calcium [Ca2+], in THP-1 cells. 2 x106 cells were loaded 
with Fura-2AM and assayed at 37°C in a continuously stirring cuvette in a Photon Technologies fluorimeter (340 
nm{Xex}; 380nm {^eJ)> with fluorescence emission recorded every 100 ms for at least 180 s. All experiments were 
conducted in the presence of extracellular calcium as indicated under ‘Materials and Methods’ unless otherwise 
stated. Cells were treated with 100nM of MCP-1, -2, -3, and -4  in A, B, C and D, respectively.
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Figure 3.5A. Induction of THP-1 cell migration in response to MCP-1 and MCP-2
Mean ± SEM Mean ± SD













Figure 3.5A The Induction of cell migration by MCP-1 and MCP-2 in THP-1 cells 1
x 105 THP-1 cells per point were assayed for chemotactic ability in a 96-well Neuroprobe 
chemotaxis chamber. Cells were left to migrate for 3 hours to either 0.1% BSA (control), 
or various concentrations of chemokine as indicated. Results are expressed as a 
chemotactic index (C:l): the ratio of stimulated over basal migration. For each 
experiment a ‘non-directed’ chemokine gradient was also established (chemokine in 
both top and bottom wells) to control for chemokinetic migration. Data represent the 
mean ± SEM (5 replicates per chamber/2 chambers per experiment). For comparative 
reasons, graphs show calculated mean ± SEM (left) and mean ± SD (right). 5 replicates 
per chamber/2 chambers per experiment. Results are from one experiment but are 
representative of at least three others. *:p<0.05, **:p<0.01, ***p<0.001.
Figure 3.5B. Induction of THP-1 cell migration in response to MCP-3 and MCP-4
















Figure 3.5B The Induction of cell migration by MCP-3 and MCP-4 in THP-1 cells 1 x 105
THP-1 cells per point were assayed for chemotactic ability in a 96-well Neuroprobe chemotaxis 
chamber. Cells were left to migrate for 3 hours to either 0.1% BSA (control), or various 
concentrations of chemokine as indicated. Results are expressed as a chemotactic index (C:l): 
the ratio of stimulated over basal migration. For each experiment a ‘non-directed’ chemokine 
gradient was also established (chemokine in both top and bottom wells) to control for 
chemokinetic migration. For comparative reasons, graphs show calculated mean ± SEM (left) and 
mean ± SD (right). 5 replicates per chamber/2 chambers per experiment. Results are from one 
experiment but are representative of at least three others. *:p<0.05, **:p<0.01, ***p<0.001.
79















vehicle MCP-1 MCP-2 MCP-3 MCP-4
Figure 3.5C. Effect of CCR2 ligands on THP-1 cell chemotaxis. 1 x 105 THP- 
1 per point were assayed for chemotactic ability in a 96-well Neuroprobe™ 
chemotaxis chamber. Cells were left to migrate for 3 hours towards either 
vehicle (0.1% BSA), MCP-1 (1nM), MCP-2 (10nM), MCP-3 (10nM) or MCP-4 
(100nM). Migration was determined as described in 'Materials and Methods'. 
Data represent the mean ± SEM (5 replicates per chamber/2 chambers per 
experiment). Results from one experiment but are representative of two other 
independent experiments. *:p<0.05, **:p<0.01, ***p<0.001.
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Figure 3.6 The relative contribution of CCR2 to MCP-1, 

























NB* Consideration was given to the fact that the basal activity of ERK-1/2 did fluctuated between 
experiments. Results indicate the degree of inhibition by the SB282241 compound between 
vehicle control and 2 m post-stimulation.
Figure 3.6 The relative contribution of CCR2 to MCP-induced signalling in THP-1 
cells. THP-1 cells (1 x106 per point), untreated or preincubated for 15 minutes with 1pM 
SB282241, were exposed to the indicated time courses to MCP-1, MCP-2, MCP-3 and 
MCP-4 (1nM, 100nM, 10nM, and 100nM, respectively). Total cell lysates (2.5 x 105 cell 
equivalents per lane) were were resolved separately by SDS-PAGE, electrophoretically 
transferred to a nitrocellulose membrane and immunoblotted with anti-active ERK 
antibodies. A corresponding set of lysates were probed with anti-inactive ERK antibody to 
ensure equal loading of proteins. The results are representative of two experiments. 
Table shows percentage inhibition of MCP-stimulated ERK activity by SB282241 
compared to vehicle (as assessed by densitometric analysis).
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Section 4: Results
CCR2 ligands activate PI3-kinase signalling pathway
Rationale
The term 'PI 3-kinase' (PI3K) is now applied to a growing family of proteins that are 
able to convert Ptdlns, Ptdlns(4)P and Ptdlns(4,5)P2 into Ptdlns(3)P, Ptdlns(3,4) and 
Ptdlns(3,4,5)P3) respectively by phosphorylating the D-3 position of the inositol heads 
of D-3 phosphoinositide lipids. PI3K pathways have for some time been regarded 
as important intracellular signals that are upstream of a variety of responses, and 
more recently have been the focus of much attention with respect to their role in 
chemokine mediated functional responses.
There were two main procedures used in this study for the measurement of PI3- 
kinase activity, both of which were based on the detection of the transfer of the y- 
phosphate of ATP to the D-3 position on the inositol ring. The first method relies on 
the metabolic labelling of intact cellular pools of ATP with [32P]P| followed by lipid 
extraction, and the measurement of lipid kinase activity by HPLC analysis. In the 
second procedure, assays of specific immunoprecipitated PI3-kinase isoforms were 
assessed for associated lipid kinase activity.
Measurement of D-3 Phosphoinositide Lipids
Analysis of the deacylated phospholipids lipids was achieved by HPLC, and the 
resulting reproducible chromatographic traces enabled the detection and 
quantification of the fluctuations in glycerophosphoryl derivatives (GroPtdlns lipids). 
Products of interest, namely Ptdlns(3,4,)P2 and Ptdlns(3,4,5)P3 were identified from 
retention times obtained with tritium-labelled phosphoinositide lipid standards. 
Increases in Ptdlns(3)P were not detectable in THP-1 cells as resolution of this lipid 
was poor. Figure 4.1 shows a representative HPLC trace of unstimulated vs. CD3- 
stimulated Jurkat cells. This treatment commonly served as a positive control for 
[32P] loading and as a standard for ligand-induced D-3-phosphoinositol lipid 
formation. Experiments showed that despite the consistency in relative accumulation 
of GroPtdlns lipids, loading efficiencies of [32P] into THP-1 cells could not be 
accurately standardised. Hence, for objective comparison some results are 
expressed as a percentage increase from baseline, whereby the maximum increases 
ranged from 150 to 700 percent from basal Ptdlns(3,4,5)P3 levels. Although relative
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kinetic profiles of D-3-lipid generation were consistent, time points for peak 
responses sometimes varied between experiments by up to 60 seconds. The time- 
courses shown are representative of at least four separate experiments
Accumulation of D-3-lipids induced by MCP-1 in THP-1 celis
The THP-1 cell line is known to have some constitutive PI3-kinase activity (Turner et 
al, 1998) and this was reflected in the basal generation of Ptdlns(3,4)P2 and 
Ptdlns(3,4,5)P3 in the unstimulated control (1835 and 1798 cpm, respectively). 
Stimulation with MCP-1 resulted in a rapid and transient increase in Ptdlns(3,4,5)P3 
that was dependent on the concentration of MCP-1 (Figure 4.2). Maximal 
accumulation of this lipid (3128 cpm) was observed at 60 seconds post-stimulation, 
with an optimal concentration of 60nM MCP-1. Similarly, the optimum time point for 
accumulation of Ptdlns(3,4,)P2 was also after 60 seconds after ligation, yet kinetics 
appeared to be slightly slower and more sustained than that observed for 
Ptdlns(3,4,5)P3. Maximum accumulation of Ptdlns(3,4)P2 (3646 cpm) was attained at 
the higher concentration of 180nM MCP-1.
As several isoforms of PI3-kinase have been identified, it was necessary to 
determine which of these were responsible for the increases in D-3-lipid generation 
following MCP-1 stimulation. The first step taken to characterising these isoforms 
was through testing the sensitivity of D-3-lipid accumulation to pharmacological 
inhibitors, LY-290042 and pertussis toxin. Treatment with PI3-K inhibitor, LY-290042 
(10^iM), appeared to have no effect on MCP-1-induced accumulation of 
Ptdlns(3,4,5)P3 or Ptdlns(3,4)P2 (Figure 4.3) whereas pre-treatment with G protein 
inhibitor, pertussis toxin (100ng/ml), completely abrogated the MCP-1-induced 
increase in Ptdlns(3,4,5)P3 to below baseline levels (Figure 4.4). The effects of 
pertussis toxin on Ptdlns(3,4)P2 generation were not assessed.
Effects of MCP-2, -3 and -4 on D-3-lipid accumulation in THP-1 cells
MCP-2 stimulated THP-1 cells also resulted in an increase of Ptdlns(3,4,5)P3 and 
Ptdlns(3,4)P2. The elevation of both lipids exhibited bell-shaped characteristics with 
the maximum response observed in the presence of 60nM MCP-2 (an increase of 
888 and 850 cpm above basal, respectively). (Figure 4.5). Furthermore, MCP-2- 
stimulated formation of Ptdlns(3,4,5)P3 and Ptdlns(3,4)P2 was rapid and transient 
since they were detectable 10 s after stimulation and peaked after 60 s. The 
observed responses were refractory PI3-K inhibition with LY-290042 (Figure 4.6).
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MCP-3 induced an increase in Ptdlns(3,4,5)P3 which was optimal at 60nM MCP-3 
(Figure 4.7). This transient response peaked at 60 s and had returned to near basal 
levels 2 m after stimulation. A rapid accumulation of Ptdlns(3,4,5)P3 was achieved 
using 180nM MCP-3, however, this increase was short lived, and had returned to 
baseline after only 30 s. With regards to formation of Ptdlns(3,4)P2, a concentration- 
dependent increase was also observed. A rapid increase in this lipid was achieved 
30 s post-MCP-3 stimulation (180nM). . Pre-treatment with LY-290042 had no affect 
on the generation of Ptdlns(3,4,5)P3 nor Ptdlns(3,4)P2 (Figure 4.8).
Figure 4.9 shows the elevation of Ptdlns(3,4,5)P3 and Ptdlns(3,4)P2 in response to 
MCP-4. There was a transient elevation in both products that increased up to 60 s 
post-MCP-4 stimulation. The response was also concentration-dependent in that 
maximum accumulation of both Ptdlns(3,4)P2 and Ptdlns(3,4,5)P3 was obtained 
using 180nM MCP-4. As expected, neither of the lipids were affected by pre­
treatment with LY-290042 (Figure 4.10).
Although MCPs 1-4 have all been shown to signal via CCR2, it appears that they 
induce signal transduction in THP-1 cells with distinct levels of efficacy. Figure 4.11 
shows the relative potencies of these CCR2 ligands on Ptdlns(3,4,5)P3 accumulation 
in THP-1 cells. By stimulating THP-1 cells with concentrations of MCP-1-4 known to 
elicit an optimal response (60nM), a direct comparison of these chemokines could be 
made. The maximum response was observed with MCP-3 which increased 
Ptdlns(3,4,5)P3 generation to approximately 500% of basal level. This was then 
followed by MCP-1 (300%), MCP-2 (190%) and MCP-4 (170%). In terms of rank 
order of potency, it transpires that MCP-3>MCP-1>MCP-4>MCP-2 in the generation 
of Ptdlns(3,4,5)P3.
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Activation of PKB by CCR2 ligands
Protein kinase B (PKB) is a proto-oncogene that is activated in signalling pathways 
initiated by PI3-kinases. It is thought to be recruited by and dependent on the 
phospholipid products of PI3-K for subsequent phosphorylation and activation. To 
support the observed CCR2-meaiated, G-protein-dependent Ptdins(3,4,5)P3 
formation, the activation of PKB (a major downstream effector of PI3K) was 
assessed. This was achieved by western blotting THP-1 cell lysates with a phospho- 
specific antibody against Ser473 within the PKB activation loop - a residue implicated 
in activation of PKB in vivo. The principle-characterised substrate of PKB is glycogen 
synthase kinase-3 (GSK-3a/|3), a protein-serine/threonine kinase whose activity is 
inhibited by PKB phosphorylation in response to growth factor stimulation. As a 
major downstream effector of PKB, evidence of GSK-3 phosphorylation was sought 
to provide additional confirmation that PI3-kinase was activated in this system.
As expected, MCP-1 stimulation of THP-1 cells resulted in a rapid and transient 
phosphorylation of PKB. Activation was evident 2 m after stimulation and had almost 
returned to basal levels after 10 m (Figure 4.12). This response was partially 
inhibited by pre-treatment with wortmannin (50nM).
THP-1 cells were shown to have constitutive activation of GSK-3 that was sensitive 
to wortmannin. MCP-1 induced a time-dependent increase in phosphorylated GSK-3 
that was evident after 2 m, and still detectable 10 m post-stimulation - The induction 
of GSK-3 activity by MCP-1 was also sensitive to wortmannin. Although the kinetic 
profile was similar to that of PKB, the activation of GSK-3 appeared to be more 
sustained.
Figure 4.13 also demonstrates that MCP-2, -3 and -4 phosphorylates PKB and GSK- 
3. MCP-2 induced rapid activation of PKB that was detectable after 2 m and was still 
evident after 10 m (Figure 4.13a). All activity of PKB was abolished by pre-treatment 
with wortmannin. The phosphorylation of GSK-3 was slower and more transient. 
Whereby activation was detectable after 2 m, maximal at 5 minutes, and had almost 
returned to basal levels by 10 m. Wortmannin greatly reduced baseline activation of 
GSK-3, however, residual signalling was still evident in response to MCP-2.
Following stimulation of THP-1 cells with MCP-3, PKB activation and GSK-3 
inactivation displayed similar kinetics (Figure 4.13B). Phosphorylation of both 
enzymes was rapid and displayed maximum activity after 2 m. Although reduced,
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the activation of PKB and GSK-3 was sustained, and remained elevated 10 minutes 
post-stimulation. The inhibition of both PKB and GSK-3 by wortmannin further 
implied PI3K activation in this pathway. Stimulation of THP-1 cells with MCP-4 
showed a modest increase in PKB and GSK-3 activity, both of which were sensitive 
to pre-treatment with wortmannin (Figure 4.13C). The kinetics were much slower 
than those observed with MCP-1, -2 and -3, as a clear response was not detectable 
until 10 m post-stimulation. In subsequent experiments, this delayed response was 
followed by a return to near basal levels after approximately 20-30 m (data not 
shown). In short, MCP-1, -2, -3 and -4, were all capable of eliciting phosphorylation 
of both PKB, and its downstream effector, GSK-3. Treatment with wortmannin 
attenuated these responses, and therefore provided further confirmation of the 
involvement of PI3-K as an upstream signalling component in this pathway.
Given that accumulation of MCP-1-induced accumulation Ptdlns(3,4,5)P3 in THP-1 
cells appeared to be a G-protein-dependent event, the effects pertussis toxin 
treatment on CCR2-mediated PKB phosphorylation were investigated. Figure 4.14 
shows that pertussis toxin completely inhibits MCP-1-induced PKB activation, but 
only partially inhibits MCP-2, -3, and -4-induced PKB activity. Even in the presence 
of this toxin there is evidence of residual signalling by MCP-2, -3, and -4.
Measurement of MCP-1'Stimulated PI3-kinase activity In Vitro
From the HPLC analysis of total phospholipid production from THP-1 cells stimulated 
with CCR2 ligands, a role for more than one PI3K in the generation of Ptdlns(3,4,5)P3 
was implied. It was important to clearly identify the PI3K isoforms involved in CCR2- 
mediated signalling. As previously discussed, another method used to identify PI3- 
kinase activation in this system was the assay of specific immunoprecipitated 
proteins (e.g. PI3K subunits, receptors, cellular proteins) for associated lipid kinase 
activity under in vitro conditions. Using distinct substrates such as Ptdlns in the 
presence of [y-32P]-ATP (Morgan et al, 1990; Ward, 2000) the formation of 
radiolabelled Ptdlns(3)P was detected using TLC and autoradiography.
Verification of expression of the prototypical p85/p110 heterodimer was achieved by 
western blotting of THP-1 cell lysates with anti-p85 antibody. Figure 4.15 shows the 
relative expression of p85 in THP-1 cells compared to Jurkat cells. In vitro lipid 
kinase assays demonstrated that stimulation of MCP-1 resulted in a time-dependent 
increase in p85 activity that was detectable at 30s and remained elevated for at least 
15 minutes. The activity of immunoprecipitated p85 was sensitive to pre-treatment
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with 10nM wortmannin, and Ptdlns(3)P formation in response to MCP-1 ligation was 
reduced to basal levels.
Since PTX completely abrogated D-3-lipid accumulation, the activation of G protein - 
specific PI3K, PI3-Ky, was assessed. Verification of the expression of this isoform 
was carried out by western blotting THP-1 cell lysates with an antibody towards 
p110y (Fig 5.16A). Confirmation of p110y activity was obtained by in vitro lipid kinase 
assay of MCP-stimulated THP-1 cells.
Figure 4.16B shows effects of various concentrations of MCP ligands on the 
generation of Ptdlns(3)P from the immunoprecipitated p110y activity. Although a 
reasonably high level of basal activity of this enzyme was observed, MCP-1 as well 
as MCP-2, -3 and -A stimulated a concentration-dependent increase in this product 
(as assessed 30 seconds post-stimulation). Maximum responses were achieved 
with MCP-1, -2, -3 and -4  were 10nM, 100nM, 100nM and 10nM, respectively. 
Further characterisation of immunoprecipitated p110y activation was assessed in 
response to MCP-1-mediated activation. MCP-1-induced a time-dependent, biphasic 
increase in p110y activity which peaked at 30s and 10 m. Figure 4.17 shows that 
treatment with wortmannin (10nM) inhibited p110y activation to below basal levels. 
Similarly, 16- hour pre-treatment with pertussis toxin (100ng/ml) also inhibited all lipid 
kinase activity.
MCP-1-stimulated THP-1 cells revealed that Ptdlns(3,4,5)P3 accumulation was 
resistant to LY290042 and yet entirely sensitive to pertussis toxin. Given these 
findings, it was necessary to investigate the involvement the novel class II PI3- 
kinases, PI3K-C2a and PI3K-C2p, in this system. Indeed, MCP-1 stimulated an 
increase in the in vitro lipid kinase activity in both PI3K-C2a and PI3K-C2p 
imunoprecipitates (Figure 4.18A). The activity of both isoforms responded in a time- 
dependent manner, albeit with slightly different kinetics. PI3K-C2a appeared to be 
transiently activated with a detectable response observed 2 m post-stimulation, and 
by 10 m had declined back down to basal levels. Elevation of PI3K-C2p was also 
transient but slightly more sustained. Increases were detectable after 15 s, maximal 
at 5 m and returned to baseline activity at 10 m. Further characterisation of MCP-1- 
stimulated PI3K-C2p was performed in the presence of pertussis toxin and 
wortmannin (Figure 4.18B). Although reported to have limited sensitivity to PI3- 
kinase inhibitors, (Domin and Waterfield, 1997), pre-treatment with wortmannin as
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well as pertussis toxin almost completely abrogated the MCP-1-induced in vitro lipid 
kinase activity of PI3K-C2J3 immunoprecipitates.
The lipid data demonstrated that MCP-1 stimulates a rapid and transient increase in 
Ptdlns(3,4,5)P3 compared with the slower, sustained increase in Ptdlns(3,4)P2. This 
could be explained by the concomitant activation of a Ptdlns(3,4,5)P3 5-phosphatase, 
which has been identified in other systems. To address this possibility, the THP-1 
cell line was screened for the expression of SH2-domain-containing inositol 
polyphosphate 5-phosphatase (SHIP) (Figure 4.19). Immunoblotting THP-1 cell 
lysates with anti-human SHIP antibody revealed a protein that corresponded to 
145kDa, consistent with expression of SHIP. The A20 cell line and peripheral blood 
mononuclear cells (PBMCs) were positive controls for this protein. The Jurkat T cell 
line, provided a suitable negative control as these cells characteristically lack 
expression of the phosphatases SHIP and PTEN (S. Burgess, unpublished data).
Immunoblotting anti-SHIP immunoprecipitates derived from resting and stimulated 
THP-1 cells with antiphosphotyrosine mAb revealed that 145kDa protein (SHIP) was 
modestly tyrosine phosphorylated following MCP-1 stimulation. Although there was 
basal activity of this protein, there was a concentration-dependent response with 
maximum phosphorylation observed using 10nM MCP-1 (Figure 4.20). A preliminary 
experiment also showed that SHIP phosphorylation was time-dependent (n=1). A 
detectable response was observed 30 s post-stimulation and remained elevated after 
10 m.
The Role of PI3-kinase on CCR2-mediated chemotaxis
The involvement of PI3K(s) on CCR2-mediated chemotaxis was characterised with 
the use of phamacological PI3-kinase inhibitor, wortmannin (Figure 4.21 A - D). As 
discussed in Section 4, MCP-1, as well as MCP-2, -3 and -4, induce chemotaxis in 
THP-1 cells in a concentration-dependent manner that is characteristic of chemokine- 
dependent chemotaxis. THP-1 cell chemotaxis towards MCP-1 at a concentration 
known to elicit optimal migration was almost completely inhibited by pre-treatment of 
cells with wortmannin (IC50= 25nM). Interestingly, residual migration towards MCP-1 
was observed even at the upper limit of wortmannin concentration (100nM) which 
implies that there is only a partial dependency on PI3-K for MCP-1-induced 
migration. Chemotaxis towards MCP-2, -3 and -4 was also sensitive to PI3K
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inhibition, albeit to much lower concentrations of wortmannin (IC50 = 2nM, <0.1 nM, 
<0.1nM, respectively).
Table 4.1. Summary of the effects of CCR2 ligands on D-3-phosphorylated lipid 
generation and downstream effectors of PI3-kinase in THP-1 cells.
increase in Ptdlns(3,4,5)P3 ? Increase in Ptdlns(3,4)P2 ?
MCP-1 Insensitive to LY. 
Sensitive to PTX.
Insensitive to LY
MCP-2 Insensitive to LY Insensitive to LY
MCP-3 Insensitive to LY Insensitive to LY
MCP-4 Insensitive to LY Insensitive to LY
Activation of PKB? Activation of GSK-3?
MCP-1 Partial sensitivity to WM. 
Sensitive to PTX
✓ Partial sensitivity to WM
MCP-2 s Sensitive to WM 
Partial sensitivity to PTX
Partial sensitivity to WM
MCP-3 Sensitive to WM 
Partial sensitivity to PTX
s Sensitive to WM
MCP-4 Sensitive to WM 
Partial sensitivity to PTX
Sensitive to WM
Table 4.2 PI3-kinase Isoforms activated by ligands of CCR2
p85 ? p110y ? PI3K-C2a/p ?
MCP-1 sensitive to WM. 
sensitive to PTX
optimal conc. = 10nM 




Sensitive to WM 
Sensitive to PTX
MCP-2 - - s optimal conc. = 100nM - -
MCP-3 - - s optimal conc. = 100nM - -
MCP-4 - - s optimal conc. = 10nM - -
Legend: s ; activation, - ;response not assessed, LY, LY290042, WM; wortmannin, PTX; pertussis toxin
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Figure 4.1 Typical HPLC trace for the separation and analysis 
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Figure 4.1 Typical HPLC trace for the separation and analysis of phosphatidyl- 
inositol(3,4,5)P3 generation in Jurkat cells. Jurkat cells (1x107 cell/point) were metabolically 
labelled with [32P], stimulated with 10ng/ml UCHT1 for 1 minute, and phospholipids were 
extracted as described in Materials and Methods. The resulting glycerophosphoryl sample 
derivatives (GroPtdlns lipids) were separated by anion exchange HPLC and analysis conducted 
by the Flo-One radiomatic program. Retention times of eluate peaks were verified for each 
experiment against 3H-labelled phosphoinositide lipid standards. Relevant phospholipid peaks 
are indicated and expressed in CPM/Time (min). Trace is taken from one experiment, and is 
representative of all lipid extraction experiments.
97
Figure 4.2 Effect of MCP-1-stimulation on Ptdlns(3,4,5)P3 and
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Figure 4.2. Effect of MCP-1 stimulation on Ptdlns(3,4)P2 and 
Ptdlns(3,4,5)P3 generation in THP-1 cells. 1 x 107 cells/point were 
metabolically labelled with 32P. Cells were stimulated with vehicle (0.05% 
BSA) or various concentrations of MCP-1 for the indicated times. Following 
stimulation, phospholipids were extracted, deacylated and the
glycerophosphorylinositol derivatives of Ptdlns(3,4,5)P3 (A) and
Ptdlns(3,4)P2 (B) were analysed using HPLC as described under ‘Materials 
and Methods’. Data are from a single experiment and are representative of 
at least three separate experiments.
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Figure 4.3 Effect of LY290042 on MCP-1-induced generation of
Ptdlns(3,4)P2 and Ptdlns(3,4,5)P3 in THP-1 cells.
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Figure 4.3. Effect of LY290042 on MCP-1-induced accumulation of 
Ptdlns(3,4)P2 and Ptdlns(3,4,5)P3 in THP-1 cells. 1 x 107 cells/point were 
metabolically labelled with 32P and pre-treated for 10 minutes with either vehicle 
(0.01% DMSO) or 10pM LY-290042. Cells were then stimulated with vehicle 
(0.05% BSA) or MCP-1 (60nM) for various times. Following stimulation, 
phospholipids were extracted, deacylated and the glycerophosphorylinositol 
derivatives of Ptdlns(3,4,5)P3 (A) and Ptdlns(3,4)P2 (B) were analysed using 
HPLC as described under ‘Materials and Methods’. Data are from a single 
experiment and are representative of at least three separate experiments.
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Figure 4.4. The Effect of Pertussis toxin on MCP-1-induced Ptdlns(3,4,5)P3
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Figure 4.4. Effect of Pertussis toxin on MCP-1-stimulated generation 
of Ptdlns(3,4,5)P3 and Ptdlns(3,4,)P2 in THP-1 cells. Following pre­
treatment for 16 hours with vehicle (0.01% dH20) or 100ng/ml pertussis 
toxin, 1x107 cells/point were metabolically labelled with 32P. Cells were 
then stimulated with vehicle (0.05% BSA) or MCP-1 (60nM) for the 
indicated times. Following stimulation, phospholipids were extracted, 
deacylated and the glycerophosphorylinositol derivative of Ptdlns(3,4,5)P3 
was analysed using HPLC as described under ‘Materials and Methods’. 




Figure 4.5. Effect of MCP-2-stimulation on Ptdlns(3,4,5)P3 and
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Figure 4.5. Effect of MCP-2 stimulation on Ptdlns(3,4)P2 and 
Ptdlns(3,4,5)P3 generation in THP-1 cells. 1 x 107 cells/point were 
metabolically labelled with 32P. Cells were stimulated with vehicle (0.05% 
BSA) or various concentrations of MCP-2 for the indicated times. Following 
stimulation, phospholipids were extracted, deacylated and the 
glycerophosphorylinositol derivatives of Ptdlns(3,4,5)P3 {A) and
Ptdlns(3,4)P2 (B) were analysed using HPLC as described under ‘Materials 
and Methods’. Data are from a single experiment and are representative of 
at least three separate experiments.
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Figure 4.6. Effect of LY290042 on MCP-2-induced generation of
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Figure 4.6. Effect of LY290042 on MCP-2-induced generation of 
Ptdlns(3,4)P2 and Ptdlns(3,4, 5)P3 in THP-1 cells. 1 x 107 cells/point were 
metabolically labelled with 32P and pre-treated for 10 minutes with either vehicle 
(0.01% DMSO) or 10pM LY-290042. Cells were then stimulated with vehicle 
(0.05% BSA) or MCP-2 (60nM). Following stimulation, phospholipids were 
extracted, deacylated and the glycerophosphorylinositol derivatives of 
Ptdlns(3,4,5)P3 [A) and Ptdlns(3,4)P2 (B) were analysed using HPLC as 
described under ‘Materials and Methods’. Data are from a single experiment 
and are representative of at least three separate experiments.
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Figure 4.7. Effect of MCP-3-stimulation on Ptd!ns(3,4,5)P3 and
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Figure 4.7. Effect of MCP-3 stimulation on Ptd!ns(3,4)P2 and Ptdlns(3,4,5)P3 
generation in THP-1 cells. 1 x 107 cells/point were metabolically labelled with 32P, 
and then stimulated with vehicle (0.05% BSA) or various concentrations of MCP-3. 
Following stimulation, phospholipids were extracted, deacylated and the 
glycerophosphorylinositol derivatives of Ptdlns(3,4,5)P3 (A) and Ptdlns(3,4)P2 (B) 
were analysed using HPLC as described under ‘Materials and Methods’. Data are 
from a single experiment and are representative of at least three separate 
experiments.
■  10nM
■  60nM 
□  180nM
■  10nM
■  60nM 
□  180nM
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Figure 4.8. Effect of LY-290042 on MCP-3-induced generation of
Ptdlns(3,4)P2 and Ptdlns(3,4,5)P3 in THP-1 cells.
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Figure 4.8. Effect of MCP-3-induced generation of Ptdlns(3,4)P2 and 
Ptdlns(3,4,5)P3 in THP-1 cells. 1 x 107 cells/point were metabolically 
labelled with 32P and pre-treated for 10 minutes with either vehicle (0.01% 
DMSO) or 10pM LY-290042. Cells were then stimulated with vehicle 
(0.05% BSA) or MCP-3 (60nM). Following stimulation, phospholipids were 
extracted, deacylated and the glycerophosphorylinositol derivatives of 
Ptdlns(3,4,5)P3 [A) and Ptdlns(3,4)P2 (B) were analysed using HPLC as 
described under ‘Materials and Methods’. Data are from a single 
experiment and are representative of at least three separate experiments.
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Figure 4.9 Effect of MCP-4-stimulation on Ptdlns(3,4,5)P3 and
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Figure 4.9. Effect of MCP-4 stimulation on Ptd!ns(3,4)P2 and 
Ptdlns(3,4,5)P3 generation in THP-1 cells. 1 x 107 cells were metabolically 
labelled with 32P and then stimulated with vehicle (0.05% BSA) or various 
concentrations of MCP-4. Following stimulation, phospholipids were 
extracted, deacylated and the glycerophosphorylinositol derivatives of 
Ptdlns(3,4,5)P3 (A) and Ptdlns(3,4)P2 (B) were analysed using HPLC as 
described under ‘Materials and Methods’. Data are from a single experiment 
and are representative of at least three separate experiments.
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Figure 4.10. Effect of LY290042 on MCP-4-induced accumulation of 
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Figure 4.10. Effect of LY290042 on MCP-4-induced accumulation of 
Ptdlns(3,4)P2 and Ptdlns(3,4, 5)P3 in THP-1 cells. 1 x 107 cells/point were 
metabolically labelled with 32P and pre-treated for 10 minutes with either 
vehicle (0.01% DMSO) or 10jiM LY-290042. Cells were then stimulated with 
vehicle (0.05% BSA) or MCP-4 (60nM). Following stimulation, phospholipids 
were extracted, deacylated and the glycerophosphorylinositol derivatives of 
Ptdlns(3,4,5)P3 [A) and Ptdlns(3,4)P2 (B) were analysed using HPLC as 
described under “Materials and Methods”. Data are from a single experiment 
and are representative of at least three separate experiments.
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Figure 4.11. Effect of MCP-1, -2, -3 and -4 stimulation on Ptdlns(3,4,5)P3 
generation in THP-1 cells. 1 x 107 cells were metabolically labelled with 32P and then 
stimulated with vehicle (0.05% BSA) or MCP-1, -2, -3 (60nM) and MCP-4 (180nM). 
Following stimulation, phospholipids were extracted, deacylated and the 
glycerophosphorylinositol derivative of Ptdlns(3,4,5)P3 were analysed using HPLC as 
described under ‘Materials and Methods’. Data are from a single experiment and are 
representative of at least two separate experiments.
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Figure 4.12/13 Effect of wortmannin on MCP-1, MCP-2, -3 and -4-
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Figures 4.12 and 4.13. Effect of wortmannin on MCP-2, -3 and -4-induced activation of PKB in THP-1 
cells. THP-1 cells (1x106 cells per point) were pre-treated for 15 minutes with vehicle (0.01% DMSO) or 
50nM wortmannin. Cells were then stimulated with vehicle (0.05% BSA) MCP-1 (Fig 4.12) MCP-2 (Fig 
4.13A), MCP-3 (Fig 4.13B) or MCP-4 (Fig 4.13C) for the times indicated. For each time course, whole cell 
lysates were split into four equal volumes. All samples were resolved separately by SDS-PAGE, and 
electrophoretically transferred to a nitrocellulose membrane. Lysates were immunoblotted with either anti- 
phospho-PKB or phospho-GSK-3. The remaining lysates were immunoblotted with anti- PKB to verify equal 
loading of proteins. The results are representative of at least three experiments.
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Figure 4.14. The Effect of Pertussis toxin on PKB activation in THP-1 cells
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Figure 4.14. The Effect of pertussis toxin on MCP-1, -2, -3, and -4-induced PKB activation in THP-1 cells. THP-1 cells (1x106 
per point) were pre-treated at 37°C for 16 hours with either vehicle (0.01% DMSO) or 100ng/ml PTX. Cells were then stimulated with 
vehicle (0.05% BSA) or MCP-1, -2, -3, -4 for the times indicated. Total cell lysates (2.5 x 105 cell equivalents per lane) were resolved 
separately by SDS-PAGE, electrophoretically transferred to a nitrocellulose membrane and immunoblotted with phospho-PKB or pan 
ERK/ERK-1/2 antibodies (to ensure equal loading of proteins). The results are representative of two experiments.
Figure 4.15 Verification of expression and activity of Class lA PI3K





o CD c o
^ — o O
COOXin x
COO o o x
c -O o
CM m X X X m X X X












</> E Eo  o  m
CO r -  r-
B) Ptdlns(3)P
Figure 4.15A. Expression of p85 in THP-1 cells. Resting THP-1 cells from 1.25x106- 2x107 cell 
equivalents were lysed, resolved separately by SDS-PAGE, and electrophoretically transferred to a 
nitrocellulose membrane as described in ‘Materials and Methods’. Lysates were immunoblotted with 
anti-p85 mAb. Jurkat cell lysates were used as a positive control. Results are from one experiment 
and representative of another 3 independent experiments.
Figure 4.15B. MCP-1 stimulates increases in p85 immunoprecipitates in THP-1 cells 1x107 
THP-1 cells were stimulated for various times with 10nM MCP-1. Cells were lysed, and lysates 
were subjected to immunoprecipitation with an anti-p85 mAb. The washed immunoprecipiates 
were analysed for PI3K activity using PI as a substrate. Extraction and TLC separation of the lipid 
products were performed as described under ‘Materials and Methods’. Lipids were detected by 
exposure to film at -70°C. Results are representative of three separate experiments. 11 q
Figure 4.16 Verification of expression and activity of Class lB PI3K
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Figure 4.16A Expression of p110y in THP-1 cells. Resting THP-1 cells from 1x106- 2x107 cell 
equivalents were lysed, resolved separately by SDS-PAGE, and electrophoretically transferred to a 
nitrocellulose membrane as described in ‘Materials and Methods’. Lysates were immunoblotted with 
anti-p110y mAb. Jurkat cell lysates were used as a positive control. Results are from one 
experiment and representative of another 2 independent experiments.
Figure 4.16B. MCP-1 stimulates increases in p110y immunoprecipitates in THP-1 cells.
1x107 THP-1 cells were stimulated for 1 minute with various concentrations of MCP-1, -2, -3 and -4. 
Cells were lysed, and lysates were subjected to immunoprecipitation with an anti-p110y mAb. The 
washed immunoprecipiates were analysed for PI3K activity using PI as a substrate. Extraction and 
TLC separation of the lipid products were performed as described under ‘Materials and Methods’. 
Lipids were detected by exposure to film at -70°C. Results are representative of four separate 
experiments.
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Figure 4.17. Effects of wortmannin and pertussis toxin on in vitro P! 3-kinase activity.
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Figure 4.17. Effects of wortmannin and pertussis toxin on in vitro PI 3-kinase 
activity. A) THP-1 cells were pre-treated for 16 h with 100ng/ml pertussis toxin, 15 
minutes with 50nM wortmannin or vehicle (0.01% DMSO) and then 1x107 cells/point 
were stimulated with MCP-1 (10nM) for the indicated times. Cells were lysed, and 
lysates were subjected to immunoprecipitation with an anti-p110y mAb. The washed 
immunoprecipiates were analysed for PI3K activity using PI as a substrate. B) 
Extended time-course of MCP-1-stimulated p110y immunoprecipitates in the absence 
of inhibitors. Extraction and TLC separation of the lipid products were performed as 
described under ‘Materials and Methods’. Lipids were detected by exposure to film at 
-70°C. Results are representative of four separate experiments.
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Figure 4.18a In vitro lipid kinase assay of MCP-1 stimulated THP-1 cells:
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Figure 4.18a. In vitro lipid kinase assay of MCP-1 stimulated THP-1 cells: 
Analysis of the Class II PI3K-C2 isoforms. 1x107 cells/point were stimulated at 
37°C with 10nM MCP-1 for various times. Cells were lysed, and lysates subjected 
to immunoprecipitation with anti-PI3K-C2a and PI3K-C2J3 polyclonal antibodies. 
The washed immunoprecipitates were analysed for PI kinase activity using PI as a 
substrate. Extraction and TLC separation of the lipid products were performed as 
described under ‘Materials and Methods’. Lipids were detected by exposure to film 
at -70°C. The data is representative of three separate experiments.
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Figure 4.18b. In vitro lipid kinase assay of MCP-1 stimulated THP-1 cells:
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Figure 4.18b. MCP-1-stimulates increases in P!3K-C2p immunoprecipitates: 
Effects of wortmannin and pertussis toxin. THP-1 cells were pretreated for 16 h 
with 100ng/ml pertussis toxin, or 15 minutes with 50nM wortmannin, and then 1x107 
cells were stimulated with 10nM MCP-1 for various times. Cells were lysed, and 
lysates were subjected to immunoprecipitation with anti-PI3K-C2p mAb. The 
washed immunoprecipitates were analysed for PI3Kactivity using PI as a substrate. 
Extraction and TLC separation of the lipid products were performed as described 
under ‘Materials and Methods’. Lipids were detected by exposure to film at -70°C. 
Results are representative of four separate experiments.
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Figure 4.19 Verification of SHIP expression in THP-1 cells
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Figure 4.19 Verification of SHIP expression in THP-1 cells. 1 x 105- 2x106 cell equivalents of 
total cell lysates were prepared from non-activated THP-1 cells. Lysates were resolved 
separately by SDS-PAGE and electrophoretically transferred to a nitrocellulose membrane as 
described in ‘Materials and Methods’. Lysates were immunoblotted with anti-SHIP mAb. A20 
and peripheral blood mononuclear cells (PBMCs) were used as positive controls (A), whereas 
Jurkat cell lysates were used as a negative control (B). Results are from one experiment and 
representative of another 3 independent experiments.
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Figure 4.20. Effect of MCP-1 stimulation on SHIP phosphorylation in THP-1 
cells. 1x107 THP-1 cells were stimulated with A) various concentrations, or B) for 
various times with 10nM MCP-1. Cells were then lysed, and lysates were subjected 
to immunoprecipitation with anti-SHIP mAb. All samples were resolved separately by 
SDS-PAGE, electrophoretically transferred to a nitrocellulose membrane and 
immunoblotted blotted with 4G10 antiphosphotyrosine antibody. Membranes were 
routinely stripped and reprobed with anti-SHIP antibody to verify equal loading of 
proteins.
*The western blot shown in A) is representative of at least three experiments, 
whereas B) is preliminary data that has not been repeated. 116
Figure 4.21 Effect of wortmannin on MCP-1 and MCP-2-induced
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Figure 4.21. Effect of wortmannin on MCP-1 and MCP-2-induced chemotaxis of THP- 
1 cells. 1 x 105 THP-1 cells per point were pre-treated for 15 minutes at 37°C with either 
vehicle (0.01% DMSO) or various concentrations of wortmannin. After incubation, cells 
were subjected to chemotaxis towards A) MCP-1 (1nM) or B) MCP-2 (100nM) in a 96-well 
Neuroprobe™ chamber for 3 hours. Migration was determined as described in ’Materials 
and Methods'. Results are expressed as a Chemotactic Index (C:l): the ratio of stimulated 
over basal migration. Data represent the mean ± SEM (5 replicates per chamber/2 
chambers per experiment). Results from one experiment but are representative of at least 
three other independent experiments. *:p<0.05, **:p<0.01, ***p<0.001.
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Figure 4.21 Effect of wortmannin on MCP-3 and MCP-4-induced
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Figure 4.21. Effect of wortmannin on MCP-3 and MCP-4-induced chemotaxis of THP- 
1 cells. 1 x 105 THP-1 cells per point were pre-treated for 15 minutes at 37°C with either 
vehicle (0.01% DMSO) or various concentrations of wortmannin. After incubation, cells 
were subjected to chemotaxis towards C) MCP-3 (10nM) or D) MCP-4 (100nM) in a 96-well 
Neuroprobe™ chamber for 3 hours. Migration was determined as described in ’Materials 
and Methods'. Results are expressed as a Chemotactic Index (C:l): the ratio of stimulated 
over basal migration. Data represent the mean ± SEM (5 replicates per chamber/2 
chambers per experiment). Results from one experiment but are representative of at least 
three other independent experiments. *:p<0.05, **:p<0.01, ***p<0.001.
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Results and Discussion: Activation of PI 3-kinase by CCR2 ligands
Section 4: Discussion 
Activation of PI 3-kinase bv CCR2 ligands
Rationale
Many signalling pathways converge on and regulate the PI3K enzymes whose 
liberation of inositol lipid products provide key mediators of intracellular signal 
transduction. Different PI3K isoforms generate specific lipids that bind to FYVE and 
PH domains in an array of proteins, which have consequences on their conformation, 
localisation and biochemical activities. The activation of PI3K has been reported in a 
number of systems in response to a variety of agonists that activate both tyrosine 
kinase -coupled and G-protein- coupled receptors (Mirmonsef et al 1999; Montaner 
et al, 1999). Recent work has highlighted the involvement of PI3K in the regulation of 
chemokine-mediated responses, including cytoskeletal reorganisation, integrin 
upregulation, and chemotaxis (Cumock et al, 2002). Moreover, the differential 
regulation of these responses by the various isoforms of PI3K is becoming an area of 
intense investigation. Many examples given in this discussion come from data 
gleaned from the SDF-1 and its cognate receptor, CXCR4. SDF-1 is one the most 
extensively studied chemokines with regards to signal transduction mechanisms. 
This is partly due to the fact that it binds exclusively to CXCR4, and therefore does 
not exhibit any promiscuity towards other receptor.
The same cannot be said for ligands of CCR2 since all four of them are known to 
bind to other CC chemokine receptors, however, this receptor is also widely studied 
in terms of signal transduction, and has provided with a strong foundation from which 
to launch our investigations. In 1998, Turner et al reported that MCP-1 activates the 
class I p85/p110 PI3K and the class II PI3K-C2a. Here, we have extended these 
investigations to MCP-2, -3 and -4 and have attempted to further elucidate the 
relative roles of PI3K isoforms to cellular function.
The two main procedures used in this study to measure PI 3-kinase activity involved 
measurement of lipid kinase activity in intact cells or broken cell lysates, and both 
relied on the detection of the transfer of the y-phosphate of ATP to the D-3 position of 
the inositol head group of the phosphoinositide lipids. The measurement of kinase
119
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activity in intact cells relied on the metabolic lipid labelling of the cellular pools of ATP 
with [32P]Pi followed by lipid extraction, separation of phosphorylated lipids by HPLC 
analysis. For the purposes of this study, we were mainly interested in the 
accumulation of Ptdlns(3,4)P2 and Ptdlns(3,4,5)P3 in chemokine stimulated THP-1 
cells. Overall the kinetics of D-3-lipid accumulation in response to MCP-1, -2, -3 and 
-4  followed similar trends. All of the chemokines induced a concentration and time- 
dependent accumulation in Ptdlns(3,4,5)P3 and Ptdlns(3,4)P2. Whereas the rise in 
Ptdlns(3,4,5)P3 was rapid and transient, the profile of Ptdlns(3,4)P2 demonstrated a 
delayed yet more sustained rise. It is quite possible that the sustained accumulation 
of Ptdlns(3,4)P2 was owed the action of a 5-phosphatase that contributed to the 
generation and breakdown of Ptdlns(3,4)P2 and Ptdlns(3,4,5)P3 respectively. This 
hypothesis was confirmed by the identification and characterisation of SHIP in THP-1 
cells. SHIP is 145kDa inositol-5-phosphatase containing an Src homology 2 (SH2) 
domain, 2 phosphotyrosine binding (PTB) motifs, and a COOH-terminal proline-rich 
region. This phosphatase selectively hydrolyses the 5’-phoshphate from both inositol 
1,3,4,5-tetraphopshate (IP4) and Ptdlns(3,4,5)P3 (Damen et ai, 1996; Lioubin et al, 
1996).
Several cytokines have been shown to induce tyrosine phosphorylation of SHIP, 
which may subsequently associate with She, the tyrosine phosphatase SHP-2, and 
Grb2. The actions of SHIP can be attributed, (at least in part) to its capacity to 
hydrolyse Ptdlns(3,4,5)P3 and restrain the PI3K pathway. By down-regulating PI3K, 
SHIP has also been shown to inhibit the activation of PKB and Btk, and subsequently 
has been strongly implicated in the negative signalling in a number of haematopoietic 
cell models (Liu et al, 1997). Given the crucial role of PI 3-kinase in chemokine 
signalling (Curnock et al, 2002) it stands to reason that SHIP activation would play a 
role in cellular responses to chemokines. Kim et al demonstrated that SHIP deficient 
cells exhibited an enhanced migration towards SDF-1 and BLC. SHIP'7' cells were 
also more efficient in calcium mobilisation and actin polymerisation in response to 
SDF-1. The observation of enhancement of chemotaxis of SHIP'7' cells versus wild- 
types was greater in thymocytes than splenocytes suggested that SHIP-modulated 
chemotaxis is dependent on the cell type, the receptor and the chemokine studied. 
In this context, it has been documented that targeted disruption of PI3K is more 
evident in B cells than T cells. (Fruman et al, 1999)
MCP-1 induced a concentration-dependent, and time-dependent tyrosine 
phosphorylation of SHIP that appeared to correlate with the observed kinetics of the
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D-3-lipids. It would have been interesting to further characterise the role of SHIP in 
CCR2 signalling pathways, perhaps by co-precipitation studies for She, SHP-2 or 
other downstream associates. From our preliminary studies, we are confident that in 
THP-1 cells, the activation of SHIP by MCP-1 would be in place to restrain the PI3- 
K/PKB pathway and subsequent functional responses.
Figure 4.22. The role of SHIP in D-3-lipid profiles
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Figure 4.22 The observed differences in kinetics between Ptdlns(3,4,5)P3 and 
Ptdlns(3,4)P2 accumulation could be owed to the phosphorylation and activation of 5- 
phosphatase, SHIP. See text for details
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In retrospect, it would have been useful to explore the role of other negative 
regulators of PI3-kinase signalling. PTEN is a tumour suppressor protein that shows 
homology to protein tyrosine phosphatases and tensin has and has been implicated 
in the biology of a diverse range of cancers (Maehama and Dixon, 1998). As a dual­
specificity phosphatase, it has control over the PI3-K/PKB pathways by 
dephosphorylating D-3-lipids on the 3’-phosphate from the inositol ring, thus, 
converting Ptdlns(3,4)P2 and Ptdlns(3,4,5)P3 to Ptdlns(4)P and Ptdlns(4,5)P2 
respectively. In the context of chemokine signalling, PTEN has been shown to inhibit 
cell migration by dephosphorylating key tyrosine-phosphorylated proteins, thereby 
antagonising interactions of integrin-triggered signalling pathways (Tamura et al,
1999). The strong interdependency between PI3-K/PKB pathways and lipid 
phosphatases are becoming increasingly apparent. A recent study in Drosophila 
demonstrated the paramount importance of PKB in mediating the effects of PIP3 
concentrations in PTEN deficiency, and confirmed that PKB appears to be the only 
critical target activated by increased levels of PIP3. It was further concluded that flies 
devoid of PTEN could survive abnormally high concentrations of Ptdlns(3,4,5)P3 if 
the affinity of PKB for Ptdlns(3,4,5)P3 (via the PH domain) is decreased (Stoker et al, 
2002).
In our experiments, the elution peaks for Ptdlns(4)P and Ptdlns(4,5)P2 were not 
consistent enough to extrapolate any data for these lipids. It would have been 
interesting to assess the profiles of these products and perhaps ascertain a role for a 
3’-phosphatase as well as the 5’-phosphatase, SHIP, in the regulation of this 
pathway. Preliminary studies showed that PTEN was highly expressed in the THP-1 
cell line (data not shown), but due to the boundaries of this project, investigations 
were not taken any further.
Activation of multiple PI3K isoforms by CCR2 ligation
Although measurement of D-3-lipid accumulation and the effects of pharmacological 
inhibitors demonstrated that PI3K was indeed an important signalling molecule in this 
system, these experiments provided limited information with regards to the specific 
isoforms of PI3K that were being activated. This is where the second method of 
PI3K measurement was employed. Here, we assayed specific immunoprecipitated 
PI3K subunits for associated lipid kinase activity under in vitro conditions using 
Ptdlns as a substrate. The application of in vitro lipid kinase assays enabled us to 
identify the involvement of specific PI3K isoform in response to CCR2 ligation. As
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expected, activation of GPCR-specific isoforms, p110y, was observed in response 
MCP-1, -2, -3, and -4 , and in the case of MCP-1, this activity was abrogated with 
pertussis toxin and wortmannin. Considering that chemokine receptors are by nature 
G protein-coupled, it would be reasonable to implicate PI3Ky in mediating 
accumulation of Ptdlns(3,4,5)P3 -  as has been previously observed in SDF-1- 
stimulated Jurkat cells (Sotsios et al, 1999). However, although this response was 
abrogated by pertussis toxin, the resistance of MCP-1-stimulated Ptdlns(3,4,5)P3 
accumulation to LY290042 makes this an unlikely hypothesis. Nevertheless, PI3Ky 
as a key mediator of D-3-lipid accumulation has been observed in similar systems. 
Interestingly, leukocytes from genetically modified mice with a PI3Ky-deficient 
phenotype are unable to produce Ptdlns(3,4,5)P3 in response to the CXC chemokine, 
IL-8 (Hirsch etal, 2000).
The kinetics of p110y activation in response to MCP-1 demonstrated an interesting 
pattern. The time-course experiments implied that there was a biphasic activation of 
this isoform which peaked at around 30 s followed by a second peak at 
approximately 10-15 m post-stimulation. Furthermore, this observation correlates 
with a similar study with IGF-1 -stimulated T cells where by PI3K and PKB activity 
followed a biphasic pattern (Hershberg and Mayer, 2000). It is possible that this 
activation profile with characteristic early and late functions denotes that PI3K could 
be capable of supporting immediate and sustained cellular responses in response to 
MCP-1 stimulation.
Although there is a wealth of strong biochemical and genetic evidence for the 
activation of PI3Ky by chemokines, it is becoming increasingly clear that this may not 
be the only isoforms capable of transducing chemokine-stimulated responses. This 
comes largely from the observation that in PI3Ky deficient mice there was only a 50- 
70% inhibition of neutrophil chemotaxis (Hirsch et al, 2000; Li et al, 2000; Sasaki et 
al, 2000). It is possible that other isoforms are activated by these receptors. Indeed, 
in vitro lipid kinase activity has been observed in p85 immunoprecipitates in response 
to SDF-1 and RANTES in T cells (Turner et al, 1995: Sotsios et al, 1999) and by 
MCP-1 in THP-1 cells (Turner et al, 1999).
Activation of the prototypical p85/p110 heterodimer was seen in response to MCP-1, 
and confirmed previous observations in this system in that it was a wortmannin- 
sensitive, time-dependent event. However, it seems unlikely that the p85/p110
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heterodimer would be significantly contributing to overall detectable D-3 lipid pool 
stimulated by MCP-1, -2, -3 or -4  due to the apparent resistance to wortmannin with 
regards to lipid accumulation. Our investigations into the role of this isoform did not 
go beyond this point, although it would have been useful to have identified any 
involvement of tyrosine kinases in D-3-lipid accumulation. Such studies have been 
carried out in SDF-1-stimulated Jurkat cells: Here, the p85/p110 heterodimer was not 
suspected to be instrumental in the generation of D-3-lipid products on account of its 
sensitivity to pertussis toxin and resistance to Herbimycin-A. This pharmacological 
evidence was further confirmed using U937:Ap85 cells, whereby the loss of coupling 
to p110a,(3,y isoforms by Ap85 had no effect on SDF-1-stimulated Ptdlns(3,4,5)P3 
(Sotsios eta!, 1999)
Previous studies have also shown that in THP-1 cells, MCP-1 induces lipid kinase 
activity to co-associate with anti-phosphotyrosine immunoprecipitates, and thus 
further evidence that the prototypical p85/p110 heterodimer was being activated in a 
phosphotyrosine-dependent manner. This has also been observed in CXCR4- 
expressing pre-B cell lines in response to SDF-1 stimulation (Ganju et al, 1998), as 
well as in MCP-1-stimulated THP-1 cell.
The observation of protein tyrosine phosphorylation has been observed in response 
to a number of chemokines, however, the assessment of tyrosine phosphorylation in 
response to MCP-1, -2, -3 and -4  stimulated THP-1 cells was a crucial set of 
experiments that failed to be carried out in this study. Although our group has 
previously shown that MCP-1-induces tyrosine phosphorylation of proteins at 50, 80 
and 120kDa in THP-1 cells, it would have been useful to out investigations to 
compare this against other CCR2 ligands.
How would CCR2 couple to the class lA p85/p110 heterodimer?
Coupling of p85/p110 PI3K is know to require interaction of the SH2 domains within 
the p85 regulatory subunit with specific phosphotyrosine-containing binding motifs 
(pYXXM; where pY represents phospho-tyrosine) located in growth factor receptors 
and adapter molecules (Ward et al, 1996). The mechanism by which chemokine 
receptors associate with p85/p110 is ill-understood. Several groups have proposed 
that the GPCR-mediated activation of p85/p110 PI3K is activated by the (3y subunits. 
However, the caveat with this theory is that few chemokines are known stimulate 
events of tyrosine phosphorylation -  and the p85/p110 is known to co-associate with
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phosphotyrosine-containing proteins (Stephens et al, 1997; Vanhaesebroek et al,
2000). A more feasible route by which chemokine receptors could regulate p85/p110 
in a phosphotyrosine-dependent mechanism, could be through modulation of the 
Gctj. This comes from the observation that GTP-bound Gai subunits can bind and 
activate Src and Hck (Ma et al, 2000). In terms of linking to the class I PI3K pathway, 
the association of Gai may also extend to other members of the Src kinase family 
(e.g. Lck and Lyn) as has been suggested for the GPCR-mediated route to Ras 
activation (Ganju etal, 1998).
Class IIPI3K: A novel class of PI3K activated by CCR2
In our system, the observation that the pertussis toxin-sensitive accumulation of 
Ptdlns(3,4,5)P3 was in fact resistant to PI3K inhibitors provided evidence that neither 
the p85/p110 heterodimer nor the PI3Ky was involved in this response. We were 
subsequently led to observe the effects of MCP-1 on the novel class II PI3Ks, PI3K- 
C2a and PI3KC2p, which have been shown to have a reduced sensitivity to 
wortmannin (Domin et al, 1997). Recent studies have shown that like the class I 
enzymes, class II PI3Ks also act downstream of receptors for growth factors 
(Wheeler and Domin, 2001) and for chemokines (Turner et al, 1998) and for integrins 
(Zhang et al, 1998). Here we have shown that MCP-1 activates PI3-KC2a and PI3- 
KC2p in THP-1 cells in a time-dependent manner, albeit with slightly different 
kinetics.
Assuming that these class II enzymes are responsible for the observed MCP-induced 
Ptdlns(3,4,5)P3 accumulation, we have a number of hypotheses as to how they may 
be involved in CCR2-mediated signal transduction. From analogy with what has 
been observed about GPCR coupling to PI3Ky, there are at least two putative 
mechanisms by which MCP-1 could activate PI3K-C2a/p in a pertussis toxin- 
sensitive manner: (i) direct interact of GPy subunits with PI3K-C2a/p as has been 
reported to occur for PI3Ky (Leopoldt et al, 1998); (ii) GPy subunits may activate 
PI3K-C2a via protein tyrosine kinases considering that there is evidence supporting 
PTKs in Gj/o-mediated cell signalling (Ptasznik et al, 1995; Lopez-llasca et al, 1997).
It could follow that the pertussis toxin-sensitive MCP-1-induced activation of PI3K-C2 
a/p, maybe solely or partly be responsible to the detectable changes in 
Ptdlns(3,4,5)P3. Interestingly, in contrast to other reports, our data show that there is 
in fact a moderate wortmannin-sensitivity in PI3K-C2P immunoprecipitates, and this
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observation has recently been confirmed in Jurkat cells (K.Patel, unpublished 
observations). It may possible that PI3K-C2a is the key mediator in D-3-lipid 
accumulation in MCP-1-stimulated THP-1 cells. However, caution must be taken 
when considering this theory since the in vitro substrate specificity of PI3K-C2a is 
restricted to Ptdlns and Ptdlns(4)P (Domin et al, 1997), and would apparently 
contradict it’s potential role in mediating Ptdlns(3,4,5)P3. That said, it is conceivable 
that the substrate specificity of this isoforms may be quite different in intact cells to 
that reported under in vitro conditions.
Further clues from the downstream effectors of PI3K
We extended our investigations of the PI3K pathway by testing the involvement of 
protein kinase B (PKB), a kinase that is activated downstream of PI3K, with the 
participation of other signalling molecules such as PDK-1 (for review: Coffer and 
Woodgett, 1999). Several G protein coupled receptors, including those activated by 
chemokines have been shown to activate PKB in a PI3K-dependent manner (Sotsios 
et al, 1999; Turner et ai, 1998), and this is supported by the observation that IL-8 is 
unable to stimulate PKB in P3Ky-deficient neutrophils (Hirsch et al, 2000). Emerging 
evidence has implicated PKB activation as a prerequisite for efficient chemotaxis in 
Dictyostelium (Meili et al, 1999). Inhibition of PI3Ks with wortmannin or LY290042 
blocks chemoattractant-induced translocation of PH-PKB green fluorescent protein 
and subsequent activation of PKB (Tilton et al, 1997). However, although 
cytoskeletal reorganisation and lamellipodium are events mediated by PI3K (Cox et 
al, 1999), they can occur independently of PKB (Ma et al, 1998).
In our system, MCP-1, -2, -3 and -4  induced a transient increase in PKB 
phosphorylation, thus confirming that the PI3K/PKB axis is a target of CCR2 
signalling. Interestingly, whereas manumycin had no effect on D-3-lipid 
accumulation, treatment with wortmannin almost completely ablated PKB activity. 
This apparent discrepancy in biochemical output is difficult to explain. Since the 
favoured substrate of PKB is Ptdlns(3,4,5)P3l and to a lesser extent, Ptdlns(3,4)P2, it 
is unlikely that any other lipid could be modulating PKB activation. So, if indeed 
Ptdlns(3,4,5)P3 and Ptdlns(3,4)P2 are responsible for it’s activation, why does 
wortmannin block the activity of PKB, but not its substrates? It is possible that 
although gross accumulation of Ptdlns(3,4,5)P3 and Ptdlns(3,4)P2 in the overall lipid 
pool can be measured in vivo, a small amount lipids generated by wortmannin- 
sensitive PI3K isoforms could go undetected -  and it is these residual D-3-lipids that 
may account for the wortmannin-sensitive PKB activation observed in our system.
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Given the role of PKB as a key player of growth factor-induced cell survival and 
protection, identification of the substrates of PKB is subject to intensive research, 
since at least one must play a role in the suppression of apoptosis. Therapeutic 
targeting strategies have progressed from inhibition of the PI3K/PKB axis, to the 
identification, and possible manipulation of the negative regulators of PKB. For 
example, the recently identified CTMP (carboxy-terminal modulator protein) inhibits 
phosphorylation of PKB by binding to the COOH-regulatory domain of PKBa. One of 
several mechanisms for preventing inappropriate kinase activation and subsequent 
excess proliferation, and thus, has potential implications for cancer biology (Maira et 
al, 2002).
The principle physiological substrate of PKB is glycogen synthase kinase-3 (GSK-3), 
which was initially identified as an enzyme that regulates glycogen synthesis in 
response to insulin (Pap and Cooper, 1998). The demonstration that stimulation of 
THP-1 cells with MCP-1, -2, -3 and -4 resulted in phosphorylation of GSK-3 was 
further evidence that the PI3K/PKB pathway is a critical element of CCR2-mediated 
signal transduction. Interestingly, this is not the first chemokine to have been shown 
to activate this pathway. For example, the TECK/CCR9 interaction activates GSK-3 
and the forkhead transcription factor (FHKR), and provides a cell survival signal to 
receptor expressing cells (Youn et al, 2001).
It was show in these studies that MCP-1, -2, -3 and -4  phosphorylate GSK-3 in a 
comparative fashion to that of PKB. However, in the case of MCP-2-stimulated THP- 
1 cells, there was a lack of correlation in THP-1 cells in terms of the sensitivity of 
GSK-3 to wortmannin. Although reduced, GSK-3 was activated by MCP-2 even in 
the presence of wortmannin suggesting that a PKB-independent route may activate 
GSK-3. and further underscores the multiple levels of cross-talk among the PI3K 
signalling cascades in this system.
There is growing evidence of mechanisms of GSK-3 phosphorylation and inactivation 
independent of a functional PI3K-PKB pathway. For example, such modes have 
been previously demonstrated in the Wnt pathway required for Drosophila 
development (Miller and Moon, 1996). More recently Fang et al, have shown that 
GSK-3a/p are also physiological substrates of cAMP-dependent protein kinase A 
(PKA). Here, PKA physically associates with, phosphorylates, and inactivates both 
isoforms of GSK-3. Thus PKA functions as a GSK-3 kinase that, in parallel with PKB, 
controls the activity of the multifunctional enzyme GSK-3. In this example, the
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convergence of the PKA and PKB signalling pathways at GSK-3 suggests that, 
depending on the environmental context, the activity of GSK-3 can be regulated 
either by growth factors (e.g., insulin and IGF-1) working through the PI3K-PKB 
cascade or by hormonal stimulation (e.g., adrenaline) of G protein-coupled receptors 
that link to changes in intracellular cAMP concentrations (Fang et al, 2001).
PI3K is a key modulator of cell migration
Having demonstrated that engagement of CCR2 activates a number of PI3K 
isoforms, it was important to determine the relative role of this enzyme on functional 
output. For some time, PI3K has been considered to be an important regulator of cell 
migration in many systems including those elicited by chemokines. Elegant molecular 
and pharmacological evidence first suggested that PI3K and its lipid products play a 
significant role in PDGF-dependent actin polymerisation and cell migration (Kundra et 
al, 1994). As discuss in Section 5, the Rho GTPases (Rho, Rac and Cdc42) are 
regulators of actin cytoskeleton and cellular polarity and there is much interest in 
ascertaining their relationship with PI3K-dependent signalling. Indeed, there is 
overwhelming evidence to indicate that Rho family kinases are regulated by PI3K is 
many systems (Hall et al, 1998; Tolias et al, 1995). Other studies have pinpointed 
the specific PI3K subunits necessary for such regulation. Jiminez et al have 
described how PDGF indirectly activates Cdc42 and further proposed that the 
regulatory subunit of PI3K, p85a, is one of the molecules controlling this process. In 
this respect, it was postulated that p85a performs as an adapter molecule by bringing 
a GTPase regulator into the complex that mediates Cdc42 activation.
The motility of the cell not only requires actin polymerisation, but also the modulation 
of cell polarisation that coordinates adhesion at the leading edge and contraction at 
the trailing edge. PI3K is just one of an emerging number of signalling molecules 
that have been heavily implicated in leukocyte polarisation in cell migration and 
immune interactions (Sanchez-Madrid et al, 1999). Chemokines can also activate 
PI3K-dependent signalling cascades implicated in the regulation of chemotaxis and 
modulation of integrin affinity (Kundra et al, 1994; Hartwig et al, 1995). This is 
highlighted by the observation that RANTES-induced T cell chemotaxis and 
polarisation is abrogated by PI3K inhibitors (Turner et al, 1995). Gerszten et al, have 
recently shown that PI3K are necessary for chemokine-triggered conversion of 
monocyte rolling to firm adhesion under physiological flow conditions
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In this system, it is clear that PI3K plays a fundamental role in the migration of THP-1 
cells towards MCP-1, -2, -3, and -4. However, with the exception of MCP-2-induced 
chemotaxis (which was totally abrogated by wortmannin), a residual level of 
migration is still observed even in the presence of high concentrations of PI3K 
inhibition. This is suggestive that cell migration in this system is mediated by other 
PI3K-independent mechanisms. Given that we have identified a number of isoforms 
activated by engagement of CCR2, it would have been interesting to elucidate which 
of these were responsible for migration. Although p110y has been heavily implicated 
in chemokine-mediated responses, it is unlikely that such complex processes are 
entirely dependent on one isoform. It is more likely that there is an integration of 
several signalling events that could be provided by more than one of the identified 
PI3Ks. Several lines of evidence are indicative that although p85/p110 heterodimer 
does not contribute to SDF-1 or MCP-1-stimulated D-3-lipid accumulation (Sotsios et 
a/,1999; Turner et al, 1998) , it may still have a functional relevance. For example, 
this isoform could perhaps account for the residual neutrophil chemotaxis observed 
in p110y-deficient mice.
As suggested from our lipid data and PKB activation profiles, it is possible that the 
wortmannin-sensitive p85/p110 heterodimer could have a small, undetectable but 
nevertheless significant role in the contribution to the overall D-3-lipid pool. Hence, 
this isoform could be providing an important role in CCR2-mediated cell migration. It 
must also be considered that physiological role for PI3K may reside in its protein 
serine kinase activity rather than it lipid kinase activity. It is important for future 
studies to establish the potential for bifurcation of lipid and protein kinase signals to 
distinct downstream effectors (Bondeva et al, 1998).Although we have suggested the 
possible involvement of PI3K-C2a and PI3K-C2p in this system, as of yet there is no 
information as to whether their activation is of functional significance. For this we 
await the development of selective pharmacologicalal inhibitors, and strategies for 
genetic modification.
Activation ofmuitiple PI3Ks: A functional strategy?
As we have demonstrated in our studies, activation of more than one PI3K can ensue 
chemokine receptor ligation. There is incredible potential for heterogeneity of 
chemokine receptor isoforms and/or G protein subunits that may give rise to 
differential regulation of PI3K isoforms. Furthermore, the contribution of PI3K 
isoforms to certain signalling events can also vary according to the cell type and 
receptor studied. For example, although CCR2A and CCR2B can couple to the Gr
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G(3y-PLCp2 pathway, their splice variants exhibit a unique specificity in coupling to 
the a subunits of the Gq class. In this respect, CCR2 is able to couple Ga16 and 
Gan, whereas CCR2A cannot couple to either of these (Kuang et al, 1996). Given 
the potential diversity within the coupling of chemokine receptor to G protein subunits 
and PI3K isoforms, it is no surprise that chemokines have the ability to elicit such a 
diverse range of functional responses. The differential regulation of signalling 
pathways through chemokine receptors permits leukocytes to have concurrent 
control of adhesion molecules regulation, cytoskeletal reorganisation, shape change, 
granule release and superoxide release.
Future Investigation
> Extend the investigation of the PI3K isoforms activated by MCP-2, MCP-3 
and MCP-4 in comparison to MCP-1. Is there differential regulation of PI3K 
isoforms via CCR2 ?
> Co-precipitation studies: Investigate the molecular associations of PI3K 
subunits. Examine the formation of PI3K-related signalling complexes 
ensuing CCR2 engagement.
> Carry out comprehensive screening of tyrosine phosphorylation events 
elicited by CCR2 ligation. Assessment by 1) western blotting, and ; 2) the In 
vitro lipid kinase activity of 4G10 immunoprecipitates derived from MCP- 
stimulated THP-1 cells.
> Look at the effects of inhibitors of tyrosine phosphorylation on MCP-induced 
accumulation of D-3-lipids, and in vitro lipid kinase activity of 
immunoprecipitated PI3K isoforms.
> Using GFP-tagged PKB constructs: Observe the cellular redistribution of PKB 
and the role of its PH domain following CCR2 engagement.
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Section 5: Results
The Role of PI 3-kinase in ERK-1/2 activation
Rationale
As discussed in Section 4, PI3-kinase is a critical enzyme for multiple cellular 
functions and may be activated by several pathways, depending on the isoform 
involved and the regulatory molecule implicated. Cross talk between PI3-kinase and 
other signalling cascades has been well documented, with the best characterised 
being that of the PI3-K-Ras/MAPK pathway. Interestingly, for several chemokines it 
has been shown that receptor binding activates the ERK (extracellular signal 
related)/MAPK pathway in multiple models including human monocytes and 
monocytic cell lines (Knall etal, 1996; Yen etal, 1997; Coffer etal, 1998; Ganju etal, 
1998). Although MCP-1 has been shown to activate several signalling cascades, 
including the PI3-kinase and ERK/MAPK pathways (Turner et a, 1998; Ashida et al, 
2001), the molecular mechanisms and cross-talk between systems remains ill- 
understood. Moreover, the ability of other CCR2 ligands (MCP-2, -3 and -4) to 
activate such systems has not yet been addressed. In this section, we attempt to 
explore 1) the ability of CCR2 ligands to activate the MAPKs including the SAPKs 
(stress activated proteins kinases); 2) the role of PI-3K in CCR2-mediated MAPK 
activation; and 3) the relevance of these signalling cascades to cell migration.
Results
Activation of MAPK cascade
We investigated whether the MCP ligands induced phosphorylation of ERK-1/2, p38, 
and JNK in THP-1 cells, with phosphorylation being a prerequisite for inducing kinase 
activity. Accordingly, THP-1 cells were incubated with MCP-1, -2, -3 and 4 using 
concentration known to elicit an optimal functional response (1nM, 10nM, 10nM and 
100nM, respectively) for varying lengths of time, and cell lysates were subjected to 
immunoblotting using antibodies that specifically recognise the phosphorylated forms 
of these kinases. In addition, the use of pharmacological inhibitors to G-proteins, 
PI3-K, PKC and MEK helped to further define the implication of individual signalling 
molecules to MCP-induced MAPK activation.
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MCP-1, -2, -3 and -4 activate MAPKs via a PI3-kinase-dependent mechanism
Figure 5.1. MCP-1-stimulated THP-1 cells showed rapid and transient 
phosphorylation of ERK-1/2 with maximal activity at 2-5 minutes after stimulation 
(kinetics varied between experiments), and returned near basal levels after by 10 
minutes. Pre-treatment with 50nM wortmannin only partially ablated ERK-1/2 
phosphorylation, which indicates that MCP-1-stimulated activity of this pathway is 
partially dependent on PI3-kinase.
MCP-2, -3 and -4 also stimulated transient increases in ERK-1/2, albeit with slightly 
different kinetics to that observed with MCP-1. Wortmannin served to completely 
abrogate MCP-3 and -4 -stimulated ERK-1/2 activation, whereas with MCP-2- 
stimulated cells, ERK-1/2 phosphorylation was only partially inhibited.
MCP-1, -2, -3 and -4 activate SAPKs via a PI3-kinase-dependent mechanism
In addition to ERK/MAPK activation in THP-1 cells, the effects of CCR2 ligands on 
stress activated protein kinases (SAPKs), p38/SAPK and JNK/SAPK were also 
assessed. Activation of p38 requires phosphorylation of Thr-180 ad Tyr-182 (Lee et at,
1994) and can be assayed directly using phospho-specific antibodies. MCP-1 and 
MCP-3 both transiently activated p38 with maximal activity seen 2-5 min post­
stimulation. Pre-treatment with wortmannin also demonstrated that p38 pathway in 
response to MCP-1 ad MCP-3 is entirely dependent on PI3-K. MCP-2 and MCP-4, 
demonstrated a lesser dependency on PI3-K since wortmannin served to partially 
inhibit phosphorylation of p38. MCP-1, -2, and -3 showed similarities kinetics of p38 
activation (peaking 2-5 min post-stimulation), however, MCP-4 was maximal at 
approximately 10 min after stimulation.
In addition, we also investigated the activation of the c-Jun N-terminal stress- 
activated protein kinase 1/2 (JNK1/2). When activated, JNK1 and JNK2 become 
phosphorylated on Thr183 and Tyr185, respectively, and this was assessed using an 
anti-dual phosphorylated JNK1/2 antibody. Figure 5.2 demonstrates how all four 
CCR2 ligands induce activation of JNK1/2 as shown by bands corresponding to 
46kDa and 55kDa. Similar to the pattern observed with p38, MCP-1 and MCP-3 
rapidly and transiently activated JNK1/2 in a manner that appeared to be entirely 
dependent on PI3K. MCP-2 and MCP-4-stimulated JNK phosphorylation, on the 
other hand, was only partially dependent on PI3K. Again, MCP-4 exhibited delayed 
kinetics in activation of SAPK, showing maximum activation of JNK1/2 after 10 min.
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Small GTP binding proteins in MCP-1-induced MAPK activation.
We used a fusion protein (GST-RBD) comprising the Ras-binding domain of Raf to 
selectively precipitate active Ras, which interacts with this domain of Raf-1 (DeRooij 
and Bos, 1997). In unstimulated cells, active Ras was clearly detectable as a single 
band at 21kDa (Figure 5.3). Stimulation of cells with MCP-1 resulted in a greater 
amount of precipitated activity after 5 m, indicating increased activity. The effects of 
MCP-2, on the other hand were inconclusive. Stimulation with this chemokine failed 
to give a clear result. As a positive control, Jurkat cells, stimulated with PMA, 
induced a detectable increase in Ras activity after 10 m.
The role of Ras in downstream signalling pathways was assessed using the selective 
bacterial toxins from Clostridium sordelli. These virulence factors, known as 'lethal 
toxins', specifically glucosylates and inhibits small GTPases. Although lethal toxins 
used in this study have the highest selectivity for Ras, other small GTPases are also 
modified. LT82 modifies Ras, Rac, Rap and Ral, whereas LT9048 modifies Rac, 
Cdc42, Rap (weakly) and Ral (very weakly). Figure 5.4 shows the dose-dependent 
effects of LT-82 on basal activation of ERK-1/2. It was demonstrated that 500ng/ml 
(2 hour pre-treatment) was the minimum concentration required to inhibit ERK-1/2 
activity in this system. Based on these results, this concentration was used in 
subsequent biochemical experiments.
When incorporated into a time-course experiment, it can be seen that LT-82 
completely abrogated MCP-1-stimulated ERK-1/2 activation (Figure 5.5). The 
densitometric analysis (normalised with equal loading controls) demonstrated that 
this toxin reduced ERK-1/2 activation to basal levels. LT-9048, on the other hand, 
reduced constitutive activity of ERK-1/2, but yet did not completely ablate MCP-1- 
stimulated activation. Although reduced, a signal was detected 2 min post­
stimulation.
We then went on to explore the role of small GTPases in PI3K activation. LT-82 
served to inhibit MCP-1-induced Ptdlns(3,4,5)P3 accumulation in THP-1 cells as 
analysed by 32P metabolic labelling of phospholipids (Figure 5.6). Protein kinase B 
(PKB) has always been recognised as a pathway that lies downstream of PI3K. 
MCP-1-induced PKB phosphorylation on the activation specific Ser-473, was 
markedly inhibited to near basal levels with LT-82 and LT-9048 (Figure 5.7). These
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results were highly indicative that Ras is involved in the PI3K-mediated accumulation 
of D-3-phosphatidylinositol lipids in this system. Figure 5.8. In vitro lipid kinase 
assays of immunoprecipitated subunits of PI3K showed the effects of lethal toxin on 
specific isoforms of PI3K, namely p85/p100 heterodimer and PI3Ky. In the case of 
p85, the basal activity of these immunoprecipitates was increased by LT-82, although 
stimulated activity was attenuated - However, due to the LT-induced increase in 
basal expression of p85 and subsequent masking of stimulated activity, these results 
were inconclusive. MCP-1-stimulated activity of the p110y immunoprecipitates was 
clearly inhibited by this toxin, and baseline activity was unaffected. Class II PI3Ks 
were not investigated.
Because we have shown that a) Ras lies upstream of PI3K, and b) cell migration is 
critically regulated by PI3K in this system, we tested the effects of the lethal toxins on 
MCP-1-induced chemotaxis. Figure 5.9. Both LT-82 and LT-9048 drastically 
inhibited cell migration towards MCP-1 (IC50 = 3.6 and 11.8 ng/ml, respectively), to 
below basal levels -  thus, indicating a role for small GTPases, such as Ras, in 
chemokinesis as well as chemotaxis.
CCR2 couples to PTX sensitive and PTX-insensitive pathways
Figure 5.10. Pertussis toxin (PTX) was used to investigate the involvement of 
specific G-protein subunits in ERK-1/2 activation is response to MCP-1, -2, -3 and -  
4. As previously established, all four ligands induced a time-dependent increase in 
ERK-1/2 phosphorylation in the absence of inhibitor. When pre-treated with PTX 
(100ng/ml, 16 hr), chemokine-stimulated ERK-1/2 activation was severely 
compromised. In the case of MCP-2, -3, and -4 , ERK-1/2 phosphorylation was 
attenuated, however, in MCP-1-stimulated cells, a small amount of residual signalling 
was evident at 5 m post-stimulation.
Interestingly, the effect of PTX on JNK phosphorylation was also assessed. Even in 
the presence of PTX, signalling was evident in response to MCP-1, -2, -3 ad 4, albeit 
reduced. This selective inhibition of ERK infers that PTX does not uncouple CCR2 
from all classes of G protein.
The effects of PTX on functional response were clear from chemotaxis assays 
(Figure 5.11). Treatment of THP-1 cells with 100ng/ml PTX totally abrogated all 
chemotaxis towards MCP-1, confirming earlier observations that CCR2 is linked to 
the Gai family of G proteins (Kuang et al, 1996; Turner etal, 1998).
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The role of MAPK in CCR2-mediated chemotaxis
To test the relative importance of ERK in transducing the chemotactic signal of MCP- 
1, it was necessary to test the effects of MEK inhibitor, PD98059. The compound, 
PD98059 (Alessi et al, 1995), which specifically inhibits MEK1, has been reported to 
be a potent inhibitor of cytokine-induced ERK-1/2 activation (Alessi et al, 1995). The 
observation that ERK-1/2 is activated by MCP-1, a potent physiological activator of 
monocytes, does not prove its functional significance in monocyte migration. We 
endeavoured to evaluate the potential role of ERK in MCP-1-mediated chemotaxis of 
THP-1 cells. The effect of MAPK inhibition on MCP-1-mediated chemotaxis was 
examined by incubating cells with/without various concentrations of the MEK inhibitor 
PD98059 (Figure 5.12). Strikingly, addition of PD98059 did not block MCP-1- 
induced chemotaxis at any concentration tested (0-50pM), in fact, pre-treatment with 
this compound served to potentiate cell migration. Certainly in the case of MCP-1, 
these results suggest that ERK-1/2 activation per se does not appear to be 
necessary for chemotaxis in this system.
To ensure that PD98059 was an appropriate compound to use in this system, we 
assessed its biochemical effect on ERK-1/2. This revealed a potent inhibition of 
MCP-1, -2, -3 and -4-induced ERK activation (Figure 5.13). This was a key 
experiment to determine that a) MCP-induced activation of ERK was a MEK-driven 
event, and b) to verify that PD98059 was efficient on its target when applied to intact 
cells in subsequent functional assays.
The contribution of PKC to CCR2-mediated MAPK activation and functional 
responses.
The observation of PKC as a lipid- and Ca2+-dependent serine/threonine kinase that 
serves as a cellular receptor for tumour-promoting phorbol ester has implicated PKC 
in the activation and mitogenesis of a variety immune cells. This has been further 
substantiated by the demonstration that cellular depletion of PKC by prolonged 
treatment with phorbol esters, or PKC inhibitory drugs, significantly inhibits cytokine- 
induced activation (Altman et al, 1990; Li et al, 2000). Recent years have seen a 
surge of interest aimed at elucidating the role of PKC in MAPK activation (Takeda et 
al, 2000). In the context of this study, we have attempted to clarify the role of PKC in 
the coupling of CCR2 to the MAPK pathway and chemotactic responses.
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The PKC inhibitor, Ro-320432, served to increase basal levels of phosphorylation of 
ERK-1/2 in THP-1 cells, but had no effect on MCP-2 ad MCP-4-induced signalling 
(Figure 5.14). Although the rise in basal phosphorylation may have masked the 
magnitude to which the ligands induced a biochemical response, MCP-1 and MCP-3 
demonstrated appeared to induce a moderate increase in ERK-1/2 activity above 
baseline. In the case of MCP-1-induced SAPK activation, inhibition of PKC with Ro- 
32o432 modestly reduced p38 phosphorylation, but completely ablated MCP-1- 
stimulated JNK1/2 activation (Figure 5.15).
Figure 5.16A. Using a concentration of MCP-1 known to elicit a chemotactic 
response (1nM), cell were pre-treated with Ro-320432 (0-50^iM) and assayed for 
chemotaxis. Migration was not inhibited by this compound, but was potentiated 
(although ot significantly) in a concentration-dependent manner. At 50jiM Ro- 
320432, the chemotactic index toward MCP-1 was increase from 2.4 to 2.8. To 
confirm this data, the effect of PKC on MCP-1-induced cell migration was assessed 
by depletion of intracellular PKC through long term exposure to phorbol ester (PMA) 
(Figure 5.16B). In conflict to the Ro-320432 data, pre-treatment of cells with PMA 
completely abrogated cell migration.
Results Summary
>  MCP-1 stimulates activation of ERK-1/2, p38 and JNK-1/2 in a PI3-kinase- 
dependent manner. Incubation of cells with MCP-1 gave rise to a modest 
increase in active GTP-bound Ras, as assessed by GST-RBD fusion protein 
assay.
> ERK-1/2 activation was severely abrogated by LT-82, but only partially reduced 
by LT-9048. LT-82 inhibited MCP-1-induced Ptdlns(3,4,5)P3 generation and PKB 
phosphorylation. This toxin also abrogated MCP-1-stimulated In vitro lipid kinase 
activity in p110y immunoprecipitates.
> LT-82 and LT-9048 attenuated cell migration towards MCP-1.
>  MCP-1-stimulated activation of ERK-1/2 and JNK-1/2 were partially inhibited by 
pertussis toxin, whereas the chemotactic response was completely abolished.
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>  MEK inhibitor, PD98059, was found to inhibit all CCR2-mediated ERK-1/2 
activation, although served to potentiate cell migration towards MCP-1.
>  Selective inhibition of PKC isoenzymes by Ro-320432 1) had no visible effect on 
MCP-1-stimulated ERK-1/2 phosphorylation, 2) a partial inhibitory effect on p38 
activity and; 3) totally inhibited JNK-1/2 activation.
> Ro-320432 modestly potentiated MCP-1-induced chemotaxis in a concentration- 
dependent manner. However, depletion of intracellular PKC stores by long-term 
exposure to phorbol ester abolished cell migration towards MCP-1.
> MCP-2 stimulated ERK-1/2, p38 and JNK-1/2 in a manner that was partially 
dependent on PI3-kinase whereas in response to MCP-3, these enzymes were 
entirely PI3-kinase dependent. On the other hand, when stimulated with MCP-4, 
ERK-1/2 activation was sensitive to PI3-kinase inhibition, but SAPKs, p38 ad 
JNK-1/2 were unaffected.
> Pertussis toxin totally inhibited MCP-2, -3, -4 -induced ERK-1/2 phosphorylation, 
but only partially reduced JNK-1/2 activation.
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Figure 5.1 The Effect of wortmannin on CCR2-mediated ERK-1/2
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Figure 5.1 The Effect of wortmannin on CCR2-mediated ERK-1/2 activation in THP-1 
cells. THP-1 cells (1 x106 per point) were pre-treated for 15 minutes with vehicle (0.01% 
DMSO) or 50nM wortmannin. Cells were then stimulated with vehicle (0.05% BSA), MCP-1, - 
2, -3 or -4 for the times indicated. Total cell lysates (2.5x105 cell equivalents per lane) were 
resolved separately by SDS-PAGE, electrophoretically transferred to a nitrocellulose 
membrane, and immunoblotted with anti-active MAPK antibodies (phospho-ERK-1/2). To 
verify equal loading of proteins, a set of corresponding lysates were probed with anti-pan 
ERK1 antibody. The results are representative of at least three independent experiments.
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Figure 5.2 The Effect of wortmannin on CCR2-mediated SAPK activation in THP-1 cells
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Figure 5.2. The Effect of wortmannin on CCR2-induced SAPK activation in THP-1 cells.
THP-1 cells (1x106 cells/point) were pre-incubated for 15 minutes with vehicle (0.01% DMSO) 
or 50nM wortmannin. Cells were then stimulated with vehicle (0.05% BSA), MCP-1 MCP-2, -3 
or MCP-4 for the times indicated. Total cell lysates (2.5x105 cell equivalents per lane) were 
resolved separately on SDS-PAGE, electrophoretically transferred onto nitrocellulose 
membrane, and immunoblotted with anti-active SAPK antibodies (phospho-p38 or phospho- 
JNK-1/2). To verify equal loading of proteins, a set of corresponding lysates were probed with 
anti-pan p38. The results are representative of at least two other experiments.
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Figure 5.3 The Effects of MCP-1 on the activation of Ras, in THP-1 cells
The plasmid encoding for the GST-RBD fusion protein (provided by Dr D 
Cantrell) was expressed in bacteria and used to obtain recombinant GST- 
RBD fusion protein. 1 x107 THP-1 cells were stimulated with MCP-1 (10nM) 
and MCP-2 (100nM) for the times indicated. Cells were lysed, and lysates 
incubated with GST-RBD fusion protein and glutathione-sepharose beads as 
described in ‘Materials and Methods’. After washing, beads were analysed 
by 15% SDS-PAGE followed by western blotting with anti-pan Ras antibody. 
Data is from one experiment and is representative of at least one other.
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Figure 5.4 The Effects of Clostridium sordelli lethal toxin on ERK-
1/2 activation in THP-1 cells
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Figure 5.4 The Effects of Clostridium sordelli lethal toxin on ERK-1/2 activation 
in THP-1 cells. 1x106 THP-1 cells/point were pre-treated for 2 hours with either 
vehicle (0.02% DMSO) or various concentrations of LT-82 at 37°C. Total cell lysates 
(2.5x105 cell equivalents per lane) were resolved separately on SDS-PAGE and 
electrophoretically transferred onto nitrocellulose membrane. Membranes were then 
immunoblotted with either anti-phospho-ERK1/2 or pan ERK. This figure shows the 
scanned western blot image along side densitometric analysis expressing results as 
activity as a % of the control. The results are representative of at least three separate 
experiments.
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Figure 5.5 The Effects of Clostridium sordelli lethal toxin on MCP-1-induced
ERK-1/2 activation in THP-1 cells.
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Figure 5.5. The effect of Clostridium sordelli lethal toxins on MCP-1-induced ERK-1/2 
activation in THP-1 cells. 1x106 THP-1 cells/point were pre-treated for 2 hours with either 
vehicle (0.01% DMSO), LT-82, or LT-9048 (500ng/ml) at 37°C. Total cell lysates (2.5x105 cell 
equivalents per lane) were resolved separately on SDS-PAGE, electrophoretically transferred 
onto nitrocellulose membrane and immunoblotted with either anti-phospho-ERK1/2, -phospho- 
PKB, or pan ERK1 antibodies (see also Fig.5.7). This figure shows the scanned western blot 
image along side densitometric analysis expressing results as activity as a % of the control. 









Figure 5.6 The Effects of Clostridium sordelli lethal toxin on MCP-
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Figure 5.6. The Effect of Clostridium sordelli lethal toxin on MCP-1 - 
induced Ptdlns(3,4,5)P3 generation in THP-1 cells. 1 x 107 cells/point 
were metabolically labelled with 32P, and then pre-treated for 2 h with either 
vehicle (0.01% DMSO) or LT-82. (500ng/ml). Cells were then stimulated 
with vehicle (0.05% BSA) or MCP-1 (1nM) for the indicated times. 
Following stimulation, phospholipids were extracted, deacylated and the 
glycerophosphorylinositol derivatives of Ptdlns(3,4,5)P3 were analysed 
using HPLC as described under “Materials and Methods”. Data are from a 
single experiment and are representative of at least three separate 
experiments.
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Figure 5.7 The Effect of Clostridium sordelli lethal toxin on MCP-1


































Figure 5.7. The Effect of Clostridium sordelli lethal toxin on MCP-1-induced PKB 
activation in THP-1 cells. 1x106 THP-1 cells/point were pre-treated for 2 hours with either 
vehicle (0.01% DMSO), LT-82, or LT-9048 (500ng/ml) at 37°C. Total cell lysates (2.5x105 cell 
equivalents per lane) were resolved separately on SDS-PAGE, electrophoretically transferred 
onto nitrocellulose membrane and immunoblotted with either anti-phospho-ERK1/2, -phospho- 
PKB, or pan ERK1 antibodies (see also Fig. 5.5). This figure shows the scanned western blot 
image along side densitometric analysis expressing results as activity as a % of the control. 
Results are normalised against equal loading blot and are representative of at least three 
separate experiments.
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Figure 5.8 Effects of Clostridium sordelli lethal toxin on MCP-1







• o  *“ -> oO r - U > r O * - U > ' r -
IP:p110y < ------  PI(3)P
Figure 5.8. Effects of Clostridium sordelli lethal toxin on MCP-1-stimulated in vitro 
lipid kinase activity in THP-1 cells. THP-1 cells (1x107 per point) were stimulated with 
MCP-1 (10nM) for the times indicated. Cells were then lysed, and lysates were 
subjected to immunoprecipitation with either anti-p85 or anti-p110y mAbs. The washed 
immunoprecipiates were analysed for PI3K activity using PI as a substrate. Extraction 
and TLC separation of the lipid products were performed as described under ‘Materials 
and Methods’. Lipids were detected by exposure to film at -70°C. Results are from one 
experiment and are representative of three separate experiments.
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Figure 5.9 The Effect of Clostridium sordelli Lethal toxins on MCP-1-Induced
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Figure 5.9 Effect of Clostridium sordelli lethal toxin on MCP-1 -induced chemotaxis 
of THP-1 cells. 1.2 x 105 THP-1 cells per point were pre-treated for 15 minutes at 37°C 
with either vehicle (0.01% DMSO) or various concentrations of wortmannin. After 
incubation, cells were subjected to chemotaxis towards MCP-1 (1nM) in a 96-well 
Neuroprobe™ chamber for 3 hours. Migration was determined as described in ’Materials 
and Methods'. Results are expressed as a Chemotactic Index (C:l): the ratio of stimulated 
over basal migration. Data represent the mean ± S.EM (5 replicates per experiment). 
Results are representative of three independent experiments (one experiment conducted 
by K. Moores, Glaxo-SmithKline Pharmaceuticals. Harlow. UK). 148
Figure 5.10. The Effect of pertussis toxin on MCP-1-induced
MAPK activation in THP-1 cells.
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Figure 5.10. The Effect of pertussis toxin on MCP-1-induced MAPK activation in THP-1 
cells. THP-1 cells (1x106 per point) were pre-treated at 37°C for 16 hours with either vehicle 
(0.01% DMSO) or 100ng/ml PTX. Cells were then stimulated with vehicle (0.05% BSA) or 
MCP-1, -2, -3, -4 (1, 10, 10, 100nM, respectively) for the times indicated. Total cell lysates 
(2.5x105 cell equivalents per lane) were resolved separately on SDS-PAGE, 
electrophoretically transferred onto nitrocellulose membrane and immunoblotted with anti- 
phospho-ERK-1/2. To verify equal loading of proteins, a set of corresponding lysates were 
probed with anti-pan ERK-1/2/ERK-1 antibodies. The results are representative of two 
experiments.
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Figure 5.11 Effect of Pertussis toxin on MCP-1-induced chemotaxis
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Figure 5.11. Effect of pertussis toxin on MCP-1-induced chemotaxis of THP-1 cells. 1 x 105
THP-1 cells per point were pre-treated for 16 hours with either vehicle (0.01% DMSO) or 100ng/ml of 
pertussis toxin at 37°C. After incubation, cells were subjected to chemotaxis towards various 
concentrations of MCP-1 in a 96-well Neuroprobe™ chamber for 3 hours. Migration was determined 
as described in ’Materials and Methods'. Results are expressed as a Chemotactic Index (C:l): the 
ratio of stimulated over basal migration. Data represent the mean + S.EM (5 replicates per 
chamber/2 chambers per experiment). Results are representative of four independent experiments. 
*: p <0.05, ** : p<0.01, : p<0.001
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Figure 5.12 Effect of PD98059 on MCP-1-induced chemotaxis of THP-1 cells 1 x 105 THP-1 
cells per point were pre-treated for 30 minutes with either vehicle (0.01% DMSO) or indicated 
concentrations of PD98059 at 37°C. After incubation, cells were subjected to chemotaxis in a 96-well 
Neuroprobe™ chamber for 3 hours. Migration was determined as described in ’Materials and 
Methods'. The concentration of MCP-1 in the lower chamber was 1nM - a concentration determined 
by previous dose-response experiments (Section 4). Results are expressed as a Chemotactic Index 150
(C:I): the ratio of stimulated over basal migration. Data represent the mean ± S.EM (5 replicates per 
chamber/2 chambers per experiment) Results are representative of four independent experiments.
*: p <0.05, ** : p<0.01, *** : p<0.001
Figure 5.13 Confirmation of ERK phosphorylation as being a MEK-driven event.
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Figure 5.13 Confirmation of ERK phosphorylation as being a MEK-driven event. THP-1 cells (1x106/cells per point), untreated or 
pre-incubated for 15 minutes with vehicle (0.01% DMSO) or 10jiM PD98059. Cells were then stimulated with vehicle (0.05% BSA), 
PMA (5ng/mM) or MCP-1-4 for the times indicated. Total cell lysates (2.5x105 cell equivalents per lane) were resolved separately on 
SDS-PAGE and electrophoretically transferred onto nitrocellulose membrane. Membranes were then immunoblotted with anti-phospho- 
ERK-1/2 antibody. Membranes were subsequently stripped (as described in ‘Materials and Methods’) and re-probed with an anti-ERK- 
1/anti-ERK-1/2 antibody, to ensure equal loading of proteins. The results are representative of two experiments.

































Figure 5.14 The Effect of PKC inhibitor, Ro-320432, on ERK-1/2 activation in THP-1 cells.
THP-1 cells (1x106 per point) were pre-treated at 37°C for 1 hour with either vehicle (0.01% 
DMSO) or 10j.iM Ro-320432. Cells were then stimulated with vehicle (0.05% BSA), MCP-1, 
MCP-2, MCP-3 or MCP-4 for the times indicated. Total cell lysates (cell equivalents of 2.5x105 
per lane) were resolved separately by SDS-PAGE, electrophoretically transferred to a 
nitrocellulose membrane, and immunoblotted with anti-phospho-ERK-1/2 antibody. To ensure 
equal loading of proteins, another set of corresponding lysates were probed with pan-ERK1/2 
antibody. The remaining lysates were stored at -70°C for further investigation. The results are 
representative of three independent experiments. 152
Figure 5.15 The Effect of PKC inhibitor, Ro-320432, on MCP-1-induced SAPK
activation in THP-1 cells
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Figure 5.15 The Effect of PKC inhibitor, Ro-32-0432 on MCP-1-induced SAPK 
activation in THP-1 cells. THP-1 cells (1x106 per point), were pre-treated at 37°C for 
1 hour with either vehicle (0.01% DMSO) or 10pM Ro-320432. Cells were then 
stimulated with vehicle (0.05% BSA) or MCP-1 (1nM) for the times indicated. Total cell 
lysates (cell equivalents of 2.5x105 per lane) were resolved separately by SDS-PAGE, 
electrophoretically transferred to a nitrocellulose membrane and immunoblotted with 
anti-active SAPK antibodies (phospho-p38 and phospho-JNK-1/2). To ensure equal 
loading of proteins, a set of corresponding lysate were immunoblotted with anti-pan 
ERK-1/2. The results are representative of three experiments.
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Figure 5.16 The role of PKC in MCP-1-mediated chemotaxis (A) 1 x 105 THP-1 cells per 
point were pre-treated with either vehicle (0.01% DMSO) or with the indicated 
concentrations of Ro-320432 for 30 minutes at 37°C. (B) 1 x 105 THP-1 cells per point 
were pre-treated either vehicle (0.01% DMSO) or 100ng/ml-1 PMA for 16 hours at 37°C. 
After incubation, cells were subjected to chemotaxis in a 96-well Neuroprobe™ chamber for 
3 hours towards indicated concentrations of MCP-1. Migration was determined as described 
in “Materials and Methods”. Results are expressed as a Chemotactic Index (C :l) : the ratio 
of stimulated over basal migration. Data represent the mean ± SEM (5 replicates per 
chamber/2 chambers per experiment). Results are from one experiment, but are 
representative of three others. *: p <0.05, ** : p<0.01, *** : p<0.001 154
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Section 5. Discussion 
The Role of PI3-kinase in MAPK activation.
The question of how GPCRs control signals that regulate the gene expression in the 
nucleus, even though intensively studied during the last few years, is not yet fuily 
answered. It has been shown that GPCRs can activate MAP kinases, ERK1/2, c-Jun 
N-terminal kinase and p38 MAPK and they represent a point of convergence for cell 
surface signals regulating cell growth and division (Marshall et a/, 1995). Several 
studies have now shown that CXC (e.g. SDF-1 and IL-8) as well as CC chemokines 
(eotaxin, MIP-3a, MCP-1) stimulate the phosphorylation of MEK-1 and or ERK-1/2 in
a variety of systems (Knall et al, 1997; Sullivan et al, 1999; Sotsios et al, 1999).
Although significant heterogeneity exists between receptors and cells types, the main 
theme in this research is to elucidate the involvement of certain signalling 
intermediates linking these receptors to the MAPK/SAPK cascade.
1) Coupling of CCR2 to the MAPK cascade.
We present here that MCP-2, -3 and -4  signals via CCR2 and activate ERK in a 
PTX-sensitive manner, and can therefore conclude that CCR2 is a Gar coupled 
receptor. MCP-1-stimulated activation of ERK-1/2 appears to be only partially 
sensitive to PTX, and therefore suggests that there is a degree of heterogeneity in 
the coupling of CCR2 to G-proteins in the ERK-1/2 pathway. It is widely accepted 
that both pertussis toxin (PTX)-sensitive and -insensitive heterotrimeric G-proteins 
mediate ERK activation, and distinct signalling pathways are ascribed to GTP-bound 
ct and free Py G-protein subunits. Gotr coupled receptors preferentially utilise a G-py 
route via PI3K-y, which feeds into the “classical” MAPK pathway involving Ras 
(Crespo etal, 1994; Lopez-llasaca etal, 1997).
However, Gpy subunits derived from PTX-insensitive Gaq proteins have also been 
implicated in Ras-dependent ERK activation. For instance, Gaq-coupled receptors 
may employ PKC to target Raf-1 directly or calcium to activate MAPK via Pyk2, Src 
and Ras (Della Rocca et al, 1997; Dikic and Blaukat, 1999). Although Grcoupled 
receptors are unanimously viewed as coupling to ERKs in a Ras-dependent manner, 
previous studies have produced contradictory results as to Ras-dependent or - 
independent ERK activation via Gq-coupled receptors in COS cells, and there are
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several studies providing evidence of chemokine receptors coupling to Gq-proteins 
(Wu et al, 1993). Furthermore, dominant-negative forms of Ras do not inhibit ERK- 
1/2 activation in IL-8-stimulated CHO transfectants, which again suggests that 
chemokines can mediate Ras-independent ERK-1/2 activation (Shyamala et al, 
1998). It is becoming increasing evident in many systems that this Ras-independent 
ERK-1/2 activation may potentially involve PI3Ky activation.
It must be highlighted that not all GPCRs mediate MAPK activation exclusively via 
the receptor catalysed release of G-(3y subunits. In 1995, van Biesen et al reported 
that activation of ERK-1/2 in COS-7 cells was mediated by the a-subunit of a PTX- 
sensitive G0-protein that was independent of Ras activation.
Delineating the precise mechanisms by which CCR2 couples to the ERK-1/2 
pathway is complicated by the diversity of possible signalling mechanisms and 
heterogeneity exhibited by chemokine receptor signalling. We shall now 
schematically consider the constituent signalling events arising from CCR2 
engagement that culminates in ERK-1/2 activation, and attempt to elucidate whether 
these biochemical responses assume functional relevance in this system.
2) The Role of Small GTP-binding proteins in MCP-1-Induced MAPK activation
The use of a fusion proteins consisting of a GST-tagged Ras binding domain has 
demonstrated that MCP-1-stimulation of THP-1 cells is associated with increased 
activation of Ras. On the whole, there is very little information directly linking Ras 
activation with chemokine stimulation, although our group has previously reported 
that SDF-1 activates Ras in Jurkat cells, and suggested further biochemical and 
functional roles for this GTPase (Sotsios et al, 1999). In these studies, however, the 
broad-spectrum farnesyl-transferase inhibitors were used as a method of 
assessment (e.g. Manumycin), and so Ras activity could only be inferred in this 
system. IL-8-stimulated activation of Ras and Raf-1 has also been reported in 
neutrophils with the use of transfected isoforms of Ras; Here, K-Ras4B was 
significantly more effective in mediating Raf-1 migration than H-Ras, K-Ras4A and N- 
Ras (Voice et al, 1999). More recently, Ras activity has been detected in CXCR3 
stimulated Hepatic stellate cells (HSC), and was shown to be a key player in PI3K 
and MAPK pathways (Bonnachi et al, 2001). In terms of Ras activation and its 
involvement in CCR2-mediated signal transduction, MCP-1 was the only ligand 
analysed against the receptor during this study, and showed a modest increase in 
Ras activity in THP-1. The relevance of Ras and other small GTPases in MAPK
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activation and other cellular responses was further analysed using selective bacterial 
toxins.
Lethal toxin (LT) from Clostridium sordelli is a glucosyltransferase that covalently 
modifies 21kDa proteins in vitro and in vivo, and glucosylates Ras, and to a lesser 
extent Rap, Rac, Ral and Cdc42 (Popoff et al, 1996). This is the first toxin to 
inactivate Ras, and is becoming an invaluable tool to explore pathways regulated by 
GTPases. Here, we have shown that LT completely abrogates ERK1/2 
phosphorylation in response to MCP-1, and conclude that Ras, at least in part, 
functions upstream of the MAPK cascade in this system. We also conducted 
experiments to analyse the effect of other toxins on MCP-1-induced chemotaxis. LT, 
as expected, completely abrogated MCP-1-stimulated chemotaxis of THP-1 cells. 
Toxin B (from Clostridium difficile) that inactivates Rho, Rac and Cdc42 (Just et al,
1995), also blocked migration towards MCP-1. Although we did not continue further 
investigation with Toxin B, this data suggests that these proteins were instrumental in 
chemotaxis and may have been implicated at a number of points in the pathway. For 
example, Rho GTPases could be acting upstream of SAPKs which themselves could 
be regulating cell migration. It is also possible that Toxin B abrogates the GTPase- 
regulation of Phospholipase D (PLD), a strong candidate in the control the 
cytoskeletal dynamics involved in cell migration. In short, Rho GTPases are likely to 
play a regulatory role wherever filamentous actin is used to drive a cellular process, 
namely cell shape, polarity, morphogenesis and chemotaxis.
Although LT would block Rap and Rac as well as Ras, the inhibiting effect on Ras 
would predominate, because of order of selectivity of this toxin. Therefore, in our 
system we have assumed that the observed effects were due to Ras inhibition alone. 
However, we cannot categorically rule out that Rac and Ral are also components of 
this pathway since these GTPases function upstream and downstream of Ras, 
respectively. The possible involvement of Rac in MCP-1-mediated ERK-1/2 
activation is highlighted by the fact that LT-82, but not LT-9048 completely inhibited 
the ERK-1/2 pathway (LT-9048 does not modify Rac proteins). It is also conceivable 
that Rap may be involved in this cascade considering that recent reports have 
pointed to Rap as a positive regulator in cell signalling, however, its major role has 
been considered to be as an antagonist towards Ras (Boussiotis et al, 1997). The 
use of constitutively active or dominant negative mutants of various G proteins, along 
side the clostridial toxins could have yielded more definitive results of G protein
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involvement in MCP-1 action. However, application of these highly specific toxins 
has paved the way for future investigation.
Ras: Upstream or downstream of PI3K?
Before we go on to discuss the role of PI3K in CCR2-mediated MAPK activation, it is 
necessary to consider the current issues facing the relationship between Ras and 
PI3K. Ras exerts its effects through a GTP-dependent interaction with several 
cellular targets including class I PI3Ks, and all class I PI3Ks have a Ras binding 
domain (RBD) similar to those found in other effectors such as Raf and Ral 
(Vanhaesebroeck et al, 2001). Although there is clear evidence of the interplay 
between these signalling molecules, it is emerging that PI3K is not a universal 
effector as once thought.
In our system, treatment with LT clearly abolished the MCP-1-stimulated generation 
of PI3K lipid products as assessed by D-3-lipid accumulation and severely reduced 
PKB phosphorylation. Examination of individual PI3K isoforms also revealed that 
p110y-associated in vitro lipid kinase activity was inhibited by treatment with LT. The 
effects of LT on the class II PI3K-C2 were not assessed, although it would have been 
useful given that this isoform is considered to be main contributor of the overall D-3 
phosphatidylinositol lipid pool. Although we have shown here that Ras lies upstream 
of PI3K in this system -  whether or not it has a dual function downstream of PI3K 
remains to be determined.
3) PI 3-kinase -  A key player in MCP-lnduced ERK activation?
Several studies have now indicated that PI3K inhibitors can abrogate chemokine- 
induced ERK activation. This correlates well with our findings in that phosphorylation 
of ERK-1/2 in response to MCP-1, -2, -3 and -4-stimulation was significantly inhibited 
with wortmannin. Although we have shown in numerous studies that ERK-1/2 is 
phosphorylated by these chemokines, we found there to be a high degree of 
variability between basal levels of MAPK between experiments, which appeared to 
be exacerbated by washing and spinning down of cells. Such variability in THP-1 
cells has been previously observed, and in support of our theory, MacKenna et al, 
reported that in fibroblasts, ERK and JNK were prematurely activated by ‘mechanical 
stretch’. Much effort was made to minimise the effects of cellular stress on 
biochemical and functional studies.
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It is interesting to note that in COS cells, LPA-induced activation of Ras and MAPK is 
blocked by inhibitors PI3K or by dominant-negative inhibitors of the p85 subunit of 
PI3K. This is a strong indication that that p110a or p110p isoenzymes are required 
for MAPK activation at a point upstream of Ras (Hawes et al, 1996). The PI3Ky 
isoenzyme has also been shown to act upstream of Ras in the G-py subunit 
activation of ERK-1/2 in COS cells. In this respect, activation of MAP kinases via G- 
py subunit complex mediated pathway is dependent upon tyrosine phosphorylation, 
Ras activation, and distal protein phosphorylation cascades (Ablas et al, 1993; Faure 
et al, 1994). This hypothesis was later refined and it was shown that the MAPK 
cascade is activated by the intrinsic protein kinase activity of PI3Ky, which represent 
a point of bifurcation from its lipid kinase activity (Hirsh et al, 2000). Further evidence 
for the role of G-Py subunits and p110y in MAPK activation was gleaned from p110y';' 
knockout mice. In this study, it was demonstrated that pHO-y'7' knockout mice 
displayed a significantly reduced activation of ERK (Li et al, 2000).
If we consider MCP-1 stimulation of CCR2, our experiments suggest that ERK-1/2 
activation is Gar coupled receptor event that appears to be dependent on PI3K, and 
Ras, but not PKC. It could follow that MCP-1 induces the “classical” growth factor 
signalling cascade that involves She, Grb2, Ras, Raf. Since we did not investigate 
the contribution of Ras to MCP-2, -3 or -4-induced ERK activation, we cannot 
speculate on the dependency of this GTP binding protein to the MAPK cascade in 
response to these ligands. However, it can be concluded that all four chemokines 
activate ERK1/2 via a Gctj-coupled receptor, and that PI3K activity is a prerequisite in 
each case. Preliminary experiments have shown that it is only in response to MCP-2 
and MCP-4 that dual inhibition of PI3K and PKC attenuates activation of ERK-1/2 
(data not shown). Here, it is conceivable that PI3Ky may involve the action of PKC^, 
which has been shown to occur via a PDK-1-dependent manner as shown in Figure 
5.17 (Chou etal, 1998).
More recently, Sonnenburg et al, have shown that PDK-1 can phosphorylate and 
activate conventional PKC isoenzymes independently of PI3K. This could present an 
alternative mechanism whereby PKC£ is allosterically controlled by PDK-1 
independently of the PH domain or 3-phosphoinositides. In neutrophillic models, 
PKC£ is also thought to play multiple roles leukocyte transmigration (Laudanna et al, 
1998). The biological consequences of such diversity in chemokine receptor 
signalling is not totally understood -  although it may offer some explanation as to
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how chemokines exert control a over a multitude of functional and transcriptional 
responses.
4) Stress Activated Protein Kinases (SAPKs) in CCR2-mediated 
signalling
In a similar fashion to the activation of the ERK pathway by proliferative stimuli, UV 
radiation, environmental stress and proinflammatory cytokines stimulate the 
JNK/SAPK and the P38 MAP kinase (p38 MAPK) cascades. These kinases have 
been shown to activate a number of transcription factors, including c-Jun and ATF-2 
(Kyriakis et al, 1994). We present evidence here that in the THP-1 cells line, MCP-1, 
-2, -3 and -4 induced activation of the SAPKs, namely p38 and JNK.
5) The c-Jun N-terminal kinase pathway- JNK/SAPK
We investigated the effects of MCP-1, -2, 3 and -4  on the activation of the JNK 
signalling pathways. All of which induced a rapid and transient phosphorylation of 
this enzyme. Previously, only a few studies have shown chemokine receptors to 
activate the JNK pathway, including CCR2 and the Herpesvirus-8 receptor, ORF74 
(Pati et al, 2001). In our system, the PI3K inhibitor, wortmannin, served to 
completely abrogate JNK-1/2 activity in response to MCP-1 and MCP-3, but was less 
efficient in the inhibiting JNK-1/2 in response to MCP-2 and MCP-4. This is an 
indication that CCR2 is able to couple to the JNK-1/2 via more than one pathway.. 
Several inflammatory cytokines, such as TNFa and EGF have been reported to 
activate JNK in a PI3K-depedent manner (Kim et al, 1999; Logan et al, 1997), 
although this has not yet been shown in the context of chemokine signalling. 
Cambien et al demonstrated that JNK activation by MCP-1 was a Gar mediated 
event dependent protein tyrosine kinase activity. Interestingly, among the best- 
characterised JNK activators that act downstream of tyrosine kinases are members 
of the PI3K family.
With respect to GPCRs coupling to the PI3K-dependent JNK pathway, the role of 
P3K-y in Gpy-dependent regulation of JNK has been well characterised. What is 
more interesting, is that signalling through this mechanism suppressed by dominant 
negative mutants of Ras, Cdc42 and Rac (Lopez-llasaca et al, 1998). Giving further 
evidence that PI3K serves to regulate the small GTP-binding proteins upstream of 
SAPKs that may ultimately facilitate cell migration. The expression of mutants in 
monocytic cells has indicated that Cdc42 regulates rearrangement of the
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cytoskeleton in response to MCP-1 and MIP-a. MCP-1 and MIP-1 a, but not Cdc42- 
stimulated cytoskeletal reorganisation can be inhibited by wortmannin. An indication 
that PI3K is involved at a point upstream of Cdc42 in CC chemokine-stimulated 
migration (Weber et al, 1998). It would have been interesting to assess the role of 
small GTPases, such as Ras and Cdc42, in CCR2-mediated activation of JNK-1/2 
using the clostridial lethal toxins.
The observation that PKC, as well as PI3K, may function upstream of JNK-1/2 leads 
us to propose an alternative mechanism whereby phosphoinositides produced by 
PI3K stimulate PKC^ activation via PDK-1, and then subsequent generated second 
messengers then proceed to activate JNK. This is based on the observation that a) 
phosphoinositide-regulated kinase, PDK-1, can activate PKC; b) our data infer that 
PDK-1 is operational in this system (See Section 5), and c) PKC£ has been 
previously shown to activate ERK-1/2 in a PI3K-dependent manner. Procyk et al 
have proposed a similar mechanism in LPS-stimulated macrophages. Here, the JNK 
pathway is activated by a PI3K-dependent, Cdc42/Rac-independent mechanism 
involving PKC£ and the generation of ceramide as a second messenger.
Indirect interaction of PKC-£ with JNK has also been observed in other systems and 
is thought to form complexes with MEKK1, SEK and JNK/SAPK in myeloid cells. In 
terms of functional relevance, several other PKC isoenzymes have been identified as 
regulators of JNK activation subsequent monocytic differentiation, and in the 
pathogenesis of myeloid leukaemia (Kaneki et al, 1999). In the CCR2-induced 
activation of JNK observed in our system, the involvement of PI3K probably occurs at 
a point upstream of the four ‘tiers’ of protein kinases, and participates in the cascade 
soon after engagement of the receptor. This quite possibly involves interaction with 
small GTP-binding proteins such as Cdc42, Rac or Ras. Alternatively, the PI3K 
could be sequentially activating PKC through PDK-1 modulation, and activating JNK 
in a manner independent of small GTP-binding proteins.
6) Activation of the p38/MAPK pathway via CCR2
Like JNK, the p38 MAPK pathway has not been as extensively studies as the 
prototypical ERK/MAPK pathway, particularly in terms of chemokine activation. 
However, recent reports have suggested p38 to be a pivotal kinase involved in 
chemotaxis induced by serum, lysophosphatidyl-choline, and chemokines in smooth 
muscle cells and leukocytes (Jing et al, 2000). MCP-1 has previously been shown to
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activate SAPKs (Yamasaki et al, 2001), and in this study, we not only reiterate these 
findings but also show that MCP-2, -3 and -4 may also activate these pathways. 
Cambien et al, recently reported SAPKs, but not ERKs to be implicated in MCP-1 - 
induced MonoMac6 cell migration. These data, along with other recent investigations 
corroborate with our findings that ERK is clearly not involved in THP-1 cell CCR2- 
mediated chemotaxis in THP-1 cells (Ashida et al, 2001; Fine et al, 2001). Figure 
5.18. The upregulation of chemokine proteins themselves are thought to be 
dependent upon p38, e.g. the production of MCP-1 in endothelial cells and IL-8 in 
neutrophils (Waterhouse et al, 2001; Marie et al, 2001). Taken together, these data 
suggest that activation of p38, and indeed JNK may facilitate the autocrine-like 
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Figure 5.18 A proposed model to explain MCP-1-mediated chemotaxis. MCP-1 activates 
MAPKs, ERK, p38 and JNK, and stimulates chemotaxis of THP-1 cells. MCP-1-mediated 
chemotaxis is not dependent on ERK in our system, and we postulate that p38 and/or JNK 
could be necessary for cell migration. Obviously, we cannot attribute the biological roles of 
p38 and JNK without the appropriate functional data. However, we can make inferences from 
our preliminary data and from previous studies by other workers. Ashia et al showed that 
activation of ERK is required for integrin activation, whereas p38 was required for chemotaxis 
in a Rho-dependent manner. Two biological functions mediated by MCP-1 may utilise two 
distinct MAPK-dependent signalling pathways.
Inhibition of the PI 3-kinase pathway allowed us to clearly establish that PI3K is 
involved in the activation of the p38 cascade by CCR2. The concept that there may
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be an element of interplay between p38 and the PI3K/PKB is not without precedent. 
In a recent study by Jing et al, p38 and PI3K was shown to functionally associate 
with and be critically involved in THP-1 cell chemotaxis induced by oxidised-LDL. 
Cross-talk is also suggested by the PKB-p38 regulation of cytoprotection versus 
apoptosis in VEGF-stimulated endothelial cells (Gratton et al, 2001).
Transcriptional regulation by these pathways has also been extensively studied. The 
controversial mechanism by which PKB activates NF-kB has been reported to have a 
dependency on p38 activation, and consistent with this is the requirement of p38 in 
IL-1p-induced transcriptional control in several systems (Madrid et al, 2001). With 
respect to CCR2-mediated signalling, it would be reasonable to assume that p38 
could be an important target of the PI3K/PKB pathway may explain how the CCR2 
ligands could exert transcriptional control in this system. Conversely, regulation of 
PKB and subsequent p38 activity may indeed promote cell death, which could offer a 
mechanism by which engagement of CCR2 conveys pro-apoptotic signals to the 
monocyte.
Apart from implicating PI3K in p38 activation, we did not further characterise this 
signalling cascade, nor did we attribute the cross talk to any functional relevance. It 
would have been interesting to investigate the MEK kinases (e.g. MEKK1) or the 
small GTP-binding proteins (e.g. Ras, Cdc42) upstream of p38. As discussed earlier, 
the Ras and Rho GTPases appear to have a major role in the control of directional 
migration of leukocytes, such as the SDF-1 -induced T-lymphocyte chemotaxis and 
polarisation (Haddad et al, 2001). Such experiments have been carried out using 
dominant negative mutants, with a recent report demonstrating the CXCR2 ligand, 
MGSA/GROa, to induce NF-kB via the activation of Ras/MEKK/p38 cascade (Wang 
and Richmond, 2001).
In the case of MCP-1-stimulated cells, our results suggest a minor role for PKC as a 
mediator of p38 activation. Here it appears that p38 is downstream and partially 
dependent upon PKC. This is consistent with reports for the role of PKC-dependent 
activation of p38 in non-cardiac myocytes. More relevantly, the thrombin-induced 
signalling pathway exhibits a PKCS-dependent activation of p38 and this particular 
interaction has been shown to facilitate ICAM-1 mediated adhesion of leukocytes to 
endothelial cells (Rahman, 2001). This concept could bear particular relevance in 
our system in that MCP-1-induced PKC-dependent-activation of p38 could be in 
place to facilitate the upregulation of integrins subsequent to adhesion of leukocytes
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during cell migration. It would be interesting to identify the specific PKC isoforms that 
appear to be involved in the CCR2-activation of JNK and p38, and perhaps dissect 
the interactions between each kinase and its respective substrate. However, the use 
of PKC inhibitors to answer such questions is complicated by the lack of isoenzyme 
specificity, and that PKC inhibitors may themselves stimulate JNK and p38 activity.
7) CCR2 exhibits differentiai coupling to PTX-sensitive and-insensitive 
MAPK pathways.
Studies over recent years have demonstrated that the multitude of proliferative 
signals elicited by one receptor are likely to be owed to the divergent MAPK 
cascades involved in connecting GPCRs to the nucleus. Until very recently, GPCRs 
have been shown to stimulate ERKs through a number of linear pathways that are 
initiated by either Gai or Gaq proteins. Previous investigation of CCR2-mediated 
signal transduction pathways has revealed that MCP-1 activates PLC activation 
intracellular calcium, inhibition of adenyl cyclase and PI3K (Sozzani et al, 1993; 
Turner et al, 1998) in a PTX-dependent manner suggesting a coupling this receptor 
to Go/Gj proteins. It has been demonstrated, however, that there can be 
considerable potential for heterogeneous coupling of chemokine receptor isoforms to 
different G protein and/or subunits depending on the receptor, the ligand and the cell 
line studied (Arai and Charo, 1996).
To evaluate the coupling mechanisms of CCR2 to downstream G proteins involved in 
MAPK activation, THP-1 cells were treated with pertussis toxin. PTX acts to 
uncouple Goti/0 proteins by ADP-ribosylating these subunits at a conserved carboxyl- 
terminal domain cysteine residue (Jones et al, 1987), and is therefore an invaluable 
tool for studying the function of Gj proteins. We found that ERK-1/2 and JNK-1/2 
exhibited differential sensitivity to pertussis toxin (PTX). ERK activation was almost 
completely abrogated PTX, inferring that this pathway is under the regulation of Gj 
proteins, whereas JNK was only partially sensitive, and therefore regulated (at least I 
part) by Gs/Gq proteins. The effect of PTX on p38 activity was not assessed. These 
data strongly imply that CCR2 exhibits heterogeneity in its coupling to the MAPK 
pathway via the G protein family.
In several cellular settings, it has been observed that ERK can be potently activated 
by with Gq-coupled or Gj-coupled receptors, respectively, in a pertussis toxin-
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insensitive and -sensitive fashion (Gutkind, 1998). In many cases, both a and fty 
subunits liberated from these G proteins can engage distinct pathways to ERK 
activation (Ablas et al, 1993; Howe et al, 1993). Blaukat et al have recently shown 
that dually coupled GPCRs require co-operation of Gat and Gaq-mediated pathways 
for efficient stimulation of the ERK cascade. Although this may not be the case in our 
system, this study has highlighted that co-operative signalling by multiple G proteins 
might represent a novel concept in GPCR-mediated cell regulation.
A more detailed hypothesis of CCR2-mediated ERK activation in THP-1 cells is 
discussed above. In short, we believe that ERK activity is regulated by a Gr protein 
coupled mechanism that induces activation of MEK and ERK1/2 through a pathway 
that exhibits differential reliance on PI3K and PKC depending on the chemokine 
studied.
The activation of SAPKs by G protein subunits is thought to occur by a novel 
biochemical route. Despite the increasing knowledge about the prominent role of 
JNK in gene transcription, relatively little is known about the signal transduction 
pathways leading to its activation, particularly by GPCRs. Using the PDGF receptor 
model in NIH 3T3 cells, activation of GPCRs was shown to induce transcription of 
early immediate gene, c-jun, through phosphorylation of JNK. Interestingly, activation 
of GPCRs and not tyrosine kinase receptors for PDGF led to the activation of JNK. 
Given that this response did not correlate with MAPK activation, it established GPCR 
signalling pathways diverge at the level of JNK from those utilised by tyrosine kinase 
receptors (Coso et al, 1995). A recent study has also shown that the Kaposi’s 
Sarcoma Herpes Virus-GPCR can be activated by a variety of downstream 
substrates that lead to the activation of JNK family members, but not MAPK. Proline- 
rich tyrosine kinase 2 (Pyk2) and Src-family kinase, Lyn, were shown to be pivotal 
signalling enzymes in this JNK pathway (Munchi et al, 1999).
In contrast to the ERK cascade, there is little evidence placing Ras upstream of JNK, 
instead, it is thought that Rho GTPases Rac1 and Cdc42 initiate an independent 
kinases cascade regulating JNK activity. Additionally, the Rac/Cdc42 pathway to 
JNK has been strongly linked to actin polymerisation. So the question is; At what 
level does the bifurcation of signals to ERK and SAPKs take place? It is quite 
possible that this may occur at the G protein level, and as inferred from our data, 
differential coupling to G protein subfamilies can lead to divergence in MAPK 
activation.
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8) Coupling of G a /G a q signals to the chemotactic response
Our functional data complies with previous reports that monocyte migration is a PTX- 
sensitive process (Sozzani et al, 1994) in that THP-1 cell migration toward MCP-1, - 
2, -3 and -4  was completely ablated by treatment with this toxin. However, this 
prompted us to investigate relationships that may exist between the MAPK pathways 
and THP-1 migration towards MCPs 1-4. It is clear that CCR2 not only exhibits 
heterogeneity in coupling to G protein subunits, but can also link to both PTX- 
sensitive (Gj) and PTX-insensitive (Gq) family members
Another explanation is in that more than one splice variants and/or receptors are 
activated by MCP-1, -2, -3, and 4 in this model, and these may differentially couple to 
different signalling pathways and functional events. Indeed, while MCP-1'7' and 
CCR2 7' mice have similar phenotypes, they are not similar in other respects (Boring 
et al, 1998; Gosling et al, 1999). It is interesting that activation of the MAPKs is 
under the regulation of distinct signalling mechanisms. The observation that CCR2 
can exert independent control of signalling pathways is yet more evidence that 
chemokine receptors could mediate not only cell movement, but also gene 
transcription and cell growth.
The dependence on operational Gj proteins for chemotaxis to MCP-1, -2, -3 and -4  
corroborated with previous reports. In these studies, inhibition of chemotaxis by PTX 
was proposed to occur as long as Gfty release was dependent on Gai activation. 
This arose from the observation that neither Gar GTP nor its effects on cAMP were 
considered a prerequisite to migration, however, the GJfy release following Gai 
activation was shown to be a key mediator (Arai et al, 1997; Neptune et al, 1999). A 
similar mechanism has been reported for IL-8 signalling; Here, the coupling of 
CXCR2 with various G-protein isoforms was possible, but only Gj, and not Gs or Gq, 
was necessary for chemotaxis (Neptune et al, 1997).
It is unlikely that inhibition of cell migration by PTX occurred due to uncoupling of 
CCR2 to the ERK-1/2 pathway because studies with MEK inhibitor, PD98058, 
revealed that ERK-1/2 was not involved in this response. With regards to the precise 
role of Gj proteins in CCR2-mediated chemotaxis, we can merely speculate. PTX 
could be exerting its influence on chemotaxis by inhibiting one or more PI3K 
isoforms, or arresting the recruitment of PLCp, PKC£ or other downstream signalling
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molecules. Alternatively, PTX could be impeding the internalisation and recycling of 
CCR2 by down-regulating GRK-mediated receptor modification via clathrin-coated 
pits or recruitment of arrestins. Gai modification could be reducing overall receptor 
surface expression and, hence, decreasing the potential for MCP-induced signals for 
migration. Although, it has been clearly shown in some systems that the events of 
Garcoupling chemokine receptors such as CXCR2 and CXCR4 do not have a major 
role in the regulation of internalisation (Feniger-Barish et al, 2000; Sotsios, 
unpublished work).
9) Involvement of PKC in cell migration
Protein kinase C (PKC) is a major serine-threonine kinase that regulates multiple 
intracellular events for which 11 isotypes have been reported. The discovery of 
these various isotypes of PKC and the postulation that they have distinct 
physiological functions have provided an explanation for the plethora of events, 
including migration, that appear to be mediated by PKC. An integral role for PKC in 
cell migration is supported by the observation that; a) many cytoskeletal proteins 
(e.g. talin, filamin) are substrates for PKC, and; b) downregulation of PKC with 
phorbol esters results in changes in cell shape that are likely to be an effect of 
cytoskeletal rearrangement (Mochly-Rosen et al, 1990).
The role of PKC activation in cell migration has been not been widely studied, but is 
thought to be cell specific. Activation of PKC enhances migration of neutrophils, 
monocytes and endothelial cells (Mercurio et al, 1988; Niggli et al, 1993), whereas in 
keratinocytes and some T cells lines, activation of PKC inhibits cell migration (Ando 
et al, 1993). Our initial studies showed that inhibition of PKC with Ro-320432 served 
to potentiate, rather than inhibit migration of THP-1 cells towards MCP-1. From this it 
could be postulated that PKC may be exerting inhibitory control of chemotaxis.
If this were the case, what would be the mechanism by which PKC produced this 
inhibitory effect on chemotaxis? Prior studies have revealed that activators of cAMP 
inhibit chemotaxis of rat smooth muscle cells (Itoh et al, unpublished observations), 
Moreover, an association between cAMP and PKA signalling pathways has 
previously been established. Stimulation of human SMCs with forskolin, a potent 
activator of cAMP, strongly inhibits the PDGF-induced migration of SMCs (Itoh et al, 
2001). It is therefore plausible that the inhibitory effect of PKC on THP-1 chemotaxis 
might have been mediated through the cAMP/PKA pathway. To investigate this
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hypothesis, it would have been necessary to measure PKA activity is response to 
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Figure 5.19. Hypothetical model of PKC-involvement in THP-1 cell migration.
This diagram offers an explanation of how two different methods of inhibiting PKC
could produce conflicting results.
1) Treatment with Ro-320432 potentiates migration. Dowregulation of PKC with Ro- 
320432 could enhance migration by activating the cAMP/PKA pathway
2) Long-term exposure with phorbol ester totally abrogated chemotaxis. This may be 
due to PMA-induced effects on CCR2 receptor expression through PKC-mediated 
endocytosis and/or recycling. Cytoskeletal organisation may also be refractory to 
PKC modulation by phorbol ester.
To test further test the hypothesis, PKC was subject to inhibition by a second method 
of downregulation, whereby intracellular PKC isoforms are depleted by prolonged 
exposure to phorbol ester. Downregulation with PMA did not corroborate with results
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obtained with the Ro-320432 inhibitor, as pre-treatment with PMA completely 
abrogated chemotaxis. The inhibitory action of PMA could have arisen from a 
number of mechanisms. As well as disrupting PKC-modulated cytoskeletal 
organisation, phorbol esters could affect migration through downmodulation of CCR2, 
thus, rendering cells unresponsive to MCP-1 stimulation. This has been shown in the 
rapid endocytosis of CXCR4 by phorbol ester (Signoret et al, 1997). Here, the 
mechanism of PMA-induced CXCR4 internalisation is thought to involve PKC- 
mediated phosphorylation of the CXCR4 cytoplasmic domain. Recycling of the 
receptor back to the membrane could also have been under the control of PKC, and 
therefore attenuated by phorbol ester treatment. Presented here is rather conflicting 
data regarding the role of PKC in MCP-1-induced chemotaxis, it is impossible to 
attribute a definitive role for PKC in this functional response.
SAPKs but not ERKs modulate CCR2-chemotaxis?
Consistent with other reports of chemokine signalling, it appears that ERK-1/2 is not 
necessary for MCP-1-directed migration of THP-1 s (Knall et al, 1997). Inhibition of 
MAPK activation using the specific inhibitor of the kinase responsible for activating 
MAPK (MAPKK or MEK), PD98059, revealed a potent inhibition of this enzyme, but 
not the migratory response induced by MCP-1. Although MAPK activation has been 
reported necessary for MCP-1-induced migration in monocytes, it is so far unclear 
exactly what role such activation plays because this enzyme can be placed 
downstream of such effectors as Ras and Rho (both implicated in migration events) 
as well as PI3-K. The differences in sensitivity to MEK inhibition of chemotaxis in 
response to chemokines and chemoattractants, implies that there are multiple 
pathways leading to leukocyte migration. It also highlights the fact that that even 
though different chemokine receptors can couple to common signalling pathways, 
there is sometimes redundancy with regards to the importance of those pathways in 
eliciting a migratory response.
As the roles of p38 and JNK were not assessed in our functional assays, it was 
impossible to conclude the precise role of each MAPK in this functional response. 
Nevertheless, considering our data in hand with recent literature, events leading to 
functional response can be postulated. As discussed earlier, Ashida et al 
characterised the divergence in MAPK signalling in MCP-stimulated THP-1 cells and 
attributed its functional consequence. These data indicate that two distinct MAPKs
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regulate two dependent signalling cascades leading to integrin activation and 
chemotaxis induced by MCP-1 in THP-1 cells. However, application this hypothesis 
to our system could only be validated by conducting further functional and 
biochemical experiments. The use of inhibitors and/or molecular constructs against 
p38 and JNK would be required to elucidate their specific role in CCR2-mediated cell 
migration.
Legend for Figure 5.20 (over page). Hypothesised models of CCR-2 mediated 
MAPK activation by MCP-1, -2, -3 and -4 in THP-1 cells
MCP-1, -2, -3 and -4, Monocyte chemotactic protein-1, -2, -3, -4; G|, inhibitory G 
protein: Gq, PLC-specific G protein; PI3K, phosphatidylinositol 3-kiase; Cdc42, Rho 
family GTPase; Rac, Rho family GTPase; MEKKK, MAPK/ERK kinase kinase kinase; 
MEKK.MAP K/ERK kinase kinase; MEK1, MAPK/ERK.
Red lines indicate ‘hypotheised’ signalling event. Black lines indicate events 
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MCP-1
MCP-1 activates ERK-1/2 and JNK-1/2 via a 
mechanism that is partially sensitive to PTX, thus 
inferring differential regulation of G protein subunits. 
p38 and JNK-1/2, but not ERK-1/2 are regulated by a 
PKC-dependent mechanism. In the case of JNK-1/2 
activation this PKC involvement could be PDK-1 - 
modulated. PI 3-kinase regulates ERK, p38 and JNK 
and in the case of ERK-1/2 this is a MEK-driven 
event. The roles of p38 and JNK in MCP-1-stimulated 
chemotaxis were not assessed, but it appears that 
ERK-1/2 is not required for cell migration.
MCP-2 and MCP-4
MCP-2 and MCP-4 exhibit similar signalling 
behaviour in the activation of MAPKs. Coupling of 
CCR2 to ERK-1/2 is PTX-sensitive, yet PTX- 
resistant in the activation of JNK-1/2. This Gr 
linked pathway to ERK initiated by both MCP-2 
and -4 appeared to be PKC-dependent and driven 
by MEK1. Although p38 and JNK were clearly 
activated by these ligands, the pathways were not 
defined. PI3-K appears to play a minor role in this 
cascade.
MCP-3
MCP-3, like the other CCR2 ligands exhibits 
heterogeneity its coupling to ERK-1/2 and JNK- 
1/2. Inhibition of PKC does not affect ERK-1/2 
activation and indicates that it does not have an 
active role. PI3-kinase, on the other hand appears 
to be a pivotal enzyme in this cascade. It is 
conceivable that Cdc42 or Rac mediates this PI3- 
K-dependent activation of ERK-1/2. A similar 
pathway could well be in place for the activation of 
p38 and JNK.
Figure 5.20. Hypothesised models of CCR-2 mediated MAPK activation by MCP-1, -2, -3 and -4 in THP-1 cells
Section 6: Results.
The role of phospholipase D in MCP-1 -medited signal transduction
Rationale
The interaction of extracellular signal molecules with cell surface receptors quite 
often activates the phospholipase-D (PLD) and mediates the hydrolysis of 
phosphatidylcholine and other phospholipids, generating phosphatidic acid and 
choline. PLD activation and the subsequent liberation of its products is now 
recognised as an important component of many cellular processes including 
vesicular trafficking, cytoskeletal dynamics and signal transduction (Billah et al 1990: 
Cook and Wakelam, 1992; Coley et al, 1997). To date, only one group has reported 
the activation of PLD by chemokines in T lymphocytes and the Jurkat T cell line 
(Bacon et al, 1995, 1998), however, its significance is speculative and features of its 
regulation remain to be elucidated. There is an emergence of evidence linking the 
PLD and PI3-kinase pathways their Ptdlns(3,4,5)P3-modulation of ADP-ribosylation 
factors (ARFs). ARFs are regulated by PH domain-containing guanine nucleotide 
exchange factors, ARF-GEFs, such as GRP-1 and ARNO, and it is their interactions 
with PI3K that has implications for our understanding of PLD regulation and control of 
cellular processes controlled by chemokines.
In this chapter, the effect of MCP-1 on phosphatidylbutanol and phosphatidic acid 
accumulation are measured, and the contribution of PI3K to this pathway was 
assessed using pharmacological inhibitors. The most potent activators of PLD are 
small G proteins of the Ras superfamily. Several members of the Ras family appear 
to regulate PLD activity, including most members of the ARF and Rho families, and 
of these, ARF proteins appear to be the most active direct stimulators of PLD 
(Hammond et al, 1999; Frohman and Morris, 1996). Brefeldin-A (BFA), a golgi- 
disturbing agent has been shown to abrogate PLD activity in several systems through 
the inhibition of the GDP-GTP-exchange of ARF proteins. Here, we have investigated 
the effect of BFA on MCP-1-induced chemotaxis of THP-1 cells. Together, these 
studies have provided a foundation for future investigations in to the contribution, if 
any, of the PLD/PI3K pathway in MCP-1-mediated transmigration.
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Results
SDF-1 induced a rapid and transient increase in both phosphatidic acid (PA) and 
phosphatidylbutanol (PtdBut) - the indicators of PLD activation. Figure 6.1 shows the 
raw counts of titrated product, and as expected basal levels of PtdBut were 
approximately 10-fold less than PA. Stimulation of cells with 5ng/ml PMA provided a 
suitable positive control for all experiments. Figure 6.2 shows a similar profile for 
MCP-1-stimulated THP-1 cells. Again, stimulation induces a time-dependent 
increase in both PA and PtdBut, although the kinetics for PtdBut appeared to be 
slower. It transpired from these time-course experiments that the maximum 
accumulation of titrated products occurred at 5 min post-stimulation, therefore, all 
subsequent experiments were performed for this length of time.
PLD activity could be induced by MCP-1 at subnanomolar concentrations with a 
stimulation concentration range of 0.1-1001 OnM. Maximum activation was observed 
as being between two- and threefold above the vehicle controls. Concentrations of 
MCP-1 greater than 10nM failed to induced increases in PtdBut (Figure 6.3 [insert]).
Figure 6.3. The role of PI3-K in MCP-1-stimulated PLD activation was also 
investigated using the PI3K inhibitor, wortmannin. MCP-1-induced PLD activation 
was completely abrogated by wortmannin, although as expected, PMA-stimulated 
cells were only partially affected. These results give a clear indication that in this 
system, PLD activation is PI3K-dependent.
Considering the emergence of data suggesting that ARF proteins are involved in the 
regulation of PLD, the effect of ARF-inhibitor, brefeldin A (BFA), was investigated. 
Figure 6.4 shows that pre-treatment with BFA severely attenuates MCP-1-induced 
PtdBut accumulation, although there is a modest amount of resistance. Interestingly, 
when incorporated into a chemotaxis assay, BFA served to potentiate MCP-1- 
induced cell migration in a concentration-dependent manner.
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Figure 6.5. This effect is also observed in response to MCP-2 and MCP-3, however, 
MCP-4 appears to be the exception to the rule. Here, MCP-4-mediated chemotaxis 
is drastically reduced in the presence of BFA. The effects of MCP-2, -3 and -4  on 
PLD activation were not assessed, and so in this regard, characterisation of the PLD 
pathway awaits further investigation.
Summary of Results
• MCP-1 induces PLD activation in a time-dependent and concentration- 
dependent manner
• MCP-1 induces PLD activation in a manner that is dependent on both PI3-K 
and ARF protein(s).
• Chemotaxis induced by MCP-1, -2 and -3 is upregulated by pre-treatment 
with ARF-inhibitor, brefeldin A, whereas MCP-4-induced chemotaxis is 
abrogated.
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Figure 6.1 Typical values for the separation and analysis of phosphatidic 
acid and phosphatidylbutanol in chemokine-stimulated cells.
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Figure 6.1. Typical values for the separation and analysis of 
phosphatidylbutanol (Ptdbut) and phosphatidic acid (PA) in chemokine- 
stimulated cells. SDF-1-stimulated Jurkat cells were initially used as a model 
for the analysis of A) PtdBut and B) PA generation in response to chemokines. 
Jurkat cells (1x107) were metabolically labelled with 50pC, 3H-palmitate for 3 
hours and resuspended in A) RPMI, B) RPMI plus 30mM butanol. Cells were 
stimulated with 10nM SDF-1 for the indicated times, quenched, and subjected to 
organic extraction. Extraction, TLC and analysis were performed as described in 
'Materials and Methods'. Each histogram represents the mean ± SEM increase in 
[3H]PA/ [3H]PtdBut (cpm) over background from three independent experiments 
performed in duplicate.
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Figure 6.2. Effect of MCP-1-stimulation on phosphatidylbutanol
and phosphatidic acid generation in THP-1 cells.
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Figure 6.2 Effect of MCP-1-stimulation on phosphatidylbutanol (Ptdbut) 
and phosphatidic acid (PA) generation in THP-1 cells. THP-1 cells (1x107) 
were metabolically labelled with 50|iC, 3H-palmitate for 3 hours and resuspended 
in A) RPMI, B) RPMI plus 30mM butanol. Cells were then stimulated with 1nM 
MCP-1 for the indicated times, quenched, and subjected to organic extraction. 
TLC and analysis of extracted samples were performed as described in 'Materials 
and Methods'. Each histogram represents the mean ± SEM increase in [3H]PA/ 
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Figure 6.3 Effect of wortmannin on MCP-1-induced PLD activation.THP-1 
cells (1x107) were metabolically labelled with SOjiC, 3H-palmitate for 3 hours and 
resuspended in RPMI (30mM butanol) and either pretreated with vehicle (0.01% 
DMSO) or 10nM wortmannin for 10 m. Cells were then stimulated with 1nM MCP-1 
for the indicated times, quenched, and subjected to organic extraction. TLC and 
analysis of extracted samples were performed as described in 'Materials and 
Methods'. Each histogram represents the mean ± SEM percentage increase in 
[3H]PtdBut over background from three independent experiments performed in 
duplicate. The insert (A) represents the demonstrates the concentration- 
dependency of the reaction at 5 m post-MCP-1 stimulation. Each point represents 
the mean percentage increase of [3H]PtdBut over background from two 
independent experiments performed in duplicate. 176
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Figure 6.4 A) Effect of Brefeldin-A on MCP-1-induced PLD activation THP-1 cells 
(1x107) were metabolically labelled with 50pC| 3H-palmitate for 3 hours and resuspended in 
RPMI (30mM butanol) and either pretreated with vehicle (0.01% DMSO) or 5>jiM for 30 m. 
Cells were then stimulated with 1nM MCP-1 for the indicated times, quenched, and 
subjected to organic extraction. TLC and analysis of extracted samples were performed as 
described in 'Materials and Methods'. Each histogram represents the mean percentage 
increase in [3H]PtdBut over background from three independent experiments performed in 
duplicate. B) Effect of Brefeldin-A on MCP-1-mediated chemotaxis of THP-1 cells. 1 x 
105 THP-1 cells per point were pre-treated for 15 minutes at 37°C with either vehicle 
(0.01% DMSO) or Brefeldin-A. After incubation, cells were subjected to chemotaxis towards 
MCP-1 (1nM) in a 96-well Neuroprobe™ chamber for 3 hours. Migration was determined as 
described in ’Materials and Methods'. Results are expressed as a Chemotactic Index (C:l): 
the ratio of stimulated over basal migration. Data represent the mean ± S.EM of duplicate 
measurements. Results are representative of three independent experiments. 177
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Figure 6.5 Effect of Brefeldin-A on MCP-2, -3 and -4-mediated chemotaxis of THP-1 
cells. 1 x 105 THP-1 cells per point were pre-treated for 15 minutes at 37°C with either 
vehicle (0.01% DMSO) or 5pM Brefeldin-A. After incubation, cells were subjected to 
chemotaxis towards A) MCP-2 (10nM), B) MCP-3 (10nM) or C) MCP-4 (100nM) in a 96- 
well Neuroprobe™ chamber for 3 hours. Migration was determined as described in 
’Materials and Methods'. Results are expressed as a Chemotactic Index (C:l): the ratio of 
stimulated over basal migration. Data represent the mean ± S.EM of duplicate 
measurements. Results are representative of three independent experiments. 178
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Section 6: Discussion 
The role of phospholipase D in MCP-1-medited signal transduction
We have measured phosphatidic acid (PA) and phosphatidylbutanol (PtdBut) in 
response to chemokine stimulation. As discussed in Section 1, the measurement of 
PtdBut accumulation is the definitive test for PLD activation, in that the unique 
transphosphatidyl reaction catalysed by PLD is only detectable in the presence of a 
primary alcohol. In directly measuring PA in the absence of an alcohol, signalling 
pathways other than PLD could be responsible to the generation of this product, such 
as de novo synthesis by DAG-kinase or acylation of glycerol-3-phosphate. In 
addition, the PA product is susceptible to further metabolism to DAG and lyso-PA, 
whereas the PtdBut is metabolically stable (Lisovitch et al, 1999). PLD activation is 
beginning to emerge as an important enzyme molecule in chemokine signalling, 
however, it is also recognised that the measurement of PA is of equal importance in 
that this lipid, regardless of its source, is now recognised as an important intracellular 
messenger. For reviews see English, 1996.
MCP-1: An example of chemokine-induced PLD activation
Bacon et al have previously shown the potent activation of PLD by chemokines in T 
lymphocytes. We have added to these findings, and have shown that MCP-1 - 
induced activation of PLD occurs at subnanomolar concentrations and is dependent 
on PI3K. MCP-1-induced PLD activation is consistently maximal at 1nM, which is 
pleasing since this concentration corresponds to the optimal dose required for 
chemotaxis. SDF-1-stimulation of Jurkat cells also induced a time-dependent 
increase in both PA and PtdBut, and thus we have clearly demonstrated in two 
separate systems that CC and CXC chemokines can induce detectable PLD 
activation.
Linking PI3K and PLD
The observation that MCP-1-induced PLD activation occurs downstream of PI3K 
comes as no surprise since there is a wealth of information suggesting a functional 
link between these two enzymes. Studies using PI3K inhibitors have suggested, as a 
possible underlying mechanism, that the products of PI3K, namely Ptdlns(3,4)P2 and 
Ptdlns(3,4,5)P3 regulate the activity of the afore mentioned small GTPases, ARF and
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Rho which have been shown to be involved in PLD activation. This could well 
explain the wortmannin-induced abrogation of PLD activity in response to MCP-1. 
Both PLD and PI3K are regulated by receptor tyrosine kinases and both enzymes 
appear to be modulated by Ral A, the downstream target of Ras in PDGF- and EGF- 
stimulated cells (Lucas et al, 2000 Slaaby et al, 1998 ). There is also evidence of 
PLD2 becoming tyrosine phosphorylated on formation of a complex with the EGF 
receptor (Lu et al, 2000), and PLD1 is thought to cooperate with PI3K in the 
translocation of GLUT4 between plasma membranes and intracellular vesicles in 
insulin-stimulated cells (Emoto et al, 2000).
In contrast, there is a wealth of information implicating PLD upstream of PI3K, and 
although we have shown that PLD activation in our system is dependent on PI3K, 
consideration of PLD as an upstream activator may help us to understand the 
interaction between these pathways.
It has been shown that anionic phospholipids, such as PA can bind to the p110 
regulatory subunit of class I PI3Ks. Banno et al have highlighted the possibility that 
in sphingosine-1-phosphate-stimulated cells, PA derived from PLD activation can 
participate in the recruitment of PI3K to the plasma membrane. The PA-stimulated 
enhancement of tyrosine phosphorylation in several cell types has been recognised 
for sometime, however, a more recent study has demonstrated that exogenous PA 
induces tyrosine phosphorylation of the p85 regulatory subunit of PI3K in neutrophils 
(Siddiqui et al, 1997, 2000). We could therefore speculate that PA-dependent 
tyrosine phosphorylation may be involved in recruitment to the plasma membrane 
and stimulation of the PI3K in leukocytes.
In retrospect, it would have been interesting to clarify the effect (if any) of PLD on 
PI3K activation in this system. Perhaps by incorporating a primary alcohol (versus 
secondary alcohol) into the stimulation buffer, followed by an in vitro lipid kinase 
assay of a PI3K immunoprecipitate. Alternatively, one could simply assess the 
effects of this inhibition on PKB phosphorylation. The primary alcohol would serve as 
a phosphatidyl group acceptor in the PLD-catalysed transphosphatidylation reaction, 
and inhibit PA/lyso-PA -mediated activation of PI3K.
PLD activation: The requirement of GTP-binding proteins
Considering the notion that ARFs may well be involved in the observed PLD 
activation, we attempted to investigate the role of these proteins in MCP-1-stimulated 
chemotaxis of THP-1 cells. Although we cannot deduce the functional significance, 
we can confirm that PLD activation in THP-1 cells conforms to the standard
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requirements for activation of cofactor ARF. Preliminary studies have been carried 
out to further investigate the role this protein in migration. For this, we used brefeldin 
A (BFA) ,a fungal metabolite originally isolated from Penicillium brefeldianum by 
Haerri et al. The mode of action of this inhibitor is thought to be through the 
disruption of vesicular and Golgi apparatus, as well as the inhibition of guanine 
nucleotide exchange factor (GNEF) activity on ARF proteins. In many studies, the 
use of BFA has clearly indicated the biochemical and functional importance of intact 
Golgi and ARF proteins in cellular processes. This suggests that BFA is a broad- 
spectrum inhibitor, and is not exclusively selective to ARF proteins -  Thus, caution 
should be taken when interpreting these results.
It stands to reason that ARF-mediated activation of PLD should be inhabitable by 
BFA, since BFA inhibits the binding of ARFs to the Golgi membrane. Indeed the 
abolishment of PLD activation by this compound has been observed in several 
systems, and was reiterated in this system. Although a good indicator, pre-treatment 
with BFA is not the definitive test for PLD activation in that some mammalian cells 
are resistant to inhibition. For instance in PtK1 cells that have natural resistance to 
BFA (Ktistakis et al, 1991), BFA appeared to have no effect on what was shown to be 
an ARF-mediated activation of PLD (Ktistakis et al, 1995).
By observation that BFA severely abrogated MCP-1-induced PLD activation was the 
first step in linking ARFs and PLD activation to a functional readout. Due to the fact 
that there are no commercially available inhibitors of PLD, we used BFA in 
chemotaxis assays as an indirect method of assessing the role of PLD in cell 
migration - a preliminary step in linking ARFs and PLD activation to a functional 
readout. Surprisingly, it was shown that BFA failed to inhibit MCP-1-induced 
chemotaxis of THP-1 cells. Furthermore, our hypothesis was complicated by the 
apparent concentration-dependent potentiation of the chemotaxis by BFA treatment. 
In addition, it was found that MCP-2 and MCP-3-induced chemotaxis was potentiated 
by BFA treatment, migration induced by MCP-4 was abrogated. This is a clear sign 
that MCP-4 is unique to the other CCR2 ligands in that it appears to be operating via 
an exclusive ARF-controlled pathway. As we did not look at MCP-2, -3, and -4 - 
stimulated PtdBut or PA accumulation, the role of PLD in cell migration cannot be 
speculated.
There were several possible mechanisms by which we expected BFA to inhibit MCP- 
1-induced chemotaxis. Firstly, by abrogating a potential ARF-mediated activation of
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PLD. Also, there is confounding evidence that the disruption of Golgi apparatus by 
BFA blocks cell polarisation and inhibits directed cell migration. For example, in 
Swiss 3T3 fiboblasts BFA totally abrogated PMA-directed migration by disturbance of 
psuedopodial activity and lamellipodia formation -  morphological prerequisites of cell 
migration (Bershadsky etal, 1994).
As previously mentioned, it possible that the THP-1 cell line exhibits a resistance to 
BFA, and like PtK1 cells, are not biochemically or morphologically modified by the 
compound. It is also noteworthy that of all the six known mammalian ARF proteins, 
only ARF1 has been found sensitive to BFA (Liang and Kornfield, 1997). It may well 
follow that chemotaxis in this system may involve ARF (s) other than the BFA- 
sensitive ARF1. Although we have confirmed that MCP-1-stimulated PLD activation 
is modulated by ARF(s), it is conceivable that PLD does not play a role in 
chemotaxis. Hence, attenuation of this pathway by BFA would not be detectable in 
this assay.
In addition, considering that we did not assess any other readout in response to BFA, 
it cannot be confirmed that the compound was effective in the modification of 
endogenous ARF proteins as was assumed. However, the action of the toxin was 
evident by light microscopy since treated cells were less spherical than those treated 
with the vehicle (data not shown), and is an indication that BFA was having the 
desired cellular response.
Since a significant amount of literature suggestive of a direct role of Rho proteins in 
receptor-mediated PLD activation has been published in recent years, the 
involvement of Rho in this system should also be considered. For example, insulin 
induces the translocation of ARF and Rho to the plasma membrane of rat adipocytes 
and that activation of PLD by insulin correlates with the activation of Rho proteins 
(Karnam et al, 1997). In hand with BFA, the use of Clostridium botulinum C3 exotxin, 
an inhibitor of Rho function, would have been a useful way in delineating the function 
of these small G proteins in PLD activation.
Given the idiosyncrasies involved in using BFA as an inhbitor of ARF proteins, the 
resistance of MCP-1-stimulated chemotaxis of THP-1 cells can be rationalised. 
However, the observed potentiation of chemotaxis by this compound is difficult to 
explain. The ARF proteins have been implicated in the retrograde transport of 
proteins between Golgi and endoplasmic reticulum (Dinter and Berger, 1998), which 
makes MCP-1-induced activation of PLD a likely candidate mechanism for CCR2
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downregulation. Given this hypothesis, it follows that inhibition of PLD by BFA would 
reverse this effect by up-regulating CCR2, and therefore rendering cells more 
responsive to MCP-1 directed migration. Although plausible, such this theory is 
wildly speculative, and until further studies are carried out, the pathways mediating 
this effect remain unclear.
PA has been shown to activate tyrosine phosphorylation, inhibit Ras-GAP, stimulate 
the recruitment of Raf-1 to cell membranes, induce mobilisation of intracellular 
calcium, and appears be more potent than DAG in phosphatidyl-inositol 
bisphosphate (PIP2)-specific PLC activation. Furthermore, PA may potentiate the 
function of kinases, G-proteins, exert transcriptional control, and other mediators that 
are involved in signal amplification or directly in cellular responses. Although our 
insight into the intracellular targets of PA is clearly advancing, the absence of 
selective and potent inhibitors of PLD, are limiting the experimental approaches that 
can be employed for implicating PLD in cell function.
Macrophages, PLD and atherosclerosis: A clinical perspective.
So how does the activation of the PLD pathway by MCP-1 fit into the pathogenesis of 
atherosclerosis and other inflammatory disorders? As discussed in Section 1, much 
of the current interest in the role of chemokines in atherogenesis stems from MCP-1 
and CCR2 knockout mice. However, while it is clear that this receptor-ligand 
interaction is involved in the initiation of atherosclerosis in vivo, it is not clear how 
MCP-1 effects contributes to the artherogenesis (development of atherosclerotic 
lesions). CCR2-mediated recruitment of macrophages and the subsequent uptake of 
oxidised LDLs is an important factor in the development of this disorder, and 
interestingly, several lines of evidence have implicated oxidised LDLs in the 
activation of the phospholipase D (PLD) pathway. For instance, it was reported by 
Natarajan et al that in arterial smooth muscle cells, oxidised LDL induced DNA 
synthesis, and this was highly associated with stimulation of PLD activity.
There are several groups that have identified that atherosclerotic plaque 
inflammatory proteins such as VCAM-1 or CD59, contain glycosylphosphatidylinositol 
(GPI) membrane anchors (Terry et al, 1993). This has highlighted the possibility that 
an enzyme associated with atherosclerosis may catalyse the cleavage of the GPI 
moiety. To date, the only recognised GPI-specifc enzyme is a GPI-specific PLD. 
Interestingly, GPI-PLD is highly expressed in the majority of myeloid cell lines, and 
infiltration of such cells is a hallmark of atherosclerotic plaque formation (Xie and
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Low, 1994). Furthermore, the cleavage products of GPI-PLD are shown to 
upregulate macrophage expression of IL-1 and TNFa, the major inflammatory 
cytokines believed to mediate atherogenesis (Schofield et al, 1996; Moyer et al, 
1991). The fact that we have shown the monocytic cell line, THP-1, to activate PLD 
in a CCR2-mediated manner is further evidence that this signalling pathway could 
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Figure 6.6. The hypothetic link between CCR2, PLD and LDL in artherogenesis
Monocytes are recruited to the artery by MCP-1 secreted from smooth muscles cells. Here, 
circulating monocytes engage in MCP-1-controlled rolling and adhesion. Following 
differentiation in to macrophages, oxidised LDLs are taken up and foam cells are formed. 
LDLs activate PLD that modulates various signalling cascades and DNA synthesis. The 
cleavage products of GPI-specifc PLD upregulate the expression of IL-1 and TNF-a, 
(cytokines highly associated with chronic arterial inflammation), and these perpetuate 
artherogeneis in an autocrine manner.
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Future studies
• Key experiments that are outstanding include: assessment of PLD activation 
in response to MCP-2, -3 and -A, and the role of PI3-K and ARF(s) in these 
pathways.
• Further delination of the coupling mechanism of CCR2 to the PLD pathway by 
determining the involvement of tyrosine kinases, PKC, and other small 
GTPases such as Ras, Rac and Rho.
• Based on studies carried out with neutrophils (English, 1996), it would be 
interesting to investigate the extracellular effects of PA and other PLD 
products on macrophage function. This could be achieved by exposing cells 
to exogenous PA and assessing cellular responses such as actin 
polymerisation, gene transcription, cell migration.
• Considering the recent interest surrounding ARF-GEF interaction with the 
lipid products of PI3-K, future studies could involve the investigation of their 
cellular function. Our group is currently using green fluorescent protein 
(GFP)- imaging of ARF-GEFs such as ARNO and cytohesin to help 
characterise the PI3-K-dependent regulation and subsequent PLD activation.
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Section 7: Results
Characterisation of signal tranduction events elicited via a novel promiscuous 
human CC chemokine receptor. D6.
Rationale
So far in this thesis, we have explored the signal transduction mechanisms arising 
from engagement of the CCR2 receptor by MCP-1, and related family members. For 
the final chapter, we briefly touch upon a different CC chemokine receptor-ligand pair 
and presenting preliminary data from macrophage inflammatory protein-1 a (MIP-1a) 
and its novel promiscuous receptor, D6.
Human D6 is a promiscuous G protein-coupled heptahelical chemokine receptor that 
is expressed is a wide range of tissues. Although assigned to the CC chemokine 
family, comparisons of the primary sequence of D6 suggests that it is equally related 
to the CC and CXC families (Nibbs et al, 1997), and so may represent a novel subset 
of chemokine receptors. Most of the information regarding this receptor comprises 
expression profiles and binding data, but to date there is no evidence of signalling 
potential. Here we used cells stably transfected with D6 cDNA in the presence and 
absence of specifically mutated residues - residues that were noticeably different in 
D6 compared to all other chemokine receptors. This model was used to evaluate the 
ability of the D6 receptor to couple to a variety of downstream effectors in an attempt 
to verify whether D6 is indeed a signalling receptor.
Table 7.1 Affinity of Human and Murine CC chemokines on hD6
Chemokine Human Murine
MIP-1ot 64nM 920pM
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Table 7.2 D6 chemokine receptor plasmids
Plasmids Comments
Wild type No mutation. No calcium flux
N92D The N at position 92 in D6 is D in all other CC 
receptors (except Duffy). No calcium flux
K142A + E145A Double mutation. Introduction of a DRYLAIVHA motif 
into the second intracellular loop (DKYLE-DRYLA), 
with the overall charge of this region being altered. 
Modest calcium flux
K142A + E145A + N92 Contains both N92D and K142A+E145A. Modest 
calcium flux
All plasmids were constructed and transfected by Robert Nibbs, Beatson Institute, Scotland
• HEK-293 cells were either untransfected or stably transfected with one of the
four plasmids above.
• 300-19 Pre-B (clones 10 and 13) were either untransfected or stably
transfected with wild-type D6.
Results
Figure 7.1. MIP-1a-stimulated wild-type HEK-293 cells did not show a measurable 
increase in ERK-1/2 phosphorylation, but appeared have constitutive activity of the 
enzyme. Conversely, the N92D mutant had relatively low basal activity, and upon 
stimulation with MIP-1a demonstrated a rapid and transient phosphorylation of ERK- 
1/2. Maximum activity was achieved 1 m post-stimulation and had returned to basal 
levels after 2 m. Stimulation with PMA for 5 m provided an appropriate positive 
control for this assay.
The same transfectants were assessed for their ability to induce PI3-kinase activity 
Both the wild-type D6 and the N92D mutant were assessed for their ability to 
phosphorylate a well-characterised downstream effector of PI3-kinase, protein kinase
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B (PKB). Figure 7.2. When stimulated with 10nM MIP-1a a rapid and transient 
phosphorylation of PKB was observed in both wild-type and N92D transfectants with 
maximum activity observed 1 m post-stimulation. In the case of N92D, the kinetics 
appeared to be slightly slower and more sustained than that of the wild-type.
Although the phosphorylation of PKB implied that PI3-kinase was being activated in 
this system, it was necessary to cleariy identify the isoforms involved in D6-mediated 
signalling. Two cell lines (HEK-293 and 300-19) containing the D6 cDNA were 
screened for the G protein-coupled receptor-specifc PI3K, p110y, by western blotting 
resting cells with an anti-p110y monoclonal antibody. Figure 7.3A shows the relative 
expression of PI3Ky in the D6 cell models compared to that of Jurkat and THP-1 
cells. Interestingly, whereas the HEK-293 cells screened positive for this isoform, 
there was no evidence of p110y expression in the pre-B cell line, 300-19.
Based on these observations, the p110y-positive HEK-293 D6 tranfectants were 
subjected to investigation of associated lipid kinase activity under in vitro conditions 
(as explored in Section 4). Such In vitro lipid kinases assays demonstrated that 
stimulation of both HEK-293 wild-type and N92D D6 transfectants with MIP-1a 
(100nM) resulted in a time-dependent increase in p110y activity. In the wild-types, 
increase in p110y activation, although modest, peaked at 1 m and declined to below 
base-line levels after 15 m. The N92D mutants appeared to be more responsive to 
MIP-1 a stimulation and demonstrated a greater increase in p110y activity. Maximum 
activity was observed at 1 m post-stimulation and had returned to near basal levels 
after 10 m (Figure 7.3B).
In a crude attempt to investigate the role of phospholipase D (PLD) in D6-mediated 
signalling, the generation of phosphatidic acid was measured in response to MIP-1 a 
stimulation (Figure 7.4). In the HEK-293 D6 transfectants generation of phosphatidic 
acid was evident after 30 s post-stimulation, maximal at 5 m (~2-fold increase) and 
had almost returned to basal levels after 10 m.
As expected, the untransfected HEK-293 cells did not respond to stimulation. In the 
300-19 D6 cell model, levels of PA increased to 286% of control upon stimulation 
with MIP-1 a. In this cell line, although maximum activity was greater, the kinetics of 
PA accumulation were slower and more sustained than observed in the HEK-293 
cells since levels of PA generation were over 200% of control after 10 m post­
stimulation.
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In the HEK-293 transfectants, the effects of the N92D and the DKYLE-DRYLA 
mutations on the D6-mediated phosphatidic acid were compared to that of the wild- 
type (Figure 7.5). Although maximum PA generation was attained with the wild-type 
(268% of control), the N92D and the DKYLE-DRYLA mutants also permitted 
activation. The DKYLE-DRYLA mutant produced the weakest response, peaking at 
-160% of control. In short, these mutations served to reduce the efficiency of 06- 
coupling to the PA pathway.
Unfortunately, due to constraints of time, the triple mutant was not introduced into 
any of the above experiments.
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Figure 7.1 Effect of MIP-1a on ERK-1/2 activation in HEK-293 cells























Figure 7.1 Effect of MIP-1 a on ERK-1/2 activation in HEK-293 cells stably 
transfected with D6 cDNA. Pools of geneticin-resistant HEK-293 cells were stably 
transfected with pcDNA3 containing D6 (A) wild type, B) N92D mutant. 5 X 105 
cells/point were then stimulated with either vehicle (0.05% BSA) or 10nM MIP-1 a for 
the indicated times . Whole cell lysates (cell equivalents of 2.5 x 105 per lane) were 
resolved separately by SDS-PAGE, electrophoretically transferred to a nitrocellulose 
membrane and immunoblotted with either anti-phospho-ERK-1/2 or pan ERK1 (to 
verify equal loading of proteins). The results are from one experiment but are 
representative of at least one other.
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Figure 7.2. Effect of MIP-1a on PKB activation in HEK-293 cells stably transfected 
with D6 cDNA. Pools of geneticin-resistant HEK-293 cells were stably transfected with 
pcDNA3 containing D6 (A) wild type, B) N92D mutant. 5 X 105 cells/point were then 
stimulated with either vehicle (0.05% BSA) or 10nM MIP-1a for the indicated times . Whole 
cell lysates (cell equivalents of 2.5 x 105 per lane) were resolved separately by SDS- 
PAGE, electrophoretically transferred to a nitrocellulose membrane and immunoblotted 
with either anti-phospho-PKB or pan PKB antibodies (to verify equal loading of proteins). 
The results are from one experiment but are representative of at least one other.
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Figure 7.3. Verification of expression and activity of Class 1B PI3K isoform,
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Figure 7.3. A) Expression of p110y in HEK-293 cells. Resting Jurkat, THP-1, 
HEK-293 and 300-19 Pre-B cells were lysed, resolved separately by SDS-PAGE 
(2.5 x105 cell equivalents per lane), and electrophoretically transferred to a 
nitrocellulose membrane as described in ‘Materials and Methods’. Lysates were 
immunoblotted with an anti-p110y mAb. Results are from one experiment and are 
representative of another 2 independent experiments B) In v itro  lipid kinase assay 
of MlP-1a-stimulated HEK-293 cells stably transfected with the D6 receptor.
1x107 HEK-293 cells/point (wild type and N92D mutant) were stimulated at 37°C 
with 10nM MIP-1a for the indicated times. Cells were lysed, and lysates subjected 
to immunoprecipitation with anti-p110y monoclonal antibody. The washed 
immunoprecipitates were analysed for PI kinase activity using PI as a substrate. 
Extraction and TLC separation of the lipid products were performed as described 
under ‘Materials and Methods’. Lipids were detected by exposure to film at -70°C. 192
The data is representative of three separate experiments.
Figure 7.4. Generation of phosphatidic acid in MIP-1a-stimulated human D6 transfectants
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Figure 7.4. Detection of phosphatidic acid generation in human D6 
transfectants. Pools of A) geneticin-resistant HEK-293 cells and B) Pre-B (300- 
19) cells transfected with pcDNA3 containing D6 were metabolically labelled with 
50pC| 3H-palmitate for 3 hours and resuspended in RPMI. Cells were then 
stimulated with 10nM MIP-1a for the indicated times, quenched, and subjected to 
organic extraction. TLC and analysis of extracted samples were performed as 
described in 'Materials and Methods'. Each histogram represents the mean ± SEM 
percentage increase in [3H]-Phosphatidic acid over background from three 
independent experiments performed in duplicate.
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Figure 7.5 Detection of phosphatidic acid generation in HEK-293 cells
stably transfected with D6 cDNA.
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Figure 7.5. Detection of phosphatidic acid generation in HEK-293 cells stably 
transfected with D6 cDNA. Pools of geneticin-resistant HEK-293 cells transfected 
with pcDNA3 containing D6 (wild type, N92D and DKYLE-DRYLA mutants) were 
metabolically labelled with 50(iC, 3H-palmitate for 3 hours and resuspended in 
RPMI. 1 X 107cells/point were then stimulated with 10nM MIP-1a for the indicated 
times, quenched, and subjected to organic extraction. TLC and analysis of 
extracted samples were performed as described in 'Materials and Methods'. Each 
histogram represents the mean ± SEM percentage increase in [3H]-phosphatidic 
acid over background from two independent experiments performed in duplicate.
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Section 7: Discussion
Characterisation of signal tranduction events elicited via a novel promiscuous 
human CC chemokine receptor. D6.
One of the most pertinent questions in the study of chemokine biology is why there is 
so much redundancy among the ligands and why are many ligands promiscuous with 
respect to receptor activation (For review see Mantovani, 1999). For instance, as 
observed in previous chapters, all four monocyte chemotactic proteins (MCPs) 
interact with CCR2, and at least MCP-2, -3 and -4  also recognise other receptors. It 
is interesting to note that each chemokine is uniquely active upon different leukocyte 
populations, and similarly, a given leukocyte population responds to a multitude of 
chemokines. So what could be the true relevance of the promiscuity observed in the 
ligand:receptor interactions that occur between multiple members of the chemokine 
family?
In 1997, Nibbs et al reported the identification and characterisation of a novel CC 
chemokine receptor, human D6. This was shown to be a highly promiscuous 
receptor that was able to bind the majority of CC chemokines, however, it 
demonstrated high specificity in that it did not show affinity for members of the C, 
CXC or CX3C families. Uncommon to most chemokine receptors, human D6 has not 
been shown to flux calcium, and so until now, it has been unclear whether this novel 
receptor is indeed capable of signalling. Addressing these issues will enable us to 
understand the biochemical and functional role of the D6 receptor and may also 
extend our understanding of promiscuous chemokine receptors in general. 
Furthermore, observing the effects of mutation on the signalling capacity of D6 will 
assist the identification of important microdomains that may be involved in agonist 
binding and the activation of CC subfamily of chemokine receptors. Although the 
ligand specificity of D6 is contentious (Bonini et al, 1997) full length D6 cDNA 
expressed in HEK-293 and CHO cells produces the highest affinity murine MIP-1a 
receptor identified to date (Nibbs et al, 1997a). Here, using murine MIP-1a, we have 
extended our studies to investigate whether D6 is in fact capable of eliciting 
detectable signal transduction.
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Northern blot analysis of several human tissues reveals that D6 is almost exclusively 
expressed in the placenta with weak expression in the liver, lung and thyroid. Early 
studies reported that there is only a weak haematopoitic expression of hD6, thus, 
supporting the observation that hD6 does not facilitate HIV-1 or SIV entry into CD4- 
expressing cells (Nibbs et al, 1997a). In disagreement, RT-PCR studies in our 
laboratory have clearly shown mRNA expression of this receptor on peripheral blood 
mononuclear cells, THP-1 and U937 cells (data not shown). Current studies have 
focused on the observation that D6 is highly expressed on lymphatic endothelial cells 
and some malignant vascular tumours. Here, it has been suggested that D6 may 
influence the chemokine-driven recirculation of leukocytes through the lymphatics 
and modify the putative chemokine effects on the development and growth of 
vascular tumours (Nibbs et al, 2001).
Despite knowledge of ligand binding relationships and tissue localization of D6, the 
precise role of this receptor in normal and pathologic physiology remains unclear. 
Based on what is known of other heptahelical membrane receptors, it seems likely 
that D6 would transmit a signal across the membrane upon chemokine binding, 
however, D6-dependent signal transduction has not yet been formally reported. This 
is the first evidence that the wild-type D6 receptor activates the PI3K/PKB pathway 
and weakly phosphorylates ERK-1/2 in HEK-293 cells, and mediates the generation 
of phosphatidic acid in both HEK-293 and 300-19 transfectants.
PLD activation in D6 transfectants
Stimulation of D6 transfectants with MIP-1 a resulted in accumulation of phosphatidic 
acid (PA), and was demonstrated in wild-types, N92D and DKY-DRY mutants. As 
extensively discussed in Section 6, the methodology employed in our studies does 
not permit us to automatically attribute the generation of PA to the involvement of 
phospholipase D. That said, PLD-mediated generation of PA is consideration here 
given that there is a growing body of evidence emerging that establishes the 
chemokine-induced accumulation of PLD. Bacon et al, have reported chemokine- 
stimulated PLD activation in the Jurkat T cell line, and although the receptor(s) 
mediating this effect await characterisation, this cell line was shown to express D6. 
Therefore, in hand with our data, it is tempting to speculate that ligation D6 receptor 
potently activates PLD. Considering the establishment of potential links between 
PI3K and PLD in such systems, future studies will be aimed at characterising the of 
cross-talk between these pathways.
Although commonly considered as a mere lipid intermediate resulting from PLD or 
DAG-kinase activation, phosphatidic acid per se is now suspected to play a role as a
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second messenger in several signalling pathways. It appears to be involved in cell 
proliferation induced by cytokines, membrane trafficking, and cytoskeletal 
reorganisation. In addition, there is a non-exhaustive list of PA-sensitive signal 
transduction proteins that further implicate PA as a regulator of cell function. 
Examples include PKC, Ras, cAMP-phosphodiesterases (Epand and Stafford, 1990; 
Tsai et al, 1989; Grange et al, 2000). Apart from it effects on Raf-1 kinase function, 
little information is available on the functional significance of PA. In this regard, PA 
has been reported to control membrane recruitment and activation of Raf-1 and as a 
consequence plays an intrical part in the Ras/MAPK cascade. (Bell et al, 1995). 
Whether the observed PA accumulation was a result of PLD activation or not, it can 
be concluded that ligation of the D6 receptor initiates the activity of this intermediate 
and/or second messenger which may be involved in important cellular processes. 
This is further evidence that this D6, contrary to the literature, is indeed a signal 
transduction-competent chemokine receptor.
D6 activation to the PI3K/PKB pathway
Phosphorylation of PKB in response to MIP-1a clearly demonstrates the formation of 
D-3-phosphorylated lipids in this system, and hence the activation of 
phosphatidylinositol-3-kinase (PI3K). Furthermore, it has been established here that 
D6 couples to the G protein-associated PI3K as observed from the in vitro lipid 
kinase activity in p110y immonoprecipitates. Wild-type D6 transfectants produced a 
modest, time-dependent increase in p110y in response to MIP-1a-stimulation. 
These data encourage us to question how the D6 receptor couples to the PI3K-y 
given that this receptor appears to be lacking the crucial motif required for G protein 
interaction. The hD6 cDNA displays 71% identity to the murine D6 receptor, and in 
common with this protein, it has an alteration in the highly conserved DRYLAIVHA 
motif in the second cytoplasmic loop that is characteristic of G-protein-coupled 
seven-membrane-spanning receptors. To date, only a few other heptahelical 
receptors that lack DRY motifs have been cloned. They include the cAMP receptor in 
Dictostelium (Klein et al, 1988), bride of Sevenless (BOS) in drosophila (Hart et al, 
1990), and the two, seven-transmembrane-spanning proteins that bear mutations in 
familial Alzheimer's disease (Rogaev et al, 1995; Sherrington et al, 1995) The yeast 
homologue of the heptahelical protein mutated in Alzheimer's disease has been 
shown to be involved in signalling via the notch pathway (Levitan et al, 1995). Thus, 
there is precedent for heptahelical receptors that signal through pathways
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independent of G-coupled proteins. On ligation of the receptor, the D6-specifc DKY 
motif could interact or "cross-talk" with other membrane components (which could 
differ depending on cell type) and may permit a novel type of G-protein interaction 
quite different to the typical GPCR interactions. This would explain the MIP-1a- 
stimulated p110y activation observed in the wild-type and N92D D6 transfectants. In 
retrospect, it would have been useful to assess the pertussis toxin-sensitivity the 
MIP-1a-stimulated PI3Kinase/PKB pathways, as this would have provided clear 
evidence of the role of the G protein subunits in D6-mediated signalling.
The Role of D6 -  Lessons from DARC.
The scope for possible biological functions of D6 is extremely broad given that there 
is limited information on this receptor. However, due to the promiscuity, the 
'apparent' non-signalling status, and the expression profiles of D6, it has commonly 
been grouped together with DARC, another promiscuous receptor for chemokines. 
The Duffy antigen is the erythroid chemokine receptor (DARC) for the malaria- 
causing protozoan Plasmodium vivax and a highly promiscuous receptor that has the 
unique capacity to bind members of both CXC and CC branches. Despite having a 
seven-transmembrane domain architecture, the binding of ligands to Duffy 
antigen/receptor for chemokines (DARC) does not induce signal transduction and or 
appear to be coupled to a G-protein (Hadley and Peiper, 1997). Therefore, the 
precise physiological role of DARC has yet to be elucidated.
Some of our hypothesised functions of D6 are reminiscent of the suggested roles of 
the DARC receptor. Firstly, it is possible that D6 may act as a "sink" for chemokines 
in which they may be impounded and neutralised. Here, pro-inflammatory D6 
chemokines (which happen to be the majority of it ligands) would be seized, but other 
non-D6 binding chemokines likely to be involved in constitutive leukocyte trafficking 
would be liberated to interact with target cells. This anti-adhesion mechanism may 
also function to inhibit chemokine-mediated firm adhesion of leukocytes in systems, 
such as the lymphatics, whereby a passive flow of cell populations is required.
Alternatively, the chemokine may in fact remain fully functional on binding to D6, but 
once bound would be presented by the receptor to leukocytes ( the chemokine 
presenting molecule theory"). Typically, tissue-derived chemokines actuate 
inflammatory leukocyte emigration by traversing the endothelial cells (ECs) by means 
of chemokine diffusion through the intercellular gaps. However, Middleton et al,
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demonstrated by electron microscopy that the IL-8 can be internalised by venular 
ECs, transcytosed to the luminal surface and presented to adherent leukocytes on 
the EC membrane. Thus, chemokine presentation could offer another functional role 
for the promiscuous D6 receptor.
Although such theories have so far offered plausible explanations, the emergence of 
signalling data from our studies are leading us away from the idea that D6 is a 
DARC-like receptor, and towards an entirely new perspective. Further in vivo and in 
vitro approaches are required to determine which hypothesis best reflects the 
function of D6 on lymphatic EC’s, vascular tumours, and leukocytes.
Figure 7.6. The “chemokine sink theory". Pro-inflammatory CC chemokines that bind to D6 are 
sequestered and rendered inactive by the receptor. Non-D6 bindingchemokines are therefore lierated to 
interact with target cells and mediate constitutive trafficking of leukocytes
Cell membrane
w  Non-D6 binding constitutively active chemokine. 
D6 binding pro-inflammatory chemokine
D 6 - A model for generic CC chemokine receptors
The characterisation of D6 cDNA. Although D6 contains the predicted seven- 
transmembrane spanning regions, with residues and phosphorylation sites common 
to CC chemokine receptors, there are subtle differences in primary structure that may 
help to explain its character. As previously discussed, the conserved DRY motif
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which is involved in G protein docking is altered to DKY in D6. Such a change would 
be assumed to affect the selection of G protein partners, however, the observed 
coupling of D6 transfectants lacking the DRY motif to PI3Ky suggests that this motif 
may not be prerequisite for G protein interaction. The DKY-DRY mutant appeared to 
generate phosphatidic acid (PA) upon stimulation with MIP-1a, albeit with less 
efficacy than the wild-type. This was a surprising result since one would expect the 
restoration of the common DRY motif would potentiate the signalling capacity. Such 
a finding has prompted us to question the importance of this motif in the general 
signal transduction of CC chemokine receptors.
The N at position 92 in D6 is D in all other receptors (except DARC), and, if this D is 
mutated to N in CCR5, then the receptor (like D6) is no longer able flux calcium 
following ligand binding (R. Nibbs, personal communication). Coupling to the PI3Ky 
was observed in the N92D mutant upon MIP-1a-stimulation that was considerably 
more potent than its wild-type counterparts. It was apparent that the N92D mutant 
was far more effective in coupling to the GPCR-specific PI3K, and thus, provides 
evidence that the D residue at position 92 in CC receptors is key to effective signal 
transduction.
Promiscuity
So why is D6 so promiscuous? It is possible that the duplicity of the D6 ligands 
allows differential regulation of receptor activation by different stimuli or tissue 
locations. This would give rise to a stimulus-dependent intensity, duration, or tissue- 
distribution of chemokines that recruit D6-bearing chemokines. Promiscuity of 
receptors allows its cognate ligands to have freedom for selectivity of the cellular 
response to alterations in environmental stimuli and conditions. It also bears 
relevance in the pathogenesis of a number of chemokine-mediated disease states. 
For example, different HIV strains possess some degree of chemokine-receptor 
promiscuity as the virus searches for CD4+ chemokine-receptor positive cell (Xiao et 
al, 1998). Similarly, chronic inflammatory disorders, including allergy have also 
shown to be modulated by multiple chemokine receptors and receptors. Conditions 
of airway hyperresponsiveness, such as asthma, appear to be operated by a similar 
chemokine-chemokine receptor system, whereby the CCR3 receptor is expressed on 
a number of cells involved in allergy, such as mast cells, basophils and Th2 
lymphocytes. The link between these cells and the pathogenesis of allergic 
inflammation has encouraged intense efforts to determine the link between the CCR3
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receptor and its ligands, however these efforts are complicated by their promiscuity in 
receptor usage (Lilly and Daugherty, 2001).
With the recent demonstration of D6 expression on vascular tumour cells, it is 
possible that this receptor could have a significant role in tumourigenesis. In this 
regard, the D6-chemokine interaction could affect the leukocyte infiltrate, or the 
overall response of the tumours to inflammatory mediators. Further investigation into 
the biochemical and functional capacity of this receptor is required to demonstrate 




In the sub-section discussions, we have addressed the scientific issues facing this 
work. Here, in our final comment, we have opened a forum for the consideration of 
the general issues arising from the project. We discuss the validity of our 
experimental model, the clinical application of our findings, and the outlook for the 
future.
Experimental Model
In this study, we used the leukaemic monocytic cell line, THP-1, due to its 
characteristic endogenous expression of CCR2. As previously discussed, we were 
confident that this cell line was a robust model in which to carry out biochemical and 
functional investigations, mainly because other workers had achieved reliable 
signalling data from these cells. Although allowing detailed manipulation of the 
regulatory pathways involved, the system was not sufficient to enable the pursuit of 
the physiological issues concerning CCR2, i.e. it’s pro-inflammatory role in chronic 
disease. That said, using the technology and the resources available, the 
combination of biochemical and functional studies described herein provided an 
appropriate in vitro model of chemokine-modulated cell migration. With regards to 
analysing signalling pathways, there were a number of minor limitations in using 
THP-1 cells. Firstly, there could, on occasion, be inconsistencies in the basal 
signalling activity of the cells, thus rendering some of the data as invalid. This was 
not the first report of such inconsistencies in monocytic cell lines, and in many cases, 
it has been ascribed to the ‘mechanical stretch’ that the cells are exposed to during 
the stimulation process (see Section 3- Results and Discussion).
Secondly, due to the observed mRNA expression of CCR1 and CCR3 (alternative 
receptors for MCP ligands), we had to ensure that all observed outputs were due to 
CCR2 engagement. Fortunately, this was achieved in full with the use of CCR2 
antagonists. Another option would have been the use of CCR2 transfectants, such 
the ‘CCR2b-HEK-283’ employed by Turner et al and Berkhout et al. This model has 
been particularly useful in that it has highlighted specific regions of the receptor 
important for functions, and has demonstrated the differential regulation by the two 
CCR2 splice variants. However, as attractive as the HEK-293 model may seem, the 
somewhat ‘abrasive’ process of introducing genetic material into intact cells could 
induce other non-specific phenotypic changes in this system. To further validate the 
physiological relevance of our findings, it may have been useful to have conducted
202
Final Discussion
some representative studies in human monocytes, and perhaps compare normal 
monocytes with those derived from atherosclerotic lesions. However, given the inter- 
donor differences observed in such studies, this may not have proved that useful 
given the constraints of time and the original objectives that we set out to achieve.
It is fair to say that the chemotaxis assays used in this thesis are the most suitable to 
the physiological conditions that we were attempting to simulate. The method, which 
is based on ‘Boyden’s chamber’, has been the most widely used system in the 
context of chemokine biology. It allows the quantitative measurement of cell 
migration towards a chemoattractant, and permits the comparison of concentration 
gradients and at least two separate experimental conditions (e.g. plus/minus 
pertussis toxin, MCP-1 vs MCP-2). The principle drawback of using such a system is 
ih that it does not take into consideration of the various transendothelial interactions 
that have been shown to be so crucial to the chemotactic process. However, we are 
confident that our assays were the most appropriate and representative way of 
analysing cell migration in the in vitro.
MCP-1 vs. MCP-2, MCP-3 and MCP-4
As highlighted in each section, there are many elements of regulation involved in 
CCR2 signalling pathways. Due to the range of pathways investigated (MAPK, 
SAPK, PLD, GTPases, and PI3K) in response to the four distinct CCR2 ligands 
(MCP-1, -2, -3 and -4 ) it would be unwise to propose a comprehensive working 
model for the CCR2 signalling system. This project has been a useful exercise in 
establishing general signalling events, but perhaps in retrospect it may have been 
more useful to concentrate on the events elicited by one particular pathway or CCR2 
ligand. Our primary aim was not to compare the behaviour or efficacy of each MCP 
chemokine, but rather to verify that they were all capable of inducing signal 
transduction in a comparable manner to that observed with MCP-1. This was 
achieved on a number of levels, and in fact we were able to observe slight variations 
in behaviour and efficacy between the four. In terms of physiological relevance, 
these observations could be applied to an environment whereby CCR2 is exposed to 
all four ligands (e.g. the atheroslerotic lesion or rheumatic joint). The differences in 
binding affinity, signalling capacity and kinetics could be a strategic mechanism 
through which to stagger the biochemical events triggered by the receptor -  and 
perhaps permit the strategic ‘firing’ of the signalling components and subsequent 
functional responses. We did not fully investigate MCP-2, -3 and -4  signalling
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profiles enough to further subscribe to this hypothesis, although it does offer 
interesting concept
Application to the pathophysiology of atherosclerosis
Throughout this thesis there has been little reference to the pathophysiological or 
therapeutic applications of our findings in terms of the chronic inflammatory 
disorders. This is mainly due to the fact that the model, although relevant, is too far 
removed from the complexities of the arterial and vascular microenvironment. 
However, it is from investigations such as this that large-scale comprehensive 
research programmes arise. The application of in vitro data to whole organ systems 
has previously yielded invaluable information with regards to the pathology of 
disease and can provide a working model in the search for therapeutic targets.
In general therapeutic terms -  there are two possible areas of clinical focus that have 
arisen through our investigations: 1) targeting he interaction of chemokines with 
CCR2, and; 2) manipulating the regulation of cell function by PI3K.
1) This refers to the simple observation that MCP chemokines actively induced the 
migration of inflammatory cells. It is no surprise that obstruction of this association 
by therapeutic means could attenuate cell migration and subsequently reduce 
inflammation. This concept has been implemented in a wide range of contexts, 
(including that of CCR2) in the form of receptor antagonists. These have shown to 
be very effective therapeutic tools but only when the antagonists are effectively 
localised to the desired area. For instance, in the atherosclerotic patient, inhibition of 
the CCR2-chemokine interaction in its entirety would indeed reduce the accumulation 
of macrophages in the cholesterolaemic artery, but it would also simultaneously 
inhibit systemic macrophage function, and consequently create a platform for 
immunodeficiency. In recent years, the implementation of elegant recepterology has 
permitted the identification of the precise residues necessary for chemokine signal 
transduction. This, in hand with more sophisticated methods of localising drug 
action, will eventually pave the way for more selective anti-chemokine therapy.
2) The most prominent feature of our findings is the impact of PI3K on CCR2- 
mediated signal transduction and cell migration. The further observation of 
differential regulation of PI3K by CCR2 makes this enzyme an ideal candidate for 
therapeutic targeting. Although our studies were not extensive enough to 
demonstrate the functional specialisation of the PI3K isoforms, we were able to
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dissect out which of these were activated, their kinetic profile, and their contribution 
to D-3-lipid accumulation. This biochemical data provides a clear framework from 
which further functional investigations could develop. We have shown here that each 
MCP-1 activates a least three separate PI3K isoforms, and that broad-spectrum 
pharmacological inhibition blocks cell migration. Future studies will be aimed at 
making the link between biochemistry and functional specialisation.
PI3K: An appropriate target for the therapy of immunological disorders?
As the evidence implicating their involvement in disease processes accumulates, the 
PI3Ks appear to be increasingly attractive targets for the treatment of inflammatory 
and immunological disorders, not to mention cancer and other proliferative 
conditions. The elucidation of the functional specialisation of the individual PI3K 
isoforms will enable us to selectively inhibit them with an acceptable level of toxicity. 
It stands to reason here modulation of PI3K may prove useful in the treatment of 
atherosclerosis, as well as other vascular disorders such as re-stenosis following 
balloon angioplasty, diabetic retinopathy and fibrosing alveolitis.
Since PI3K is a ubiquitous enzyme family that regulates a diverse (and often 
contrasting) range of cellular processes, chronic inhibition of this pathway is likely to 
yield undesirable results. It may be more beneficial to look further into these 
signalling cascades and perhaps concentrate on effectors downstream of the 
individual isoforms, thus developing more stringency in the targeting of pathways 
specific functional responses.
D6.
As a subsidary to this project, we also investigated the signalling potential of the 
promiscuous CC chemokine receptor D6. We present here the first report of any 
signalling events elicited through this receptor, and this has paved the way for some 
exciting future studies. What makes these investgations more interesting is that D6 
could well have a function quite unique from those normally associated from 
chemokine receptors. Elegant studies are currently being considered in our 
laboratory to extend this research. Moreover, the process of elucidating the novelties 
of D6 receptor will at the same time help us to understand the signalling behaviours 
of CC chemokine receptors in general.
Specific guidelines for future studies are outlined at the end of Sections 3,4,5,6 and 7.
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Appendix 1 -  Tissue Culture 
THP-1 cells






0.1 mM MEM non-essential amino acids 
2mM gltamine 
1 mM sodium pyruvate
800fig/ml geneticin (G418) *only for transfectants 




200mM Tris-HCL (pH 6.8)
5% 2-mercaptoethanol




Adjust to pH 7.5







0.05% sodium azide 
Made up in TBS
Running buffer
192 mM glycine 
25mM Tris-base 
0.1% SDS.




62.5 mM Tris-HCL 
Made up in TBS
Coomassie Blue
0.25% Coomassie Blue (w/v) 
45.4% Methanol (v/v)
9.2% glacial acetic acid 
Made up to final volume in H20
Preparation of acrylamide gels
Component 7.5% 10% Stacking
gel
29.2% Acrylamide/ 0.8% N,N- 
methylene-bis-acrylamide
3.5 5 1.6
1 M  Tris 8.8 (ml) 5.6 5.6 -
Water (ml) 5.6 4.35 7.3
1 M  Tris pH 6.8 (ml) - - 3.5
10% SDS (ml) 0.25 0.25 -
10% APS (ml) 0.05 0.05 0.065
TEMED (ml) 0.02 0.02 0.012
Final Volumes 15 15 12.477
Antibodies used for Western blotting.
Assay Primary antibody Secondary antibody
Source Cone. Cone.
Phospho-ERK1/2(42/44) Rabbit 1/1000 1/10,000
Pan ERK-1 Rabbit 1/1000 1/10,000
Pan ERK-1/2 Rabbit 1/1000 1/10,000
Phopsho-JNK(mr183/,yr185) Rabbit 1/1000 1/10,000
Phospho-p38(Thr180/lyr182) Rabbit 1/1000 1/10,000
ERK-1 Rabbit 1/1000 1/10,000
pJNK Rabbit 1/1000 1/10,000
p38 Rabbit 1/1000 1/10,000
Phospho-PKB (ser473) Rabbit 1/1000 1/2000 (in 5% Marvel/TBS)
Phopsho-GSK-3ot(3(ser21 /9) Rabbit 1/1000 1/2000 (in 5% Marvel/TBS)
PKB/Akt Rabbit 1/1000 1,10,000
GSK-3a Rabbit 1/1000 1/10,000
PI3K-C2a Rabbit 1/1000 1/10,000
PI3K-C2p Rabbit 1/1000 1/10,000
p110y Rabbit 1/1000 1/10,000
p85a Mouse 1/1000 1/20,000
Antiphophotyrosine (4G10) Mouse 1/10,000 1/20,000
Gab2 Rabbit 1/1000 1/20,000
Ras (p21) Mouse 1/1000 1/4000
Anti-myc (9E10) Mouse 1/10,000 1/4000
Appendix 3 -  Lipid kinase assay
Lipid kinase buffer
5mM MgCI2 
0.25 mM EDTA 
20mM HEPES 
pH -  7.4
TLC so lve n t
Propan-1-ol, glacial acetic acid, water [130:4:66(w/v)]
Appendix 4 -  RT-PCR










5’T GT CAT ACCAGG AAAT G AGC3’
P-Actin 176 Sense:
Antisense:
5’GACCCCTT CATT G ACCT CAAC3’ 
5’GCAGT AAT CT CCTT CT GCAT C3’
CCR1 327 Sense:
Antisense:
5’ACCT GCAGCCTT CACTTT CCT CAC3’ 
5’GGCG AT CACCT CCGT CACTT G3’
CCR2 255 Sense:
Antisense:










Appendix 5. Biochemical reagents
p-glycerophosphate Sigma, UK
[32P]-ATP Dupont NEN, USA
[32P] -orthophosphoric acid Dupont NEN, USA
pH] Ptdlns (4)P Amersham International, UK
[3H] Ptdlns (4,5)P2 Amersham International, UK
pH] -  palmitic acid Amersham International, UK
2-mercaptoethanol Sigma, UK
Adenosine triphoshate Sigma, UK
Ammonium persulphate BDH, UK
Ammonium Phosphate Sigma, UK
Anti-Gab2 Cell Signalling Technologies, USA
Anti-PKB/Akt Cell Signalling Technologies, USA
Anti-P38 antibody Upstate Biotech. USA
Anti-CCR2 -  PE conjugate R&D systems, UK
Antiphosphotyrosine (4G10) Upstate Biotech. USA.
Biorad ‘Bradford’ reagent Biorad, UK
Bovine serum albumin Sigma, UK
Bromophenol blue BDH, UK
Calcium chloride Sigma, UK
Chloroform BDH, UK





Enhanced Chemiluminescence Reagent Amersham Internation, UK
Ethyl Formate BDH, UK
Flowscint IV Scintillation Cocktail Canberra Packard, UK
Foetal bovine serum Gibco BRL, Scotland
Folsh Lipids Sigma, UK
Fura-2/AM Calibiochem, UK
Geneticin (G418) Gibco BRL, Scotland
GF/A filter paper Whatman, UK
Glacial acetic acid BDH, UK
Glycerol Sigma, UK
Goat anti-mouse peroxidase conjugate Santa Cruz, UK
Goat anti-rabbit peroxidase conjugate Santa Cruz, UK
Hank balanced salt solution Gibco BRL, Scotland, UK
HEK 293 human D6 transfectants Gift from R. Nibbs, Glasgow, UK
HEPES (1 M liquid) Gibco BRL, UK
HEPES (solid) Gibco BRL, UK




Linear K Preadsorbent TLC plate Whatman, UK
Lithium chloride Sigma, UK
LT-82 (lethal toxin) Gift from M Popoff, Institut Pasteur, Paris
LT-9048 (lethal toxin) Gift from M Popoff, Institut Pasteur, Paris
Magnesium chloride Sigma, UK
MCP-1 R&D Systems, UK
MCP-2 R&D Systems, UK
MCP-3 R&D Systems, UK
MCP-4 R&D Systems, UK
Methanol BDH, UK
MIP-loc Peprotech, Rocky Hill, USA
M -  MLV Reverse transcriptase Promega, UK
Molecular weight markers Gibco BRL, UK
MRNA QuickPrep Isolation kit Pharmacia, UK
N-butanol BDH, UK
NP-40 Fisons, UK
Optiphase Scintillation fluid Canberra Packard, UK
Orthophosphoric acid BDH, UK
p85a antibody Wyman, UK
p110y antibody Santa Cruz, USA
Pan ras antibody Santa Cruz, USA
Penicillin/Streptomycin Gibco BRL, UK
Pepstatin Sigma, UK
Pertussis Toxin Sigma, UK
Petroleum Ether BDH, UK
Phosphate buffered saline Sigma, UK
Phosphatidylinositol Sigma, UK
Phospho-ERK1/2 antibody New England Biolabs, USA
Phospho-GSk-3ap antibody Cell Signalling Technologies, USA
Phospho-JNK/SAPK antibody Cell Signalling Technologies, USA
Phospho-P38 antibody Cell Signalling Technologies, USA
Plasticware (tissue culture grade) Nunc, UK
PMA Sigma, UK
PMSF Sigma, UK
Potassium oxalate Sigma, UK
Propan-1-ol BDH, UK
Protein G beads Sigma, UK
Roche compound (Ro-320432) Calibiochem, UK
RNAsin Ribonuclease Inhibitor Promega, UK
RNAzol™B Biotex, USA
RPMI 1640 Gibco BRL, UK
Sodium azide Sigma, UK
Sodium chloride Sigma, UK
Sodium dodecyl sulphate Sigma, UK
Sodium hydroxide Fisons, UK





THP-1 cells ECCAC, UK
Tris-Base Sigma, UK
Tris-HCL Sigma, UK
Tween 20 Sigma, UK
Versene Gibco BRL, UK
Wortmannin. Sigma, UK
X-OMAT film Amersham International, UK.
